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1.1 Transmissible spongiform encephalopathies 
1.1.1 Classification 
Transmissible spongiform encephalopathies (TSE’s) or prion diseases are a group of lethal 
neurodegenerative diseases affecting humans and a wide range of animal species (Imran and 
Mahmood, 2011). They can occur as sporadic, infectious, iatrogenic or familial diseases 
(Table 1.1). In humans, 85% of the prion cases are all of a sporadic nature e.g. sporadic 
Creutzfeldt-Jakob disease (sCJD), sporadic fatal insomnia (sFI) and variably protease-
sensitive prionopathy (VPSPr) (Wadsworth and Collinge, 2007; Gambetti et al., 2008). In the 
United Kingdom (UK), sCJD has an average annual mortality rate between 1990 and 2011 of 
0.7-1.2 cases per million per year depending on the region (Papasavva-Stylianou et al., 2011). 
In Belgium, 5 to 20 sCJD cases a year occurred in the last 10 years (personal communications, 
Scientific Institute of Public Health, Belgium). Less common, around 15% of the human prion 
cases, are genetic in nature and include Gerstmann-Sträussler-Scheinker syndrome (GSS), 
fatal familial insomnia (FFI) and familial Creutzfeldt-Jakob disease (fCJD), which are 
autosomal dominant hereditary diseases. There are over 30 different known mutations in the 
PRNP gene that cause a form of familial prion disease (Wadsworth and Collinge, 2007). 
Transmissible prion diseases are generally rather rare in humans apart from infectious 
outbreaks in which geographical spread stays limited, like the kuru and variant Creutzfeldt-
Jakob disease (vCJD) outbreak. Another group of prion diseases are the iatrogenic diseases, 
caused by secondary infection of healthy individuals via administration of contaminated blood 
or human growth hormone (hGH) or chirurgical interventions with contaminated equipment 
or transplants like corneal grafts or dura mater. 
All human prion diseases are characterized by a long incubation period and the accumulation 
of misfolded aggregates of the host encoded prion protein (PrP) mainly in the central nervous 
system (CNS) (Lasmezas, 2003). This leads to occasionally amyloid formation, spongiform 
changes, neuronal loss and reactive astrocytosis with symptoms like progressive dementia and 
ataxia, behavioural changes, resulting in death, frequently caused by a complicating infection 
(Wadsworth and Collinge, 2007).  
On the European continent, the most common TSE diseases in animals are scrapie in sheep 
and goat, and bovine spongiform encephalopathy (BSE) in cattle. However, BSE can also 
occur in goats. In the USA and Canada, chronic wasting disease (CWD) is an important TSE 
disease in mule deer, white-tailed deer, moose and elk and causes new food safety concerns. 
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In Europe, no cases of CWD are described until now. Furthermore, there is a group of less 
common TSE diseases in animals. The one first diagnosed was transmissible mink 
encephalopathy (TME) which occurred in farmed minks. The other uncommon TSE diseases 
occurred in animals held captive in zoos i.e. non-human primates TSE (NHP), a TSE disease 
of non-human primates, exotic ungulate spongiform encephalopathy (EUE), a disease of 
exotic ungulates and feline spongiform encephalopathy (FSE), a TSE of captive wild cats but 
also of domestic cats. They all arose due to the feeding of feed derived from TSE infected 
sheep or cattle (Imran and Mahmood, 2011). 
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Table 1.1: Prion diseases in humans and animals (Imran and Mahmood, 2011). 
Disease Host Etiology Year of 
Description 
Human diseases   
Kuru Humans Ritualistic Cannibalism 1900s 
sCJD Humans 
Spontaneous PrP
C
 → PrPSc conversion or somatic 
mutation 
1920 
fCJD Humans Germline mutations in PRNP 1924 
GSS Humans Germline mutations in PRNP 1936 
iCJD Humans 
Infection with Prions of human origin by cadaveric 
corneal grafts, hGH or dura mater 
1974 
FFI Humans PRNP haplotype 178N-129M 1986 
vCJD Humans Infection with Prions of BSE origin 1996 
sFI Humans 
Spontaneous PrP
C → PrPSc conversion or somatic 
mutation 
1999 
VPSPr Humans 
Spontaneous PrP
C
 → PrPSc conversion or somatic 
mutation 
2008 
Animal diseases   
Scrapie 
Sheep, 
Goats 
Infection with Prions of unknown origin 1732 
TME Mink Infection with Prions of either sheep or cattle origin  1947 
CWD Cervids Infection with Prions of unknown origin  1967 
BSE Cattle Infection with Prions of unknown origin 1986 
EUE 
Nyala, 
Kudu 
Infection with Prions of BSE origin  1986 
FSE Cats Infection with Prions of BSE origin  1990 
NHP Lemurs Infection with Prions of BSE origin 1996 
sCJD=sporadic Creutzfeldt-Jakob disease, fCJD=familial Creutzfeldt-Jakob disease, 
GSS=Gerstmann-Sträussler-Scheinker syndrome, iCJD=iatrogenic Creutzfeldt-Jakob disease, 
FFI=fatal familial insomnia, vCJD=variant Creutzfeldt-Jakob disease, sFI=sporadic fatal insomnia, 
VPSPr=variably protease-sensitive prionopathy, TME=transmissible mink encephalopathy, 
CWD=chronic wasting disease, BSE=bovine spongiform encephalopathy, EUE=exotic ungulate 
spongiform encephalopathy, FSE=feline spongiform encephalopathy and NHP=non-human primates 
TSE.  
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1.1.2 Pathogenesis 
Prion diseases are not caused by a virus, bacteria, fungi or parasite but by the misfolded prion 
protein (PrP
Sc
) itself (Prusiner, 1982). They occur when the normal cellular body’s own prion 
protein (PrP
C
) converts into the pathological protease resistant form called resistant PrP 
(PrP
Res
) or Scrapie PrP (PrP
Sc
), later changed in disease causing PrP (PrP
Dis
). The pathological 
form has the same primary structure as the cellular form but their secondary and tertiary 
structure differs largely from each other, therefore creating different chemicophysical 
properties (Figure 1.1) (Stahl et al., 1993). PrP
Sc
 has a higher amount of β sheets, is insoluble 
and is partially protease resistant. The conversion of PrP
C
 to PrP
Sc
 is the key event in the TSE 
diseases and can be considered as an autocatalytic process (Bieschke et al., 2004; Castilla et 
al., 2008) but until this day many questions stay unanswered. 
 
Figure 1.1: Schematic representation of the structured part of the normal cellular form of 
PrP (PrP
C)
 and the abnormal disease causing form (PrP
D) 
(du Plessis, 2008). The normal 
cellular form has a higher amount of α helixes (in green and red) and the abnormal disease 
causing form has a higher amount of β sheets (in green and red). 
 
It is still an open question which exact effect causes neurotoxicity. It was suggested that the 
loss of PrP
C
 function could cause the symptoms but studies with PrP knock-out mice and 
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cattle disproved that theory (Bueler et al., 1992; Bueler et al., 1993; Richt et al., 2007). The 
gain of toxic properties following conversion or the generation of a toxic intermediate or by-
product was also supposed. Because the neurodegenerative changes were reversed when PrP
C
 
expression was inhibited in vivo, it is most likely that conversion itself causes the 
neurodegenerative changes (Mallucci et al., 2003; Mallucci et al., 2007). 
Nevertheless, each prion disease is characterized by self-propagating conformational change 
of the prion protein. It is thought that the cellular PrP
C 
is refolded into its pathological form by 
a template-assisted process in which PrP
Sc 
acts as the template. It is supposed that there is an 
intermediate partially unfolded state between PrP
C
 and PrP
Sc 
designated PrP* (Colby and 
Prusiner, 2011). Furthermore, the better the PrP structure of the template resembles the 
structure of the PrP
C
, the more efficient the conversion will be. This partially explains the 
sequence barrier and the existence of prion strains (Colby and Prusiner, 2011). 
In vivo, a first requirement for cellular PrP
C
 to convert to PrP
Sc
 is interaction between the 
template PrP
Sc
 and PrP
C
. Studies with cell lines have been able to localize this interaction 
(Figure 1.2). In a non-infected cell, PrP
C
 molecules (Figure 1.2: red round) are trafficking to 
the cell membrane, get internalized in the subcellular compartments and cycle back to the cell 
membrane (Shyng et al., 1993).  
When a cell becomes infected, PrP
Sc
 (Figure 1.2: red square) interacts with PrP
C
 on the cell 
membrane, gets internalized and PrP
C 
gets converted to PrP
Sc
. The conversion takes place on 
the cell surface or in endosomes that are drawn in from the cell surface (Caughey and 
Raymond, 1991; Borchelt et al., 1992). Subsequently, PrP
Sc
 is partially protease degraded to 
form PrP 27-30 and these newly converted PrP molecules become bound to the already 
existing PrP
Sc 
aggregates. 
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Figure 1.2: Prion pathway in TSE-infected cells (adapted from Grassmann et al., 2013). 
PrP
C
 is synthesized in the endoplasmic reticulum (ER) and passes through the secretory 
pathway to the cell surface, where it resides in lipid rafts. In many cells, PrP
C
 leaves lipid 
rafts prior to being internalized by clathrin-dependent endocytosis (I). Ribosomal protein SA 
(RPSA), a transmembrane protein, acts as a receptor for PrP
C
 and PrP
Sc
 and mediates its 
internalization by clathrin-dependent endocytosis. Clathrin-independent raft/caveolae-
dependent internalization (II) of PrP
C
 has also been proposed for some cells. PrP
C
 can be 
degraded by lysosomes or rapidly recycled back to the cell surface by recycling endosomes 
(RE). In cultured scrapie-infected cells the conversion of PrP
C
 to PrP
Sc
 is believed to take 
place on the cell surface and/or in vesicles along the endolysosomal pathway. After 
conversion PrP
Sc
 can accumulate at the cell surface or in intracellular vesicles (e.g. 
lysosomes). 
 
1.1.3 TSE in ruminants: impact on food safety and economy 
1.1.3.1 BSE in cattle 
BSE first appeared in the mid-1980s in the UK as an epizootic that peaked in 1992 with more 
than 37.000 cases worldwide (Table 1.2) (Caughey and Raymond, 1991). Since then, BSE has 
been detected in several countries all over the world (Figure 1.3). Several epidemiological 
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studies suggest that the major infection route of the epizootic in the UK was probably the 
Meat and Bone meal (MBM) produced from cattle given to young dairy cows. Therefore, 
control measurements restricting cannibalism were implemented in the UK in 1988 and in 
July 1994 a feed ban for mammalian MBM to cattle, sheep and goats was introduced in the 
European Union.  
 
Table 1.2: Evolution of the number of BSE cases in the UK and the rest of the world (adapted 
from the Office International des Epizooties (OIE) website, TSE section). 
 
BSE cases that occurred in the UK are represented in grey and cases that occurred in the rest of the 
world are represented in black. 
 
In humans, a previously unknown form of Creutzfeldt-Jakob disease, affecting much younger 
patients than the known CJD forms, emerged in the UK in 1994 (Will et al., 1996). This new 
form, called vCJD, is most likely caused by the ingestion of products derived from BSE 
infected cattle (Bruce et al., 1997; Hill et al., 1997). This CJD epidemic has focused concern 
on the risk for humans to get infected by the exposure to prions in their diet or through other 
means. In 2001, the feed ban was extended to processed animal proteins in feed for any 
animals farmed for the production of food with some exceptions. The vCJD epidemic has 
caused 235 deaths worldwide whereof 177 in the UK until June 2014 (The National CJD 
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Research & Surveillance Unit website: Data & Reports section). The highpoint of vCJD was 
reached in 2000, a decade after the peak of the BSE crisis. Since then the epidemic declined to 
a current incidence of about 1 to 2 diagnoses/death per year. In 2013, one confirmed case was 
reported in the UK (The National CJD Research & Surveillance Unit website: Data & Reports 
section).  
 
Figure 1.3: Geographical distribution of countries that reported at least one BSE confirmed 
case since 1989. Countries having reported BSE in indigenous animals in red and 
countries/territories having reported BSE in imported animal(s) only in yellow (adapted from 
the OIE website, TSE section). 
 
In cattle with BSE, the infection occurs through the oral route. Subsequently, the gut 
associated lymphoid tissue (GALT) of the tonsils and the intestines get infected and 
afterwards the infection reaches the CNS (brain and spinal cord). In cattle, the main 
infectivity is concentrated in the central nervous system and the replication in the lymphoid 
tissue is minimal (Van Keulen et al., 2008). When the organs, designated as specified risk 
material (SRM), are removed, the risk of exposure to BSE is minimal for consumers (Table 
1.3). In 2000, the European Union (EU) established a list of SRM that has to be removed 
during slaughtering (2000/418/EG) (Table 1.4). Because the TSE infection spreads relatively 
slow, the removal of SRM is age specific. The oldest animals have the highest probability that 
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the infection is already spread further into the body and has reached the CNS. Therefore, in 
young cattle, only tonsils and intestines has to be removed and in older cattle, also parts of the 
CNS. Furthermore, the EU includes a prohibition to use certain by-products for food and feed 
like gelatin. 
 
Table 1.3: Infectious load per tissue (table based on EFSA Panel on Biological Hazards, 
2010). 
Tissue % of total infectious load per animal Cumulative load 
Brain 64.1% 64.1% 
Spinal cord 25.6% 89.7% 
Trigeminal ganglia 2.6% 92.3% 
Dorsal root ganglia 3.8% 96.1% 
Ileum 3.3% 99.4% 
Spleen 0.3% 99.7% 
Eyes 0.04% 99,74% 
 
Besides food safety issues, the BSE crisis is having a huge economic impact as well. Because 
the BSE crisis had a great effect on the trust of the consumer in cattle derived products, the 
loss to the EU livestock industry has been estimated at 2.75 billion euros a year, which is the 
equivalent of 10% of the total value of beef output. Furthermore, the resulting BSE control 
strategies that are established by the European Commission such as removal of specified risk 
materials (SRM) from slaughter animals, the MBM ban, post-mortem testing for BSE and the 
culling of cohorts of BSE cases, based on the received feed and the age, is costing a lot of 
money too. A Dutch study estimated that the cost of all measurements taken between 2002 
and 2005 ranged from 43 to 64 million euros a year in the Netherlands (Benedictus et al., 
2009). The costs for post-mortem testing for BSE and the culling of feed and age cohorts of 
BSE cases in Belgium in 2013 is calculated to be 1.6 million and 125.000 euros respectively 
(2012/761/EU). The last decade, the prevalence of BSE cases is still dropping, with only 
seven confirmed cases worldwide in 2013. The last confirmed case in Belgium dates from 
2006. Since 2012, the OIE has granted Belgium the status of “EU member state with 
negligible BSE risk” (FAVV website: TSE section). Due to this, since the first of January 
2013, healthy cattle that are slaughtered in the slaughterhouse do not have to be tested 
anymore with the rapid TSE test. 
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Table 1.4: Specific Risk Material (adapted from FAVV website, TSE section). 
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Cattle of all ages   X  X   
Cattle > 12 months X X X  X   
Cattle > 30 months X X X X X   
Sheep and goats of all ages      X X 
Sheep and goats > 12 months
1
 X X X   X X 
1
or which have a permanent incisor erupted through the gum 
2
from the duodenum to the rectum 
 
1.1.3.2 TSE in sheep 
In sheep, scrapie is an endemic disease already described in the 18
th
 century, long before the 
disease causing agent was identified. There are even indications that the disease was already 
present in the period of the pharaohs. It affects both sheep and goats and is widespread 
throughout the world (Hunter, 2007). Scrapie spreads usually via horizontal transmission and 
the infection occurs mainly around birth in affected flocks (Andreoletti et al., 2002). The 
dissemination of PrP
Sc 
in natural infected sheep starts in the gut associated lymphoid tissue 
(GALT), then spreads to other lymphoid tissue and then reaches the CNS (Figure 1.4) 
(Andreoletti et al., 2000; van Keulen et al., 2008). PrP
Sc 
deposits were also detected in 
skeletal muscle, liver, blood, milk, semen and colostrum (Andreoletti et al., 2004; Lacroux et 
al., 2008; Terry et al., 2009; Everest et al., 2011; Rubenstein et al., 2012). Due to the 
horizontal transmission and the widespread dissemination, usually multiple animals of a flock 
are infected with scrapie. Scrapie is mainly considered as a threat for animal health and no 
real indications are found that scrapie would be a risk for public health. 
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Figure 1.4: Schematic representation of PrP
Sc 
accumulation (in red) in the enteric nervous 
system (ENS), represented as a line, and central nervous system (CNS,) represented as a 
figure, in naturally scrapie affected sheep of the VRQ/VRQ genotype at (a) 10 months and (b) 
26 months of age (adapted from van Keulen et al., 2008). In the animals of 10 months of age, 
only a part of the ENS and a few structures of the CNS (GMCC and DMNV and a small part 
of the thoracic segment of the spinal cord) are infected). In the animals of 26 months of age, 
the complete ENS and CNS are infected. CNS (figures):C, T, and L – cervical, thoracic, and 
lumbar segments of the spinal cord; DMNV=dorsal motor nucleus of the vagus; 
GMCC=ganglion mesentericum cranialis/coeliacum; ENS (lines) O – esophagus; R – rumen; 
Re – reticulum; Om – omasum; Ab – abomasum; Du – duodenum; Je – jejunum; il – ileum; 
Ca – caecum; Co – colon; Rec – rectum. Animal numbers are indicated on the left and on the 
right: the ENS and CNS of the same animal are aligned to the left or to the right. Only 
efferent nerve fibers are shown.  
GMCC 
DMNV 
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Furthermore, TSE in sheep has also an economic impact. European Commission Control 
strategies such as testing of slaughtered animals, removal of SRM from slaughter animals 
(Table 1.4) and compensation for sheep farmers for the culling of their infected flock are the 
main costs. The Belgian programs to test both sheep and goat and for compensating sheep and 
goat farmers in 2013 is estimated to cost around 100000 and 130000 euros respectively. 
Breeding programs are costing an additional 16000 euros a year (2012/761/EU) (European 
Commission, 2012).  
 
However, during and after the BSE crisis in cattle, the possibility of sheep being infected with 
BSE in the UK was suggested because sheep were also fed with contaminated MBM (Kao et 
al., 2002). Therefore, researchers started to look more carefully at TSE in small ruminants 
with the consequence that new strains of scrapie were discovered. 
In 1998, a new neurological disease in sheep was discovered in Norway that was clearly 
distinguishable from classical scrapie in a pathological, molecular and epidemiological way, 
and was therefore considered as an atypical form of scrapie (Benestad et al., 2003). The 
disease affects sheep with genotypes that are rarely infected with classical scrapie and was 
called Nor98. Later on, other cases of scrapie, clearly differing from classical scrapie but not 
of the Nor98 type, were discovered and all these aberrant cases were grouped under the term 
‘atypical scrapie’. Atypical scrapie, including the Nor98 variant, has now been identified in 
most EU member states and has been reported in countries that were considered free of 
classical scrapie by the OIE (Australia and New Zealand). Mostly, just one sheep is affected 
with atypical scrapie in each flock and the disease is mostly found in older sheep suggesting 
that atypical scrapie is probably a spontaneous, non-contagious prion disease like sCJD in 
humans (Benestad et al., 2008). 
Due to the detection of those new strains, the question raised if BSE could also be present in 
sheep and goats. In 2005, BSE was transmitted between sheep of an experimental flock and it 
was proven that even sheep highly resistant to classical scrapie (ARR/ARR, see next 
paragraph) could get infected when orally exposed (Bellworthy et al., 2005; Andreoletti et al., 
2006). In contrast to BSE in cattle, BSE in sheep spreads through the lymphoid system just 
like scrapie, leading to an extensive dissemination of PrP
Sc
 in sheep compared to the limited 
dissemination in cattle (Schreuder and Somerville, 2003). This makes the disease in sheep a 
major threat for public health. However, no natural BSE cases in sheep have been detected 
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until now, in contrast to two cases detected in goat (Priem et al., 2014). Archived brain 
samples of sheep clinically suspected of scrapie during the period of 1998 and 2001, were re-
examined to discriminate between scrapie and BSE. Some of those samples showed unusual 
results and those sheep were therefore suspected to be infected with BSE. Further tests with 
more advanced techniques, however, showed no evidence of the presence of BSE in those 
sheep but the possibility of BSE in sheep cannot be excluded completely (Stack et al., 2006). 
Moreover, in vitro experiments revealed that the virulence of BSE increases after passage 
through sheep, leading to a more efficient transmission to sheep, cattle and human (Priem et 
al., 2014). 
The European Food Safety Authority (EFSA) has listed in 2005 a number of criteria to 
categorize TSE in sheep as classical scrapie, BSE in small ruminants or atypical scrapie, 
including Nor98 (Table 1.5).  
In Belgium, the first monitored scrapie case was detected in 1992 following a clinical 
suspicion (Roels et al., 1999). Five sheep of the same flock tested positive on histopathology 
and in all five animals scrapie associated fibrils (SAFs) were identified with electron 
microscopic examination. During the years following this first case, several more cases were 
detected, varying from 1 to 5 primary cases per year (Figure 1.5). The normal population of 
adult sheep in Belgium consists of approximately 200000 sheep (Depoorter et al., 2014). 
Since then, 78 cases in 25 herds were diagnosed. Each positive TSE case was further 
examined to differentiate between classical scrapie, atypical scrapie or BSE and of the 78 
confirmed cases, 9 cases were atypical scrapie (personal communications, Belgian National 
Reference Laboratory for veterinary TSEs, CODA). 
Between 2002 and 2007, active surveillance of scrapie in the slaughterhouses was 
implemented but not all slaughtered sheep were tested. The lowest number tested was 39 
sheep in 2004 and the highest number tested was 8076 sheep in 2006 (FAVV website: TSE 
section).  
In 2002, the first sheep with atypical scrapie in Belgium was diagnosed in a ARQ/ARQ lamb 
and later on, 8 more cases, including an ARR/ARR sheep, were found (De Bosschere et al., 
2004; De Bosschere et al., 2007; Fediaevsky et al., 2008; European Commission: Directorate-
General for Health and Consumers, 2010). In all atypical cases, no additional cases were 
discovered after culling of the cohort. The last 3 scrapie cases date from 2007 (Figure 1.5) but 
the active surveillance in sheep was limited to dead animals not slaughtered for human 
Chapter 1: General introduction 
16 
 
consumption in 2008 and weakened to a sample size of 1500 sheep (Regulation (EC) No 
999/2001 + amendments). Therefore, the chance of detecting a new scrapie case after 2008 
became even smaller. 
 
Table 1.5: Criteria for the categorization of TSEs in small ruminants (adapted from EFSA 
Panel on Biological Hazards, 2005). 
TSE type 
 
Approved 
rapid 
screen
1
 
Stringent PK 
Western blot
2
 
Mild PK 
Western 
blot
3
 
Pathology Genotype 
Classical 
scrapie 
 
positive positive positive Grey matter 
vacuolation 
IHC labeling of 
PrP 
in medulla and 
DMNV 
Susceptible 
BSE in 
small 
ruminants 
 
positive positive 
unglycosylated 
band lower 
molecular 
weight than 
for classical 
scrapie 
controls 
positive 
 
Usually grey 
matter 
vacuolation 
IHC labeling of 
PrP  
in medulla and 
usually also 
DMNV 
Likely to be 
ARQ/ARQ 
but not 
genotype 
exclusive 
 
Atypical 
scrapie 
including 
Nor98 
positive negative positive 
including 
band at 15 
kDa 
 
Vacuolation and 
IHC negative or 
low levels in 
obex, DMNV, 
medulla. 
Cerebellum is 
IHC positive for 
PrP and has 
vacuolation 
Genotypes 
include those 
resistant to 
classical 
scrapie often 
with at least 
one AHQ or 
AF141RQ 
allele 
TSE=transmissible spongiform encephalopathy, PK=proteinase K, IHC=immunohistochemistry, 
PrP=prion protein, DMNV=dorsal motor nucleus of the vagus, BSE=bovine spongiform 
encephalopathy, kDA=kilodalton 
1
Rapid tests approved for surveillance for TSEs in small ruminants, mostly ELISA tests (e.g. Bio-Rad 
TeSeE)  
2
Stringent PK=Western blot with stringent conditions for proteinase K digestion 
3
Mild PK=Western blot with mild conditions for proteinase K digestion 
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Figure 1.5: Scrapie in Belgium until 2010 by their year of confirmation. The total number of 
scrapie cases is represented in blue, the number of atypical scrapie cases is represented in 
orange, the number of affected flocks is represented in grey and the number of preclinical 
scrapie cases is represented in yellow (personal communications, Belgian National Reference 
Laboratory for veterinary TSEs, CODA). 
 
1.1.3.3 TSE in goats 
Natural cases of scrapie in goats are reported since the forties of the previous century in 
Europe and other parts of the world, although with a much lower incidence than in sheep. The 
clinical signs, epidemiology, molecular pattern, the distribution of histopathological lesions 
and the dissemination of the infection are very similar to scrapie in sheep (Gonzalez et al., 
2009). 
TSE in goats is rather rare in comparison with TSE in sheep, except for the caprine population 
in Cyprus. More than 85% of the goat scrapie cases detected in the EU between 2002 and 
2007 occurred in Cyprus (Vaccari et al., 2009). Scrapie was endemic in Cyprus since it was 
first reported in 1985 but the incidence reached epidemic proportions during the years 2000, 
involving sheep as well as goats. The involvement of goats is probably due to the practice of 
mixed herds of sheep and goats in Cyprus (Vaccari et al., 2009).  
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Atypical scrapie is also observed in goats but only in a few cases. Like classical scrapie, the 
atypical form is very similar to the disease observed in sheep in all aspects (Vaccari et al., 
2009).  
In 2005, the first naturally BSE infected goat was discovered in France through active 
surveillance (Eloit et al., 2005). Before that time, experimental BSE transmissions to goats 
were successfully conducted (Foster et al., 1993). After the first naturally BSE case, the active 
surveillance of TSE in small ruminants was intensified in the member states of the European 
Union but no additional BSE cases were detected.  
Even though active surveillance was implemented in Belgium after the identification of the 
first BSE case in goat (France) for each slaughtered sheep and goat older than 18 months, 
there was never a caprine TSE case identified in Belgium. The normal population of adult 
goats in Belgium consists of approximately 60000 goats (Depoorter et al., 2014). In 2008, 
active surveillance in goat was weakened to a sample size of 100 goats a year and was limited 
to dead animals not slaughtered for human consumption. 
 
1.1.4 Influence of PRNP genotype on TSE susceptibility  
1.1.4.1 Humans 
In humans, the genotype of codon 129 of PRNP (encoding either methionine (M) or valine 
(V)) is very important for the susceptibility to human prion diseases. In the European 
population, 38% of the people are homozygous for the methionine allele, 51% are 
heterozygous, and 11% are homozygous for valine (Wadsworth and Collinge, 2007). In the 
case of vCJD, all patients were homozygous for methionine (Table 1.6). Additionally, most 
sCJD occurs in methionine homozygous individuals (Bishop et al., 2009). Furthermore, the 
most elderly survivors of the Kuru epidemic, an acquired prion disease transmitted by 
cannibalism in Papua New Guinea, are heterozygotes. Incubation periods of more than 50 
years in those individuals were not exceptional. This raises questions about heterozygous 
individuals possibly infected with vCJD. Is there still no case of vCJD in heterozygotes 
because they have a very high resistance to infection or are these heterozygous individuals, 
infected during the BSE epidemic, asymptomatic carriers? Large studies on healthy patients 
of which tonsil and appendix tissues were examined on the presence of abnormal prion 
protein, suggested a prevalence of 1 per 10.000 asymptomatic carriers in the UK (Ironside, 
2012). These figures suggest that the tail of the epidemic could be potentially longer than 
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earlier predicted, representing both primary infections of heterozygotes or valine homozygous 
individuals with BSE and secondary iatrogenic transmission via blood or other tissues coming 
from asymptomatic carriers (Clarke and Ghani, 2005). 
In three of the four known cases of iatrogenic transmission of vCJD infection via blood 
transfusion, the recipients were homozygous MM at codon 129. They all developed clinical 
vCJD. In the fourth case, the recipient was heterozygous (MV) and did not develop a clinical 
disease during his lifetime. There was no neuropathological evidence of the disease, only the 
spleen and a lymph node contained abnormal prion protein. In conclusion, susceptibility to 
prion diseases in humans is largely dependent on the PRNP genotype. 
 
Table 1.6: PRNP codon 129 genotype frequencies in the European population (Wadsworth 
and Collinge, 2007). 
 
MM MV VV 
Normal population 38% 51% 11% 
vCJD 100% 0% 0% 
sCJD 71% 15% 14% 
MM=homozygous for methionine at codon 129 of the gene encoding for the prion protein, 
MV=heterozygous for methionine/valine at codon 129 of the gene encoding for the prion 
protein, VV=homozygous for valine at codon 129 of the gene encoding for the prion protein, 
vCJD=variant Creutzfeldt-Jacob Disease, sCJD=sporadic Creutzfeldt-Jacob Disease 
 
1.1.4.2 Cattle 
In cattle, several PRNP polymorphisms were discovered but none of the known 
polymorphisms in the bovine coding sequence was associated with BSE susceptibility. Two 
insertion or deletion (indel) mutations however, situated in the regulatory region of the gene, 
are affecting expression of the PRNP gene in some tissues and are associated with BSE 
susceptibility in several breeds (Sander et al., 2004; Sander et al., 2005; Juling et al., 2006; 
Haase et al., 2007). Another mutation, a single nucleotide polymorphism (SNP) in intron 2, 
was reported to be associated with BSE susceptibility and may exhibit a regulatory function 
(Murdoch et al., 2010). However, none of them were used in the control programs of BSE in 
cattle. 
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1.1.4.3 Sheep 
1.1.4.3.1 General observations 
It was long believed that scrapie was a simple genetic disease because the familiar influence 
was so high. Nowadays, scientists agree that scrapie is an infectious disease caused by prion 
proteins but with a high genetic influence on the susceptibility (Hunter, 2007). At present, 
more than 40 amino acid polymorphisms are found in the ovine PrP protein (Meydan et al., 
2013). The polymorphisms at codon 136, 154 and 171 are considered to have the highest 
influence on resistance to classical scrapie. On codon 136, two amino acids are common, 
namely valine (V) or alanine (A). The most common amino acids of codon 154 are histidine 
(H) or arginine (R) and the ones of codon 171 are arginine (R), histidine (H) or glutamine (Q). 
Only five allotypes commonly occur in different sheep breeds: ARQ, VRQ, ARR, AHQ and 
ARH (Hunter et al., 1996). The National Scrapie Plan of the UK (NSP) classified 15 common 
genotypes in 5 groups evolving from very resistant to scrapie to very susceptible (Table 1.7) 
(Gubbins and Roden, 2006). It is clear that ARR/ARR resistance is very high to absolute with 
only one case reported worldwide, which is possibly even not a case of classical scrapie 
(Ikeda et al., 1995; Hunter et al., 1997; McIntyre et al., 2008). Homozygous VRQ animals on 
the other hand are extremely susceptible.  
 
Table 1.7: NSP classification system used in the United Kingdom for genetic resistance to 
classical scrapie. 
NSP class Genotypes
1
 Genetic resistance 
NSP1 ARR/ARR Genetically most resistant 
NSP2 ARR/ARQ ARR/AHQ ARR/ARH Genetically resistant 
NSP3 
ARQ/ARQ ARQ/AHQ ARQ/ARH 
AHQ/AHQ AHQ/ARH ARH/ARH 
Genetically little resistant 
NSP4 ARR/VRQ Genetically susceptible 
NSP5 
ARQ/VRQ AHQ/VRQ ARH/VRQ 
VRQ/VRQ 
Genetically highly susceptible 
NSP=the National Scrapie Plan of the UK 
1
Genotypes refers to the amino acid at codon 136, 154 and 171 of the gene encoding for the prion 
protein with A=alanine, R=arginine, Q=glutamine, H= histidine and V=valine. 
 
In ‘atypical scrapie’, the genetic susceptibility of the sheep is quite different. Of the three 
codons important for classical scrapie (136, 154 and 171), only codon 154 (R/H) seemed to be 
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associated with the Nor98 cases. The VRQ haplotype, in classical scrapie associated with high 
susceptibility, remarkably gives the highest resistance against atypical scrapie (Moum et al., 
2005), while atypical scrapie also occurs in ARR/ARR sheep, the most favored genotype 
according to Commission Regulation 1915/2003 (Buschmann et al., 2004; Saunders et al., 
2006). In addition, codon 141 of the ovine PRNP gene seems to play an important role in the 
susceptibility to atypical scrapie. Codon 141 has two amino acid variants, namely leucine (L) 
or phenylalanine (F). The phenylalanine allele on codon 141 occurs only in combination with 
A136, R154 and Q171, forming the AFRQ haplotype (Moum et al., 2005). This haplotype is 
highly associated with susceptibility to atypical scrapie, in addition to the AHQ haplotype that 
is also highly overrepresented in atypical scrapie cases (Moum et al., 2005; Arsac et al., 2007; 
Moreno et al., 2007).  
1.1.4.3.2 Selective breeding in Belgium 
The association between the PRNP genotype and the susceptibility to scrapie in sheep led to 
the establishment of programs to create scrapie resistant flocks by selective breeding in many 
European countries, including Belgium. 
In 2003, a voluntary breeding program was developed in Belgium, which became compulsory 
in 2005 for purebreds. The goal of the breeding program was to diminish the VRQ haplotype 
and to elevate the percentage of ARR haplotype in the flocks. All breeding rams of the 
participating flocks had to be tested and those rams carrying a VRQ allele had to be 
slaughtered or castrated in the period of 6 months after the test. All ewes carrying this 
haplotype could only leave the flock to be slaughtered (KB of 6 March 2007).  
At the end of 2007, the breeding program became voluntary again for purebreds as several EU 
countries reported atypical and Nor98-like cases in sheep with the ARR/ARR genotype, the 
genotype most favored by Commission Regulation 1915/2003. Owing to these developments, 
breeding programs were criticized because the genotypes of sheep susceptible to BSE and 
atypical scrapie are completely different from sheep with classical scrapie. 
Furthermore, the question rose if the breeding program caused the increase of cases of 
atypical scrapie because the program selected sheep that were susceptible for atypical scrapie 
(Baylis and McIntyre, 2004). Most likely this is not the case. The rise in cases of atypical 
scrapie is just a consequence of a better detection due to the combination of high active 
surveillance and the development of a new rapid test in which a smaller amount of proteinase 
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K (PK) is used allowing the preservation of the protein signal of atypical scrapie cases (Table 
1.5) (Hunter, 2007). Moreover, when selection continues towards ARR/ARR sheep, this will 
not result in an overall increase of scrapie prevalence whereas this genotype is very protective 
for classical scrapie and the capacity of atypical scrapie to transmit to other sheep under field 
conditions is very low (Barret et al., 2003).  
Recently, the evolution of genetic resistance to scrapie since the selection programs were 
implemented was evaluated in different countries. In the Netherlands and Belgium, an 
increase of the genetically resistant ARR haplotype was indeed observed during the last years 
(du Plessis, 2008; Konold et al., 2008, Dobly et al., 2013). The scrapie prevalence is showing 
a downward trend in both countries, showing that the selection programs have the desired 
effect.  
1.1.4.4 Goat  
In contrast to the PRNP gene in cattle, the caprine PRNP gene shows a high variability similar 
to the ovine PRNP gene. However, other PrP variants are related to TSE susceptibility in 
sheep and goats. Twenty five amino acid changes have been found in the caprine PRNP gene 
of common European goat breeds. Many of the polymorphisms are breed and region specific 
but five of them are occurring worldwide in various breeds and are associated with TSE 
susceptibility (Vaccari et al., 2009). The most studied polymorphism is the one on codon 222 
that codes for a glutamine (Q) or lysine (K). A lysine on position 222 of PrP seems to be 
associated with resistance to scrapie in goats (Acutis et al., 2006; Vaccari et al., 2006; Barillet 
et al., 2009). No positive scrapie cases were observed in K222 homozygotes but it is too early 
to declare that K222 homozygotes are total resistant to TSE because of their low frequency of 
that genotype in goats. Experimental challenging of homozygotes with TSE will be needed to 
prove this hypothesis (Corbière et al., 2013). Additionally, studies of goat scrapie cases in 
Cyprus, where a classical scrapie epidemic is ongoing in the mostly mixed flocks of sheep 
and goats, are pointing towards codon 146 to have a major effect on scrapie susceptibility. A 
serine (S) at that position gives a high resistance to classical scrapie in contrast to an 
asparagine (N). No scrapie positive homozygous S146 animals were found in a study that 
genotyped 218 scrapie positive animals (Papasavva-Stylianou et al., 2011). 
Atypical scrapie and BSE in goats are until now too rare to examine associations between 
genotypes and TSE susceptibility. Nevertheless, all Nor98 cases in goats were clearly 
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associated with a H154 haplotype, the same haplotype that is very important in atypical scrapie 
cases in sheep (Colussi et al., 2008). 
The EU is still in the process of evaluating the possibility of introducing breeding programs in 
goats. 
1.1.5 Proteins and other cofactors involved in the propagation  
Decades of research were done to prove the theory that a misfolded protein is the main (or 
sole) component of the infectious agent causing TSEs and to determine possible cofactors 
(Figure 1.6). In the last decade, the development of protein misfolding cyclic amplification 
(PMCA) has opened a new way to evaluate factors that facilitate or inhibit prion propagation 
(Saborio et al., 2001). This technique is based on the incubation of a small amount of 
abnormal prion with an excess of normal protein until some conformational conversion takes 
place. The growing aggresome of misfolded protein is then broken into smaller aggresomes 
(usually with ultrasound) and these new seeds can then initiate further conversion. By 
repeating the cycle, the mass of normal protein is rapidly changed into misfolded prion. Soto 
and colleagues (2002) showed that cellular PrP
C
 could be transformed into PrP
Sc
 in a cell-free 
environment, making it highly unlikely that foreign nucleic acids or viruses are needed for the 
conformational change and subsequently, Castilla and colleagues (2005) were the first to 
prove that this new generated PrP
Sc 
is also infectious. The discovery of PMCA led to an 
abundance of papers of research groups who created ‘synthetic prions’ in vitro, but a lot of 
these prions had different biological, biochemical and structural characteristics of in vivo 
produced prions. For example, Legname and colleagues (2004) produced synthetic prions 
from bacterially expressed recombinant prion protein that were only infectious in transgenic 
animals overexpressing PrP with very long incubation periods. 
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Figure 1.6: Protein only controversy (Soto, 2011). A timeline represents the major milestones 
that prove that a protein could be the sole component of the infectious agent that causes prion 
diseases. It starts with the first indication that prion diseases can be transmissible, owing to 
the accidental transmission of scrapie in sheep, and it ends with the demonstration that 
infectious material can be generated in vitro using pure recombinant prion protein. 
 
PMCA experiments that produce PrP
Sc 
with characteristics resembling in vivo produced PrP
Sc 
are mostly using brain homogenate suggesting that some cellular co-factors are needed 
(Castilla et al., 2005). These co-factors were sometimes designated as “protein X” in the early 
days but they are most likely not of a protein nature (Cohen and Prusiner, 1998).  
Intensively studied genes and proteins that could be involved in the prion pathway can be 
divided in three classes. The first class is a group of genes that are showing some similarities 
with the PRNP gene. The PRND gene, coding for the Doppel protein, the PRNT gene, which 
codes for a protein that is only expressed in the testis of primates, and the SPRN gene, coding 
for the Shadoo protein, are the three known members of this class. The second class 
comprises proteins that have altered expression intensity in normal and TSE infected 
individuals. This is a very large class as numerous expression studies detected over a hundred 
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genes. RPSA (Ribosomal Protein SA) is one protein for instance that is present in higher 
amounts in several tissues of mice and hamsters after scrapie infection (Rieger et al., 1999). 
Molecules that bind to PrP are forming the last class. Various poly-anionic cofactors like 
glycosaminoglycans (GAGs) are part of this group. These are long polysaccharides that are 
linked to proteins to form proteoglycans or that are secreted. Well-studied proteoglycans are 
heparan sulphate proteoglycans (HSPGs), known to bind with PrP
C 
on the cell surface 
(Grassmann et al., 2013). Recent study showed that Glypican-1, a HSPG anchored at the cell 
membrane, interacts with both PrP
C
 and PrP
Sc
, and facilitates their conversion (Hooper, 2011). 
Furthermore, PrP binding proteins like clusterin are well studied members of this class. 
Multiple studies reported that RPSA, a cell surface receptor, is involved in the prion pathway 
and is therefore also an excellent candidate to have an effect on prion propagation (Figure 1.2) 
(Rieger et al., 1999; Leucht et al., 2003; Morel et al., 2005; Vana and Weiss, 2006).  
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1.2 Ribosomal protein SA 
1.2.1 Involvement of RPSA in prion diseases 
The first report of the connection between the prion protein and RPSA was made by Rieger in 
1997 (Rieger et al., 1997). They identified the protein in a yeast two-hybrid screen as 
interaction partner of PrP
C
 and confirmed this interaction by coinfection and cotransfection 
studies in insect and mammalian cells. Moreover, they determined that RPSA concentrations 
were highly increased in organs of scrapie-infected hamsters where PrP
Sc
 accumulation takes 
place. A further study established that both the 37 kilodalton (kDA) isoform and the 67 kDA 
isoform of RPSA were acting as receptor for the cellular prion protein and that the binding 
and internalization of PrP is inhibited by the administration of anti-RPSA antibodies 
(Gauczynski et al., 2001).  
Figure 1.7: Binding domains of RPSA with PrP (adapted from Hundt et al. 2001). The PrP 
molecule binds to RPSA via 2 binding domains. The first binding domain (aa 53–93) is 
dependent on the presence of a heparan sulfate arm of a HSPG molecule whereas the second 
binding domain (aa 144–179) interacts directly with RPSA. The simultaneous presence of 
both binding domains would stabilize considerably the binding of the entire PrP molecule to 
its receptor. Direct binding of RPSA to PrP occurs via the direct binding site located between 
aa 161 and aa 179 of RPSA. The indirect HSPG-dependent binding domain might locate 
between aa 180 and aa 285 of RPSA. 
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The binding domain for PrP on RPSA and vice versa was examined in a yeast two-hybrid 
study and two binding regions were localized: a direct and an indirect HSPG-dependent 
binding domain (Hundt et al., 2001). On RPSA, the direct binding domain is located between 
amino acid (aa) 161 and 179, and the indirect HSPG-dependent binding domain is presumed 
to be located between aa 180 and 285. On PrP
C
, the domain between aa 144 and 179 was 
identified as the direct binding domain to RPSA and the domain between aa 53 and 93 as the 
indirect HSPG-dependent binding domain to RPSA (Hundt et al., 2001) (Figure 1.7). Later 
research proved that RPSA not only acts as a receptor for the cellular prion protein (PrP
C
) but 
also for the pathogenic isoform (PrP
Sc
) (Gauczynski et al., 2006). Furthermore, Nikles and 
colleagues (2008) showed that RPSA and PrP not only colocalize on the cell surface but also 
intracellularly. Several in vitro experiments suggest that RPSA is necessary for prion 
propagation since blocking the receptor with antisense RPSA messenger ribonucleic acid 
(mRNA), RPSA specific silencing RNA (siRNA) or RPSA specific antibodies resulted in 
reduction or even abolishing of PrP
Sc
 accumulation (Leucht et al., 2003). Moreover, when a 
scrapie-infected neuroblastoma cell line was transfected with an RPSA mutant composed 
solely of the extracellular domain, PrP
Sc 
propagation was inferred probably due to the 
entrapment of the prion proteins (Vana and Weiss, 2006).  
As most natural TSE infections are transmitted orally, the uptake of prion proteins in the 
intestine was closely investigated. Shmakov and colleagues (2000) proved that the RPSA 
receptor is expressed on the apical brush border of the epithelial cells of the small intestinal 
mucosa. Consequently, enterocytes might play a role in the internalization of infectious prion 
proteins. Furthermore, Morel and colleagues (2005) showed that the RPSA proteins of human 
enterocytes internalized bovine PrP
Sc 
particles of BSE infected cows. Later studies reported 
that the internalization of prion proteins by the RPSA receptor, located on enterocytes, is not a 
general feature but that the uptake is dependent on the prion strain and on the species of the 
receptor (Kolodziejczak et al., 2010). Prion proteins from CWD for example colocalize with 
RPSA on human enterocytes but not on bovine, ovine or porcine enterocytes. On the other 
hand, ovine enterocytes failed to colocalize with prion proteins of BSE nature but did 
colocalize with ovine prion proteins of scrapie nature. 
1.2.2 Function of RPSA 
RPSA was first isolated as a laminin binding protein in 1983 by three independent 
laboratories (Lesot et al., 1983; Malinoff and Wicha, 1983; Rao et al., 1983). The receptor 
had a molecular mass of 67 kDa and bound laminin with a high affinity and specificity and 
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was therefore named 67 kDa laminin receptor (67 LR). Later on, it became clear that the 
coding mRNA sequence of the protein was 888 bp long, resulting in a peptide with a 
calculated molecular mass of approximately 33 kDa. This precursor protein with a real mass 
of 37 kDa was therefore named 37 kDa laminin receptor precursor (37 LRP). These two 
isoforms are the most frequent observed isoforms but several other isoforms, corresponding to 
different maturation states of the receptor, exist. Simoneau and colleagues (2003) detected a 
44, 60, 67 and 220 kDa form in the mouse brain and proved that all these isoforms bind to PrP. 
Furthermore, the distribution of the protein in the rat brain differs largely between the 67 kDa 
isoform and the 37 kDa isoform (Baloui et al., 2004). On subcellular level, the protein is 
located in multiple compartments of the cell where it exhibits a variety of functions. 
1.2.2.1 Nucleus 
RPSA is present in the nucleus and is tightly associated with both the nuclear envelope and 
chromatin (Sato et al., 1996). Moreover, it binds to the core histones H2a, H2b and H4 and 
also weakly to deoxyribonucleic acid (DNA) itself (Kinoshita et al., 1998). The localization 
of RPSA in the nucleus was later on confirmed with fluorescence microscopy (Nikles et al., 
2008). It is suggested that the transportation to the nucleus is dependent of midkine but further 
research to confirm this finding is necessary (Van Everbroeck et al., 2006).  
1.2.2.2 Cytoplasm 
In the cytoplasm, the RPSA protein used to be called p40 protein and plays the role of a 
normal ribosomal protein. A ribosomal protein is a protein that is part of the ribosome, a 
structure located in the cytoplasm and responsible for translation. Ribosomes are either free or 
attached to the rough endoplasmic reticulum. The eukaryotic ribosome consists of a small 
subunit (40S) and a large subunit (60S). Each subunit is composed of ribosomal proteins and 
ribosomal RNA (rRNA). A typical mammalian ribosome is composed of four RNA molecules 
and plus minus 80 ribosomal proteins (Zhang et al., 2002). RPSA is associated with the small 
subunit 40S. Ribosomal proteins are facilitating the RNA folding, protecting them from 
nucleases and coordinating the protein synthesis. Some have extra-ribosomal functions 
(Saunders et al., 2006). The ribosomal proteins are essential for the survival of the cell hence 
their genes are classified as housekeeping genes.  
1.2.2.3 Cell surface 
The RPSA protein, alternatively called the 37 kDa/ 67 kDa high affinity laminin receptor, acts 
as a high affinity receptor for laminin in normal cells as well as in cancer cells (Lesot et al., 
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1983; Malinoff and Wicha, 1983; Rao et al., 1983). The expression of RPSA is upregulated in 
multiple cancer types like breast, lung, prostate and cervical carcinomas (Nelson et al., 2008). 
The level of upregulation is often positively correlated with the level of aggressiveness or 
metastatic potential of the tumor cells since laminin is a protein of the extracellular matrix and 
the ability of cancer cells to attach to the basement membranes is essential to metastasis 
formation (Ardini et al., 1998). Furthermore, RPSA binds also to elastin, another extracellular 
matrix protein (Acutis et al., 2006). 
The protein also acts as receptor for different viruses like Dengue virus, Sindbis virus, 
Venezuelan Equine Encephalitis virus and Adeno-associated-viruses and various bacteria like 
Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenza (Tio et al., 
2005; Malygin et al., 2009; Orihuela et al., 2009).  
Recently, it was proven that the receptor is involved in the internalization of amyloid-beta 
peptides (Da Costa Dias et al., 2014). The deposition and accumulation of those peptides in 
the cell is causing neurotoxicity leading to Alzheimer's disease. Moreover, knock-down of 
RPSA by antibodies leads to the reducing of shedding of amyloid-beta peptides and could 
therefore be used as new therapeutic tools in the treatment of Alzheimer's disease (Jovanovic 
et al., 2013).  
At last, anti-thrombotic, anti-allergic and anti-obesity effects are ascribed to the binding of 
RPSA to green tea catechin epigallocatechin-3-gallate (EGCG) and moreover, the binding 
inhibits cell growth resulting in cancer prevention (Fujimura, Umeda et al. 2008; Umeda, 
Yano et al. 2008; Holy, Stampfli et al. 2009; Ku, Chang et al. 2009). 
1.2.3 Genetic characteristics of ribosomal proteins 
1.2.3.1 General features of ribosomal proteins 
The RPSA protein is part of a large family, consisting of at least 79 different ribosomal 
proteins in mammals. They are all constitutive genes; in other words, they are expressed in 
every cell in every tissue. The ribosomal proteins exhibit a lot of similar characteristics on 
genetic level. The sequences of the ribosomal proteins of different species have a high 
similarity among eukaryotes. Wool and colleagues (1995) compared the amino acid 
sequences of related rat and human ribosomal proteins and found that the average sequence 
identity is 99%. They also have similar characteristics on mRNA level, namely mostly short 
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mRNA sequences of 700 basepairs on average. One ribosomal protein is encoded by a single 
functional gene and multiple pseudogenes, resulting in large gene families. 
1.2.3.2  Pseudogenes of ribosomal proteins 
In humans, an in silico genome-wide analysis with BLAST detected over 2000 ribosomal 
protein pseudogenes (Zhang et al., 2002). Pseudogenes were only included in the study if they 
produced transcripts longer than 70% of the full-length ribosomal protein peptide. Only 16 
pseudogenes were duplicated and 2090 were processed pseudogenes. The majority of the 
processed pseudogenes are almost full-length. If the sequence is missing a part, it is at the 5’ 
site. The reverse transcription that is necessary to create the double stranded sequence from 
mRNA starts at the poly-A tail and therefore, premature truncation is more likely to occur at 
the 5’ site of the complementary DNA (cDNA) sequence. On average, each human ribosomal 
protein has 26 (3-145) pseudogenes. No correlation was found between the number of 
pseudogenes and the extra-ribosomal function of the ribosomal protein.  
A pseudogene is a sequence in the genome that has a high similarity with a paralogous gene 
but is not functional. The functionality is lost due to failure of transcription or translation; or 
because the encoded protein does not exhibit the same functions anymore as the active 
functional gene. They have been found in the genomes of bacteria, plants, insects and 
vertebrates. Pseudogenes arise in two manners: either by duplication or by retrotransposition 
(Figure 1.8) (Mighell et al., 2000). 
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Figure 1.8: Pseudogene formation. The formation of duplicated pseudogenes by duplication 
of DNA and the formation of processed pseudogenes by reverse transcription of spliced 
mRNA are represented schematically.  
 
1.2.3.2.1 Duplication 
Duplication is a frequent event that is responsible for the expansion of gene families. New 
gene family members arise by the duplication of genomic DNA (gDNA) segments (Maeso et 
al., 2012). Because whole segments are duplicated, the promoter is mostly also duplicated and 
these genes are hence transcribed. During evolution some duplicated genes acquire other 
functions due to mutations; others become silenced and therefore become pseudogenes. They 
reside mostly close to their functional paralog. 
1.2.3.2.2 Retrotransposition 
Pseudogenes arisen by the insertion of a double stranded sequence generated from mRNA are 
known as processed pseudogenes or retro-pseudogenes. Therefore, they are characterized by 
the absence of introns, the presence of the remains of a poly-A tail at the 3’ site and no 
upstream regulatory or transcription factor sites at the 5’ end. The insertion can occur in any 
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part of the genome. Processed pseudogenes are dispersed and randomly distributed over the 
chromosomes of a species (Zhang et al., 2002). The majority of the retrotransposed genes 
become non-functional but some are maintained as a functional intronless gene. They use the 
promoter of an unrelated gene to get transcribed. If they are inserted in an intron of a gene 
they can be transcribed together with that gene (Mighell et al., 2000). 
If they are inserted in an exon of a gene, they can have a deleterious effect and often do not 
persist over time. On the contrary, pseudogenes located in loci where they are harmless will 
persist. Therefore, pseudogenes are typically clustered together in a region of the genome. 
They will undergo genetic drift as there is no apparent selection pressure. Nevertheless, 
Balakirev and Ayala (2003) found that the accumulation of mutations is lower than expected 
and there are more synonymous mutations than non-synonymous mutations. This points 
towards some sort of selection pressure and function for the pseudogenes.  
Genes that give rise to processed pseudogenes have generally some characteristics in common. 
They are mostly widely expressed, highly conserved, have a short coding sequence and are 
GC poor (Goncalves et al., 2000; Devor and Moffat-Wilson, 2003). To become fixed in the 
genome, retroelements have to fulfill multiple requirements. First of all, pseudogenes have to 
arise in the germ line. Consequently, retrotransposition has to occur of a gene that is 
expressed in germinal tissue. It is more likely that widely expressed genes are expressed in 
germ cells than tissue specific ones. Goncalves and colleagues (2000) suggest that high 
conservation is a consequence of the germ line expression. Mutations in these genes will have 
greater effect than in genes expressed in diploid cells and will therefore disappear under 
selection pressure. The reverse transcription process or insertion mechanism is probably more 
efficient for short sequences than for long sequences. The low GC content of the genes is 
probably also due to the higher efficiency of reverse transcriptase of GC poor mRNA 
(Goncalves et al., 2000).  
1.2.3.2.3 Possible functions of pseudogenes 
Even if pseudogenes are not transcribed, they can have a function. Some pseudogenes act as 
reservoirs for generating genetic diversity (Balakirev and Ayala, 2003). A well-known 
example is the immunoglobulin gene family. Immunoglobulin gene diversity is generated by 
gene conversion between sequences of different alleles but also between sequences of a gene 
and its pseudogene. Although the pseudogenes are not transcribed or translated, it seems that 
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the sequences are maintained by selection for their functional role in antibody diversity 
(McCormack et al., 1993).  
The gene conversion between gene and pseudogene can also have a deleterious effect on the 
functional paralog. If a part of the functional gene is replaced by a part of a non-functional 
pseudogene, this can give rise to a disease. An example in humans is congenital adrenal 
hyperplasia where most of the mutations present in the steroid 21-hydroxylase gene 
(CYP21A2) result from recombination between the gene and its pseudogene (Concolino et al., 
2012).  
Some pseudogenes are transcribed but not translated. Duplicated pseudogenes are mostly 
duplicated together with their transcriptional control element. Processed pseudogenes on the 
other hand do not have their own promoter and have to use transcriptional control elements of 
an unrelated gene nearby. Therefore, pseudogenic transcripts can occur at a higher or lower 
level than their functional paralog and can also be transcribed in other tissues than the 
functional gene. Mostly these transcripts are not translated and nonfunctional but some do 
exhibit a function (Balakirev and Ayala, 2003). Recent studies also showed that some 
pseudogenes can regulate the effect of microRNA on the ancestor gene by competing for 
microRNA binding (Swami, 2010). Until now, no such function has been found for RPSA 
pseudogenes. 
They also can be transcribed from the opposite strand. These transcripts can possibly have a 
function as inhibitor of their paralogous gene. They can regulate the expression by binding as 
an antisense RNA to the sense RNA of the functional gene (Muro and Andrade-Navarro, 
2010). In summary, pseudogenes are not functionless and could therefore be favored by 
natural selection (Balakirev and Ayala, 2003). This raises the question if pseudogenes that are 
functional still can be named ‘pseudogenes’. 
1.2.3.2.4 Practical implications of the presence of pseudogenes 
The existence of pseudogenes hinders the molecular study of the corresponding functional 
gene. Especially pseudogenes with high similarity to their functional paralog can interfere 
with gene identification and annotation studies (sequencing, mapping), gene variation studies 
(polymorphism detection, genotyping, association analysis) and expression studies of the 
functional gene. When using genomic DNA in molecular studies, processed pseudogenes can 
be differentiated by intron-trapping strategies. On the other hand, when conducting expression 
Chapter 1: General introduction 
34 
 
studies, differentiation between the mRNA of the protein-coding gene and a transcribed 
pseudogene is more difficult.  
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1.3 Prion disease therapies 
Despite the amount of research that has been carried out to detect a therapy to cure patients 
suffering from prion diseases, none of the candidate molecules could fulfill the high demands 
required of an effective therapy. Prion diseases are hard to battle as the diseases are having 
long incubation periods in which the CNS tissue is getting damaged without clinical 
symptoms. Moreover, as most of the pathology of prion diseases is located in the brain, 
therapeutic molecules have to be able to pass the blood-brain barrier (BBB). Therefore, they 
have to be small and lipophilic or need to be injected directly intracerebrally, with a high risk 
of complications (Weissmann and Aguzzi, 2005).  
There are two different strategies to develop a new therapeutic drug. The first conventional 
strategy is to screen putative therapeutic agents that already exist in the hope that they have a 
therapeutic impact in one way or another on prion diseases. Their exact working mechanism 
is not known in the test phase. A second innovative strategy is to develop a new compound, 
based on the pathogenesis of the disease by blocking one aspect of the prion pathway. Both 
strategies are discussed below. 
1.3.1 Conventional therapies  
Quinacrine is a human medicine used as antimalarial drug and known to cross the BBB. In 
vitro, it was described as efficient inhibitor of PrP
Sc
 formation. In vivo, on the other hand, no 
therapeutic effect was seen following quinacrine treatment of CJD patients. Animal studies 
also failed to demonstrate efficacy in the treatment of TSEs (Barret et al., 2003; Doh-ura et al., 
2004). 
Pentosan polysulfate is a second candidate drug that is normally used as anticoagulant and to 
treat interstitial cystitis. It can not cross the BBB and is therefore administered intracerebrally. 
Studies in TSE infected mice reported prolonged incubation times up to 160% (Doh-ura et al., 
2004). The drug was also tested in vivo in human patients and isolated case reports are 
suggesting that prolonged survival times can be ascribed to this drug (Parry et al., 2007). 
More detailed research on this drug is needed.   
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1.3.2 Innovative therapies 
1.3.2.1 Based on the PrP protein 
The functional role of PrP is not exactly understood. Bueler and colleagues (1992) showed 
that PrP knock-out mice are viable and are developing normal, although neuronal defects are 
detected. Moreover, PrP knock-out mice seem to be resistant to infection with prion diseases 
(Bueler et al., 1993; Mallucci et al., 2003). Deletion of the prion protein is therefore a putative 
therapeutic strategy but this has to be achieved in other ways than knock-out in human 
patients. The prion protein can for instance be neutralized by immunization or RNA 
interference.  
Passive immunization with PrP antibodies as prion therapy seems promising. In vitro studies 
showed that infected cells could be cured by administering a certain antibody (Enari et al., 
2001). Moreover, intraperitoneal infected mice, treated with PrP antibodies, had significant 
longer incubation periods than non-treated mice (White et al., 2003). However, these 
antibodies can not cross the BBB. Therefore, recent research is testing camelid PrP antibodies, 
known for their small structure and ability to cross the BBB (Jones et al., 2010).  
Active immunization was also studied by several research groups and promising results were 
published. Prolonged incubation times were observed in mice in several studies, using 
recombinant PrP, PrP dimers, retroviruses expressing PrP or mucosal immunity stimulating 
vaccines (Sigurdsson et al., 2002; Gilch et al., 2003; Schwarz et al., 2003; Goni et al., 2005; 
Nikles et al., 2005). 
At last, RNA interference can block the expression of the PrP protein. In vitro studies were 
successful in inhibition of the prion propagation (Daude et al., 2003). In vivo studies were 
already performed in mice and prolonged survival times, the decline of clinical symptoms and 
histological changes in the CNS were reported (Pfeifer et al., 2006; White et al., 2008).  
1.3.2.2 Based on the RPSA protein 
During the last decade, several in vivo experiments to develop innovating therapies based on 
the blocking of the RPSA receptor were published. A schematic overview of the different 
strategies to block the receptor is given in Figure 1.9. In summary, RNA interference, by 
mRNA degradation or inhibition of translation, blocking of the RPSA receptor by antibodies 
or trapping of PrP
Sc
 molecules by a RPSA decoy mutant, are therapeutic pathways that were 
recently examined. 
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In the various studies on mice with diverse experimental designs (use of antibodies, antisense 
mRNA, siRNA or trans-dominant negative mutant) a decrease in the levels of PrP
Sc
 
accumulation up to 82% was found in a number of organs (Zuber et al., 2007b; Zuber et al., 
2008a; Zuber et al., 2008c; Pflanz et al., 2009a; Pflanz et al., 2009b). Nevertheless, the in 
vivo results vary depending on the used method: in the studies using single chain antibodies, 
there was no effect on the incubation or survival time (Zuber et al., 2008a; Zuber et al., 2008c) 
but in studies using siRNA, decoy mutants or polyclonal antibodies, significant prolongation 
of the pre-clinical phase or survival time after the first symptoms, have been reported (Zuber 
et al., 2007b; Pflanz et al., 2009a; Pflanz et al., 2009b).  
 
 
Figure 1.9: Prion therapies using RPSA (adapted from Vana et al. 2009). Several strategies 
can be employed to interfere with either the expression of RPSA or binding of PrP to RPSA. 
To ablate RPSA expression an antisense RNA and a small interfering RNA (siRNA) approach 
have been used. To interfere with the binding of PrP, both the polyclonal anti-RPSA antibody 
W3 (immunoglobulin structure) and the single chain (scFv) anti-RPSA antibody S18 (single 
chain antibody structure) have been used. As an alternative therapeutic system, an RPSA 
decoy mutant has been used to interfere with the PrP propagation. 
38 
 
  
 39 
 
 
 
 
 
 
 
 
Chapter 2: Objectives
 40 
 
 
 
 
 
  
Chapter 2: Objectives 
41 
 
TSEs are a group of fatal neurodegenerative diseases of which many aspects of the 
pathogenesis and pathology are studied extensively. However, a lot of facets of these fatal 
diseases are still unknown, e.g. the exact function of PrP
C
, the exact PrP
C
-PrP
Sc
 conversion 
mechanism and the strength of certain species barriers. As knowledge is missing, it is not easy 
to take adequate measures to lower the incidence of the diseases or to develop effective 
therapies.  
Sheep is an important species in prion disease research. Apart from animal welfare and 
economic losses for the breeding industry, TSE is also posing a major threat for public health 
because sheep can get experimentally infected with BSE, a zoonotic TSE causing vCJD in 
humans. The spread of PrP
Sc
 aggregates in the body of TSE infected sheep is extensive as 
opposed to the minor spread in cattle (majority in CNS). Moreover, in vitro experiments 
revealed that the virulence of BSE increases after passage through sheep, leading to a more 
efficient transmission to sheep, cattle and human (Priem et al., 2014). In sheep, a major 
association between polymorphisms in PRNP and scrapie susceptibility was found. Selective 
breeding appeared to be a promising tool to create scrapie resistant flocks. After a decade of 
selective breeding however, it is clear that no PRNP genotype is associated with 100% TSE 
resistance. Therefore, it is essential to evaluate other candidate genes that can possibly play an 
additional role in scrapie susceptibility. Moreover, the study of other genes involved in the 
TSE pathway can lead to the development of new treatments for prion diseases in humans. 
The ribosomal protein SA is a protein that is involved in many pathological processes 
including TSE. The protein is responsible for the binding, internalization and propagation of 
PrP
Sc 
in the cell
 
and is therefore a promising candidate gene. Structural mutations in this gene 
could lead to loss of binding affinity of RPSA to PrP and therefore have an effect on the 
pathogenesis and propagation of the disease. 
However, the genetic background of RPSA in sheep was not yet characterized. It has to be 
expected that the genetic background in sheep is complex because previous studies in other 
species have shown that RPSA is a member of a multicopy gene family. The general objective 
of this study was to analyze the complex RPSA gene family in sheep in order to be able to 
characterize the active functional full-length gene and to evaluate functional variations in that 
gene. 
More specifically, our first objective was to identify and sequence all the members of the 
RPSA gene family in sheep and the genomic region surrounding them (Chapter 3). The 
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presence of pseudogenes in a genome can interfere with molecular studies of the 
corresponding functional gene. Furthermore, some RPSA gene family members besides the 
active full length gene could be functional and could also have an effect on TSE 
susceptibility. It is therefore essential to identify all RPSA family members, to know their 
sequence and their chromosomal location.  
Our second objective was to identify all transcribed RPSA gene family members and assess 
their functionality (Chapter 3.1). It is important to know which RPSA gene family member is 
transcribed and which derived protein can interact with PrP and play a role in the prion 
pathway.  
The third objective was to perform a mutation detection of transcribed RPSA gene family 
members in the Flemish sheep population (Chapter 3.2). Amino acid polymorphisms in the 
binding region of PrP could have a major influence on the binding affinity of the receptor and 
indirectly on the life cycle of PrP
C
 and the propagation of PrP
Sc
.  
The fourth objective was to perform a binding affinity study between all transcribed RPSA 
gene family members that showed amino acid polymorphisms in the binding region and the 
PrP protein. If altered binding affinity of a variant of an RPSA gene family member can be 
detected, genetic association studies between this mutation and TSE susceptibility could be 
performed and if there would be an association present, selection towards this mutation would 
strengthen the selective breeding program towards less scrapie susceptible sheep. Moreover, 
the altered binding affinity between the RPSA and PrP protein, created by a structural 
mutation, could serve as a model for new TSE therapies in humans. If the ovine RPSA protein 
is highly conserved and no structural variability exists, a second option is to investigate if 
structural variability of PrP could also affect the binding between the RPSA and PrP protein. 
To assess binding differences between RPSA and PrP molecules of different species and in 
the case of sheep, different genotypes, recombinant proteins of humans, cattle and sheep are 
required (Chapter 4).   
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3.1.1 Abstract 
3.1.1.1 Introduction 
The ribosomal protein SA (RPSA), previously named 37-kDa laminin receptor precursor/67-
kDa laminin receptor (LRP/LR) is a multifunctional protein that plays a role in a number of 
pathological processes, such as cancer and prion diseases. In all investigated species, RPSA is 
a member of a multicopy gene family consisting of one full length functional gene and several 
pseudogenes. Therefore, for studies on RPSA related pathways/pathologies, it is important to 
characterize the whole family and to address the possible function of the other RPSA family 
members. The present work aims at deciphering the RPSA family in sheep. 
3.1.1.2 Results and Discussion 
In addition to the full length functional ovine RPSA gene, 11 other members of this multicopy 
gene family, all processed pseudogenes, were identified. Comparison between the RPSA 
transcript and these pseudogenes shows a large variety in sequence identities ranging from 
99% to 74%. Only one of the 11 pseudogenes, i.e. RPSAP7, shares the same open reading 
frame (ORF) of 295 amino acids with the RPSA gene, differing in only one amino acid. All 
members of the RPSA family were annotated by comparative mapping and fluorescence in 
situ hybridization (FISH) localization. Transcription was investigated in the cerebrum, 
cerebellum, spleen, muscle, lymph node, duodenum and blood, and transcripts were detected 
for 6 of the 11 pseudogenes in some of these tissues. 
3.1.1.3 Conclusions 
In the present work we have characterized the ovine RPSA family. Our results have revealed 
the existence of 11 ovine RPSA pseudogenes and provide new data on their structure and 
sequence. Such information will facilitate molecular studies of the functional RPSA gene 
taking into account the existence of these pseudogenes in the design of experiments. It 
remains to be investigated if the transcribed members are functional as regulatory non-coding 
RNA or as functional proteins. 
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3.1.2 Introduction 
The ribosomal protein SA (RPSA), previously named 37-kDa laminin receptor precursor/67-
kDa laminin receptor (LRP/LR) is a multifunctional protein. In the nucleus it binds to DNA 
via the histones H2A, H2B and H4 (Kinoshita et al., 1998), in the cytoplasm it is associated 
with the 40S ribosomal subunit (Nelson et al., 2008), and at the cell surface it acts as a 
receptor for a number of components i.e. laminin, elastin, the green tea catechin EGCG, 
carbohydrates, the prion protein, different viruses like Dengue virus, Sindbis virus, 
Venezuelean Equine Encephalitis virus and Adeno-associated-viruses and various bacteria 
like Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenza (Nelson et 
al., 2008; Orihuela et al., 2009). 
The receptor is involved in many pathological processes. It is upregulated in cancer and its 
expression is positively correlated with metastasis and the aggressiveness of tumour cells in 
breast, ovary, lung, prostate and cervical carcinomas (Nelson et al., 2008). In the context of 
prion disease, RPSA is needed for the internalization and propagation of prion proteins 
(Nelson et al., 2008). Several therapeutic approaches based on down-regulation (e.g. via RNA 
interference) and/or blocking (e.g. with specific antibodies or trans-dominant negative 
mutants) of the receptor result in reduced adhesion, migration and invasion of tumour cells 
(Zhou et al., 2006; Zuber et al., 2008b; Chen et al., 2009; Li et al., 2009), and reduced 
accumulation of the pathogenic isoform of the prion protein in many organs involved in the 
pathogenesis of transmissible spongiform encephalopathies (Zuber et al., 2007b; Zuber et al., 
2008a; Zuber et al., 2008c; Pflanz et al., 2009a; Pflanz et al., 2009b), leading to a significant 
prolongation of the pre-clinical phase or survival time after the occurrence of the first 
symptoms (Zuber et al., 2007b; Pflanz et al., 2009a; Pflanz et al., 2009b). 
In addition, it has been shown that binding of green tea catechin EGCG to RPSA causes anti-
thrombotic, anti-allergic and anti-obesity effects and mediates cancer prevention by inhibiting 
cell growth (Fujimura et al., 2008; Umeda et al., 2008; Ku et al., 2009; Holy et al., 2010), 
thus RPSA is a target in new therapies against this large group of diseases. 
However, in order to unravel the multiple pathways in which RPSA is involved and to 
develop RPSA-based diagnostic/therapeutic tools, it is necessary first to characterize in full 
detail the complex genetic background of RPSA. Indeed, previous studies have shown that in 
most investigated species thus far, RPSA is a member of a multicopy gene family consisting 
of one full length functional gene and several pseudogenes (e.g. at least 63 in man; Table 3.1). 
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Moreover, the presence of pseudogenes in a genome can interfere with molecular studies of 
the corresponding functional gene (i.e. sequencing, mapping, polymorphism detection, 
genotyping, association analysis, mRNA expression studies, ...) and transcribed pseudogenes 
can produce endogenous small interfering RNAs that regulate the expression of the functional 
gene or other genes (Khachane and Harrison, 2009).  
 
Table 3.1: Number of RPSA pseudogenes identified in different species. 
Species Processed 
pseudogenes 
/transcribed 
Duplicated 
pseudogenes 
Reference 
Homo sapiens 63
(a)
 / 1
(b)
 / 
(Balasubramanian et al., 2009)
(a)
 
(Asano et al., 2004)
(b)
 
Bos taurus 60
(c)
 / 1
(b)
 / (Germerodt et al., 2004)
(b)
 
Sus scrofa 2
(b)
 1
(b)
 (Knorr et al., 2007)
(b)
 
Mus musculus 45
(a)
 / 2
(b)
 / 
(Balasubramanian et al., 2009)
(a) 
(Fernandez et al., 1991)
(b)
 
Gallus gallus / / (Bignon et al., 1991)
(b)
 
Ovis aries / 1
(b)
? (Marcos-Carcavilla et al., 2008)
(b)
 
Pan troglodytes 52
(a)
 
 
(Balasubramanian et al., 2009)
(a)
 
Rattus norvegicus 45
(a)
 
 
(Balasubramanian et al., 2009)
(a)
 
(a)
In silico genome-wide screening studies in species with fully sequenced genomes. 
(b)
In vitro studies 
screening genomic or cDNA library, 
(c)
In silico genome-wide screening study carried out in this paper. 
 
Previously, Marcos-Carcavilla and colleagues (2008) have postulated the existence of an 
ovine RPSA pseudogene. The present work aims at providing a genetic basis for future 
studies on RPSA related pathways/pathologies in sheep by identifying and characterizing the 
complex RPSA gene family. 
 
3.1.3 Results and Discussion 
3.1.3.1 BAC screening and STS content mapping  
Eight different primer pairs were designed in conserved ovine RPSA regions identified by 
aligning previously described mRNA and expressed sequence tag (EST) sequences, 
representing each exon at least once. Using these primers, 34 bacterial artificial chromosome 
(BAC) clones, containing members of the RPSA family, were isolated by polymerase chain 
reaction (PCR) screening of the INRA sheep BAC library (Vaiman et al., 1999), with an 
annealing temperature (Ta) that was at least 8°C lower than the melting temperature (Tm) of 
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the primers to allow primer mismatches (Additional file 3.1). By sequence tagged site (STS) 
content mapping, performed with 54 unique STS primer pairs that were designed from the 68 
BAC End Sequences (BES) [GenBank:GS375851-GS375918], 6 mini-contigs could be 
constructed and another 6 single BAC clones could be identified, each containing a different 
family member of the ovine RPSA family (Figure 3.1 and 3.2; Additional file 3.2). 
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Figure 3.1: Comparative mapping of the region of RPSA in sheep and cattle. The ovine BAC 
mini-contig is drawn in part A. Triangles represent BAC end sequences; pointing towards the 
3'-end of the BAC clone. Black triangles represent BES from which primers were designed to 
construct the mini-contig. White triangles are BES from which it was impossible to design 
STS-primers. Black squares show overlaps between BES and other BAC clones. Black circles 
represent genes annotated by PCR. Annotated sequences are shown in a plane map in part B. 
The position and orientation of the genes present in the syntenic region of Bos taurus are 
represented with arrows (C). 
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Figure 3.2: Comparative mapping of the region of 11 RPSA pseudogenes in sheep and cattle. 
The ovine BAC mini-contigs are drawn in part A. Triangles represent BAC end sequences; 
pointing towards the 3'-end of the BAC clone. Black triangles represent BES from which 
primers were designed to construct the mini-contigs. White triangles are BES from which it 
was impossible to design STS-primers. Encircled triangles represent BES that are not 
annotated. Black squares show overlaps between BES and other BAC clones. Black circles 
represent genes annotated by PCR. Annotated sequences are shown in a plane map in part B. 
The position and orientation of the genes present in the syntenic region of Bos taurus are 
represented with arrows (C).  
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3.1.3.2 Characterization of the 12 RPSA gene family members  
Each member of the RPSA gene family was sequenced by direct sequencing on BAC DNA 
starting with the PCR primers as sequencing primers and finishing by primer walking. The 
sequences were assembled with the CAP3 program (Huang and Madan, 1999) and annotated 
with BLAST (Altschul et al., 1990). 
The full length functional gene, which was first described by Marcos-Carcavilla and 
colleagues (2008), was present in one of the contigs composed of 6 BAC clones 
[GenBank:GQ202529]. We have sequenced for the first time, the complete intron 3, 
comprising 8846 bp, which like the other introns, has consensus acceptor and donor splice 
sites. The full length ovine RPSA gene consist thus of 13287 bp. 
Besides the full length functional gene, 11 other RPSA gene family members were sequenced 
[GenBank: GQ202530-GQ202540]. A schematic representation of all the family members, 
based on sequence alignments with the full length functional gene (Additional file 3.3), is 
included in Figure 3.3. They all are considered as processed pseudogenes and in accordance 
with RPSA pseudogenes described in other species, they have been assigned the names 
RPSAP1-RPSAP11. Pseudogenes arise in 2 different manners: either by retrotransposition of 
the mRNA of the ancestral gene into the genome or by duplication of genomic DNA (Mighell 
et al., 2000). The first class is known as processed pseudogenes, the second one as non-
processed pseudogenes. The majority of the pseudogenes is processed and originates from 
housekeeping genes, with ribosomal protein genes as largest subgroup (Mighell et al., 2000; 
Zhang et al., 2004). As processed pseudogenes are inserted without internal promoter, they 
are released from selection pressure and accumulate mutations during evolution leading to 
frameshift mutations and/or premature stopcodons which prevents them of encoding a 
functional protein (Ding et al., 2006). In some cases nevertheless, they have obtained a 
(regulatory) function (Khachane and Harrison, 2009). 
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Figure 3.3: Schematic overview of the RPSA (pseudo)genes. The genomic structure of the 
ovine RPSA gene is drawn in part A, the mRNA of the RPSA gene is drawn in part B. Part C 
represents the genomic structure of the different RPSA pseudogenes. The squares represent 
exons and the lines stand for introns. The coding sequence (CDS) is drawn in yellow; the 
untranslated sequences in green. The blue squares are parts of the pseudogene sequence that 
are analogous with the exons of the RPSA mRNA. The pink squares symbolize interspersed 
sequences and the white gaps deletions. SNORA62 is represented as a black square. Start 
codons and stop codons, analogous with the ones of RPSA, are represented by a dotted line. 
 
To investigate this possibility, all the RPSA pseudogenes were further characterized in silico 
and their main characteristics are listed in detail in Table 3.2 and 3.3. Comparison with the 
full length RPSA gene transcript shows that the pseudogenes vary greatly both in structure 
and sequence identity. These differences range from structurally identical pseudogenes 
sharing 99% sequence identity (RPSAP7) to pseudogenes lacking half of the gene (RPSAP8, 
RPSAP9 and RPSAP10) or containing many deletions throughout the whole gene sharing a 
sequence identity of only 74% (RPSAP2).  
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Table 3.2: Characteristics of RPSA (pseudo)genes-general characteristics 
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RPSAP1 GQ202530 93% ATG/TAA Yes No Yes 83 aa (1-83) 
95%/95% 
RPSAP2 GQ202531 74% ATG/TAA Yes Yes Yes 70 aa (34-103) 
56%/63% 
RPSAP3 GQ202532 80% ATG/TAA No Yes Yes 84 aa (1-84) 
82%/87% 
RPSAP4 GQ202533 83% No/No No Yes N/A 90 aa (10-99) 
48%/53% 
RPSAP5 GQ202534 90% ATG/TAA Yes Yes Yes 129 aa (10-138) 
91%/92% 
RPSAP6 GQ202535 80% No/No No Yes N/A 106 aa (160-
265) 
65%/70% 
RPSAP7 GQ202536 99% ATG/TAA Yes No No 295 aa (1-295) 
99%/99% 
RPSAP8 GQ202537 86% No/TAA Yes Yes N/A 82 aa (177-258) 
80%/80% 
RPSAP9 GQ202538 98% ATG/No No No No 171 aa (1-171) 
100%/100% 
RPSAP10 GQ202539 94% No/TAA Yes Yes N/A 57 aa (174-230) 
95%/100% 
RPSAP11 GQ202540 76% No/No Yes Yes N/A 107 aa (185-
291) 
46%/49% 
RPSA= ribosomal protein SA,  ORF=open reading frame, aa= amino acid 
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Table 3.3: Characteristics of RPSA (pseudo)genes-repeats and transcription 
Gene Interspersed 
repeats in gene 
Flanking 
repeats/family/class 
Transcription 
RPSAP1 / / / 
RPSAP2 / 3': L2c/L2/LINE 
Cerebrum, cerebellum, spleen, 
muscle, lymph node and 
duodenum 
RPSAP3 / 
5': ERV3-16A3_I-
int/ERVL/LTR 
Cerebrum 
3': CHR-2A/tRNA-
Glu/SINE 
RPSAP4 
ART2A/RTE-
BovB/SINE 
5': L1M3/L1/LINE 
Cerebrum, cerebellum and spleen 
3': L1M3/L1/LINE and 
(CA)n/Simple_repeat and 
L1M3/L1/LINE 
RPSAP5 / / Cerebrum 
RPSAP6 
ART2A/RTE-
BovB/SINE 
3': CHRL/tRNA-
Glu/SINE and tRNA-
Glu-GAA/tRNA 
/ 
RPSAP7 
Bov-
tA1/BovA/SINE 
5': LTR16A2/ERVL/LTR 
/ 3': L1MEc/L1/LINE and 
L1M3/L1/LINE 
RPSAP8 / / Cerebrum and cerebellum 
RPSAP9 / 
5': MIR/SINE and 
MIR/SINE and 
L1M2/L1/LINE / 
3': L1M2/L1/LINE and 
(CATA)n/Simple_repeat 
RPSAP10 / / / 
RPSAP11 / 5': Bov-tA2/BovA/SINE 
Cerebrum, cerebellum, spleen, 
muscle, lymph node and 
duodenum 
 
Analysis of the primer binding sites in the pseudogenes showed that in our experimental 
design the screening primers could anneal to targets down to 83% sequence identity, even in 
the case of RPSAP2. 
All BAC clones and thus all RPSA family members were isolated with at least 2 primer pairs 
and there was no concordance between the number of BACs in a mini-contig and the level of 
sequence identity with RPSA. We conclude that it is most likely that we have isolated all the 
ovine RPSA pseudogenes sharing a high level of sequence identity and that therefore can 
interfere with the functional RPSA gene in genetic studies. 
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To obtain a first indication of possible functionality, in silico ORF and promoter prediction 
analysis were carried out. 
The pseudogene RPSAP7 is the only member sharing almost an identical ORF with the full 
length RPSA gene. The only one amino acid difference (amino acid 31: D → G) is located in 
the intracellular part of the receptor that does not belong to any binding site. All the other 
pseudogenes either lack the start codon or contain a premature stop codon due to nonsense or 
frameshift mutations. The size of the potential ORF of the other pseudogenes varies and the 
largest reaches 171 amino acids sharing 100% identity with RPSA (Table 3.2). Most ORFs lie 
in the intracellular region of RPSA (amino acid 1-101). In case of RPSAP6, RPSAP8, 
RPSAP10 and RPSAP11, the ORF contains a part of the binding sites of RPSA with PrP 
(direct binding aa 161-180; indirect binding aa 180-285) (Hundt et al., 2001), but most of 
them have a low level of amino acid identity. 
In silico promoter analysis predicted a possible promoter for RPSAP1, RPSAP2, RPSAP4, 
RPSAP8, RPSAP9 and RPSAP10 (Additional file 3.4). A consensus polyadenylation signal is 
present in 7 of the 11 pseudogenes (including RPSAP7). 
Repeated sequences were identified with Repeatmasker (Repeatmasker Webserver) and 
showed that 4 pseudogenes are disrupted by interspersed repeats belonging to the class/family 
SINE/RTE-BovB, SINE/BovA, tRNA and SINE/tRNA-Glu, and that 7 pseudogenes were 
flanked by repeats belonging to the SINE, LINE, tRNA, LTR and simple repeat classes. 
According to Zhang and colleagues (2004), processed pseudogenes are mostly found in 
genomic regions with a relatively low GC content, as do LINE repeats. Thus, it is not 
surprising that such repeats are present in the regions flanking many of the RPSA 
pseudogenes. 
A remarkable observation is that part of the RPSA intron 4, containing the small nucleolar 
RNA (snoRNA) SNORA62, is present in the RPSAP8 and RPSAP9 pseudogenes. Therefore, 
these pseudogenes can be considered as semi-processed pseudogenes, which are very rarely 
reported and defined by Zhang and colleagues (2008) as "pseudogenes that contain remnant 
introns, which suggests that they were derived from semi-processed RNA transcripts". 
SnoRNAs are encoded in introns of ribosomal protein genes and other housekeeping genes 
(Lestrade and Weber, 2006; Zemann et al., 2006), and are responsible for both sequence-
specific methylation and pseudouridylation of RNA (Reichow et al., 2007). SNORA62 is an 
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H/ACA box snoRNA that guides the isomerization of uridine into pseudouridine (Lestrade 
and Weber, 2006) by binding with 2 uridines of 28S rRNA (U3830 and U3832). Sequence 
comparison shows that these important regions display mutations in RPSAP8 but are 
conserved in RPSAP9 (Figure 3.4). As a result, the paralog of SNORA62 is probably not 
functional in RPSAP8. In RPSAP9 on the other hand, the paralog of SNORA62 could, in 
addition to SNORA62, exhibit the function of pseudouridylation in case of transcription 
(Zemann et al., 2006). Marcos-Carcavilla and colleagues (2008) had already postulated the 
existence of a non-processed pseudogene that differed from the active RPSA gene by the 
absence of a G at position 29 of intron 4. Thus, we hypothesize that this previously mentioned 
non-processed pseudogene is in fact the semi-processed pseudogene RPSAP9, because it 
lacks the G at position 29 of intron 4 and it can co-amplify with the active RPSA gene 
because of its high sequence identity (98%). 
 
 
Figure 3.4: Alignment of the snoRNAs in RPSA, RPSAP8 and RPSAP9. The ACA-box, H-box 
and 28S rRNA U3830 and U3832 PU guide are highlighted in yellow. 
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3.1.3.3 Annotation of the mini-contigs by comparative mapping and FISH 
localization  
The genomic regions containing the 12 members of the RPSA gene family were further 
investigated by sequence comparison of both BES and internal BAC sequences using NCBI 
BLAST (Altschul et al., 1990) (Figure 3.1 and 3.2). Sixty-two of the 68 BES were annotated 
while the remaining 6 contained either too many repeat sequences or no specific orthologous 
sequence to allow annotation. The different characteristics (length, repeat sequences and 
genes) are listed in the Additional file 3.5. Based on sequence annotation results, 40 ovine 
genes, of which 37 have not been described in sheep yet, could be mapped on the mini-
contigs by comparative mapping with the bovine genome (Figure 3.1 and 3.2). The primers 
used to perform the PCR for annotating the genes, together with another 18 optimized primer 
pairs, amplifying genes not present in the mini-contig but flanking the genomic region of the 
different RPSA family members, are listed in Additional file 3.6. 
The 11 pseudogenes were localized by FISH on different sheep chromosomes (Table 3.4 and 
pictures of the FISH experiments in Additional file 3.7). All the localizations confirmed the 
positions predicted from the genes present in the mini-contigs by using the online tool Virtual 
Sheep Genome Assembly v2.0. 
As expected, most RPSA pseudogenes are located in intergenic regions except 3 found in the 
intron of other genes (RPSAP2 in DAP3; RPSAP4 in LOC789684 and RPSAP5 in EPHA6; 
Table 3.4), which confirms the fact that most processed pseudogenes persist in regions where 
they do not cause deleterious effects (Mighell et al., 2000).  
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Table 3.4: Location of RPSA (pseudo)genes. 
Gene Chromosomal location Ortholog Bos taurus 
RPSA 
OAR19q13 intergenic between LOC515736 and 
MOBP 
ortholog BTA22: GeneID: 
281898 
RPSAP1 
OAR20q22 intergenic between LOC401242 and 
LOC538046 
no 
RPSAP2 OAR1p13 in intron 2 DAP3 
ortholog BTA3: not 
annotated yet 
RPSAP3 
OAR 5q22.3 intergenic between PCDHB15 and 
TAF7 
ortholog BTA7: not 
annotated yet 
RPSAP4 OAR19q12 in intron 1 LOC789684 
ortholog BTA22: not 
annotated yet 
RPSAP5 OAR1q21-q22 in intron 2 EPHA6 no 
RPSAP6 
OAR17q26prox intergenic between PXN and 
SIRT4 
ortholog BTA17: not 
annotated yet 
RPSAP7 
OAR23q23prox intergenic between RBBP8 and 
LOC100138286 
no 
RPSAP8 
OAR7q12-q13 intergenic between SERINC5 and 
GNPNAT1 
no 
RPSAP9 
OAR1p37 intergenic between LOC100141009 
and LOC522241 
no 
RPSAP10 
OAR17q21prox intergenic between MDK and 
LOC783956 
no 
RPSAP11 
OAR23q21 intergenic between ZNF24 and 
LOC767868 
ortholog BTA24: GeneID: 
100138378 
RPSA=ribosomal protein SA; BTA=Bos taurus chromosome; OAR= Ovis aries chromosome 
 
The genomic region around the ovine RPSA family members show conserved synteny (same 
genes, same orientation and same order) with the bovine genome. LOC784055, probably a 
processed pseudogene of GOLPH3L located in intron 2 of GON4L on Bos taurus 
chromosome (BTA) 3 and expected in the ovine mini-contig containing RPSAP2, was the 
only bovine ortholog not present in sheep and therefore is most probably a bovine specific 
pseudogene. The flanking sequences (500 bp upstream and 500 bp downstream) of each 
RPSA pseudogene were blasted against the bovine and human genome. Out of the 11 
identified orthologous bovine sequences, 5 were interrupted by a bovine RPSA pseudogene; 
in the 6 other cases, the upstream sequence continued into the downstream sequence without 
an interruption of a pseudogene. The latter was also the case with the 11 orthologous human 
sequences. Thus we found 5 orthologous bovine RPSA pseudogenes but no human orthologs 
(Table 3.5).  
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Table 3.5: Bovine orthologs 
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RPSA BTA22 NC_007320.3 
12885045-
12898467 
100% 
CDS 96% RPSA: 12886519-
12898467 Gene 87% 
RPSAP2 BTA3 NC_007301.3 
16411109-
16410143 
75% 91% 
DAP3 intron 2: 
16430465-
16408264 
RPSAP3 BTA7 NC_007305.3 
51802201-
51801057 
81% 95% 
LOC786980: 
51801077-
51802181 
RPSAP4 BTA22 NC_007320.3 
2925069-
2925867 
78% 91% 
LOC789684: 
2840530-3050478 
RPSAP6 BTA17 NC_007315.3 
65883767-
65884909 
81% 92% 
LOC783583: 
65881027-
65884941 
RPSAP11 BTA24 NC_007325.3 
22831525-
22830341 
77% 91% 
LOC100138378: 
22830405-
22834810 
RPSA=ribosomal protein SA; BTA=Bos taurus chromosome; CDS= coding sequence 
 
A BLAST analysis of the bovine genome (reference assembly, based on Btau_4.0) with both 
ovine and bovine RPSA and RPSA pseudogene sequences identified 60 potential RPSA 
family members (Additional file 3.8). These included the only bovine pseudogene described 
so far, designated as RPSAP1 and located on BTA4 (Germerodt et al., 2004). No ortholog of 
this pseudogene was found in sheep. Twenty-five sequences were annotated as 'similar to 
Ribosomal protein SA pseudogene' but only one corresponded to an ovine ortholog i.e. 
RPSAP11. To date, the 35 remaining sequences have not been annotated, but we have 
identified an ovine ortholog in 4 cases (Table 3.4 and 3.5; Additional file 3.8). Apart from 
RPSAP3, the ORF of the ovine and bovine orthologs differ substantially, suggesting that there 
is no selective pressure to conserve the ORF of these pseudogenes. 
No bovine ortholog was found for the 6 sheep RPSA pseudogenes sharing 86 to 99% 
nucleotide identity with RPSA whereas the 5, for which a bovine ortholog was identified, 
only displayed 74-83% sequence identity with RPSA. As the amount of mutations 
accumulated by the pseudogenes during evolution can be used to infer their age (Zhang et al., 
2002), it's not surprising that the first group, consisting of recently arisen pseudogenes which 
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have not yet accumulated many mutations, is lineage specific and that the pseudogenes of the 
latter group, comprising the oldest pseudogenes, all have a bovine ortholog. In addition, none 
of the 11 ovine pseudogenes were orthologous with any of the 63 annotated human RPSA 
pseudogenes. As a result, we can conclude that all 11 ovine RPSA pseudogenes detected 
originated after the divergence between primates and ungulates and 6 of these after the 
divergence between cattle and sheep. 
3.1.3.4 Transcription profiling by RT-PCR  
To investigate whether some of the ovine RPSA pseudogenes were potentially functional, 
transcription profiling was performed by reverse transcription PCR (RT-PCR) for all sheep 
RPSA family members in 7 tissues (Figure 3.5) i.e. cerebrum, cerebellum, spleen, muscle, 
lymph node, duodenum and blood. To be sure that no genomic DNA was present in the RNA 
samples, they were treated with DNase and checked by minus RT control PCR (Additional 
file 3.9). A minus RT control PCR is a RT-PCR without reverse transcriptase. This means that 
only genomic DNA can amplify because the RNA in the sample is not reverse transcribed into 
cDNA. We performed the minus RT control PCR with actin, beta (ACTB) primers, which is a 
housekeeping gene that is expressed in each tissue. The ACTB primers give a different 
amplicon length on gDNA and cDNA.  
For 8 members of the RPSA family, gene-specific primers could be designed and their 
specificity was proven by checking that the primers did not amplify any other RPSA family 
member using the respective unique BAC clones as template (Additional file 3.10). Because 
RPSA, RPSAP1, RPSAP7 and RPSAP9 share a high level of sequence identity, no specific 
primers could be designed for these RPSA family members, they were tested with aspecific 
primers. All generated amplicons were sequenced. RPSA was expressed in all tested tissues. 
This agrees with the results of Marcos-Carcavilla and colleagues (2008) and Qiao and 
colleagues (2009). None of the pseudogenes was transcribed in blood. RPSAP2 and 
RPSAP11 were transcribed in all other tested tissues, while RPSAP3, RPSAP5 and RPSAP8 
were only transcribed in one or more brain regions and RPSAP4 was transcribed in brain 
regions and spleen. RPSAP6 and RPSAP10 were not expressed in any of the tested tissues. In 
the case of RPSAP1, RPSAP7 and RPSAP9, tested with aspecific primers which all could 
also amplify RPSA, we generated amplicons which, after sequencing, turned out to be all 
RPSA transcripts. Thus we can conclude that RPSAP1, RPSAP7 and RPSAP9 are not 
expressed or at a very low level compared to the active RPSA gene. Therefore it would be 
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interesting to do reverse transcription quantitative real-time PCR (RT-qPCR) with specific 
probes in order to be sure if the pseudogenes are expressed at very low levels or not at all. No 
clear relationship between the transcription profile of the various pseudogenes and the in 
silico prediction of possible promoters was observed. For instance, RPSAP10 is not expressed 
in any tissue tested although we did predict a promoter in the upstream sequence. Thus it may 
be possible that RPSAP10 is expressed in other tissues not examined in this study or that it 
has a low level of transcription. In addition, the in silico predicted promoter might not act as a 
cis-regulatory element in vivo. In contrast, RPSAP3 is transcribed in certain brain regions 
although we did not predict any promoter, probably because the promoter is located more 
upstream than the region analyzed here. 
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Figure 3.5: Transcription profile of the RPSA gene family members. Marker (M) is the 
Hyperladder V or IV (Bioline). Samples are cerebrum (Cbu), cerebellum (Cbe), spleen (Sp), 
muscle (Mu), lymph node (Ln), duodenum (Dd), blood (SA) genomic or BAC DNA (+) and 
water (-). The bands lower than 100 bp, which are also present in the negative controls, are 
primer dimers, a complex of primers that have hybridized to each other because of strings of 
complementary bases in the primers.  
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3.1.4 Conclusions 
In addition to the already described ovine RPSA gene, we have identified 11 members of the 
ovine RPSA gene family, and designated them RPSAP1-RPSAP11 since they are all 
considered to be processed pseudogenes. The flanking genomic regions of each RPSA family 
member was analyzed by annotating the constructed BAC contigs, which revealed 40 genes 
(of which 37 had not been previously described in sheep) based on comparative mapping. All 
these regions show conserved synteny with the orthologous bovine counterparts and the 
locations were confirmed by FISH. Five pseudogenes have a bovine counterpart. In silico 
analysis predicted the presence of 55 more RPSA pseudogenes in the bovine genome. 
Compared to the RPSA transcript, RPSA pseudogenes differ significantly both in structure 
and sequence identity, ranging from structurally identical pseudogenes sharing 99% sequence 
identity to pseudogenes lacking half of the gene or containing many deletions throughout the 
whole gene, sharing only 74% sequence identity. A remarkable result is that at least 6 of the 
11 pseudogenes are transcriptionally active. However, whether these transcripts are functional 
as regulatory non-coding RNA or as functional proteins remains to be investigated. 
In previous studies, 1 to 3 RPSA pseudogenes per species, discovered while screening with 
the intention to isolate the full length functional RPSA gene, were characterized. Furthermore, 
the number of RPSA pseudogenes in 4 species with fully sequenced genomes was determined 
by genome-wide in silico screening but those pseudogenes were not characterized (Table 3.1). 
Here we report in detail the characterization of the RPSA gene family in a species. A strategy 
was developed to isolate all the ovine RPSA pseudogenes sharing a high level of sequence 
identity with RPSA. We screened with 8 different primers representing each exon at least 
once and with a Ta that was at least 8°C lower than the Tm. All BAC clones were positive for 
at least 2 primer pairs and there was no concordance between the number of BAC in a mini-
contig and the level of sequence identity with RPSA. Therefore, we conclude that it is most 
likely that we have isolated all the ovine RPSA pseudogenes that could interfere with the 
functional RPSA gene in genetic studies. The discrepancy between the numbers of ovine 
RPSA pseudogenes found (11) and the numbers described in genome-wide screenings (45-61) 
might be explained by the low sequence identity of most pseudogenes found in silico. In Bos 
taurus for instance, 51 of the 60 pseudogenes share an overall nucleic acid identity with the 
bovine RPSA gene beneath 80% (Additional file 3.8). Due to our experimental design, 
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pseudogenes with a low sequence identity were not isolated since it is not likely that those 
pseudogenes would interfere with molecular studies on the functional full length RPSA gene. 
In conclusion, we describe 11 ovine processed RPSA pseudogenes. This knowledge on their 
structure and sequence will facilitate the molecular genetic studies of the functional gene 
since it will now be possible to take into account the existence of the pseudogenes in the 
design of such studies. 
3.1.5 Materials and Methods 
3.1.5.1 Construction BAC mini-contigs  
The ovine INRA BAC library, consisting of 90.000 clones with an average insert length of 
123 kilo base pairs (kb) and a genome equivalent of 3.4, was screened by PCR (Vaiman et al., 
1999). The primers were designed using Primer3, based on conserved regions in the sheep 
RPSA gene (Rozen and Skaletsky, 2000). The conserved regions were detected by 
comparison of all ovine ESTs available in GenBank that shared similarity with the published 
ovine mRNA sequence of RPSA [GenBank: EF649775] with BLAST and ClustalW (Altschul 
et al., 1990; Larkin et al., 2007) PCR was conducted with Faststart Taq DNA Polymerase 
(Roche). PCR conditions were 5 min at 95°C, 40 cycles of 30 s at 95°C, 30 s at 50°C and 1 
min at 72°C, and a final 10-min elongation step at 72°C. Thirty-nine superpools, each 
consisting of 44 pools (24 plates, 8 rows and 12 columns), were screened. Each positive 
combination was verified by colony PCR. 
All isolated BACs were grown in a 200 ml culture from which DNA was purified with the 
Qiagen Plasmid Midi kit (Qiagen) according to the manufacturer's instructions. The BAC 
ends were sequenced with the universal primer (UP) (5'-
CGACGTTGTAAAACGACGGCCAG-3') and reverse primer (RP) (5'-
CACAGGAAACAGCTATGACCATGATTACG-3') primers with 1 μg of purified BAC 
DNA as template. Unique STS primer pairs (Additional file 3.2), based on the BESs, were 
used to screen all isolated BACs and to construct mini-contigs. 
All sequencing was performed with the Big Dye Terminator mix (Applied Biosystems) and 
analyzed on an ABI-3730xl Analyser (Applied Biosystems).  
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3.1.5.2 Characterization of RPSA gene family members  
The primers used to screen the INRA BAC library were used as initial sequence primers to 
sequence the RPSA family member in one BAC of each mini-contig by direct sequencing. 
The obtained sequence was then used to develop new sequencing primers until the whole 
gene and an additional ± 500 bp upstream and ± 500 bp downstream of the sequence showing 
similarity with RPSA, was sequenced. If the screening primer did not work as sequencing 
primer, the amplicon generated with the screening primer was cloned into a pCR 2.1 vector 
with the TA Cloning Kit (Invitrogen) and the vector was transformed in DH5α Competent 
Cells (Invitrogen). The insert was then sequenced with UP and RP primers. All sequences 
were assembled into continuous sequences with CAP3 and analyzed with FGENESH and 
NCBI ORF Finder (Huang and Madan, 1999; FGENESH Webserver; NCBI ORF Finder 
Webserver). Promoter sequences were searched with CISTER, Neural Network Promoter 
Prediction, FPROM and TFsearch (Frith et al., 2001; Neural Network Promoter Prediction 
Webserver; TFsearch Webserver). 
3.1.5.3 Annotation of the mini-contigs by comparative mapping  
All mini-contigs were annotated by comparing the BESs against bovine and human genomic 
sequences with NCBI BLAST (Altschul et al., 1990). Internal sequences were also annotated 
by PCR with primers based on bovine sequences of genes that were expected to be present in 
the mini-contig. All amplicons were verified and repeats were detected with Repeatmasker 
(Repeatmasker Webserver). 
3.1.5.4 FISH  
Fluorescent in situ hybridization was performed at INRA in Jouy-en-Josas (France). To 
prepare the probes, BAC DNA was extracted according to standard protocols and purified 
with the S.N.A.P. K1900-01 Miniprep kit (Invitrogen). DNA was then nick-translated with 
biotin-14-dATP (BioNick 18247-015 labeling system, Invitrogen) and mixed with 100× total 
sonicated herring sperm DNA and 100× total sonicated sheep DNA. Subsequently, it was 
precipitated with ethanol, slightly dried and resuspended in hybridization buffer. 
For R-banded sheep chromosomes, embryo fibroblast cell cultures were synchronized with an 
excess of thymidine and treated with 5-bromo-2'-deoxyuridine during the second half of S 
phase (Hayes et al., 1991). 
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FISH, signal detection and R-banding were performed as previously described (Hayes et al., 
1992). Briefly, labeled probes were denatured at 100°C for 10 min and pre-hybridized at 37°C 
for 30 to 60 min before hybridization to the chromosomes. Chromosome identification and 
band numbering followed the standard sheep ideogram reported in ISCNDB2000 (Cribiu et 
al., 2001). 
3.1.5.5 Transcription profiling  
Fresh tissue samples were obtained from a commercial sheep slaughterhouse, frozen in liquid 
nitrogen immediately after slaughtering, crushed into powder and frozen at -80°C. Total RNA 
was isolated with the Aurum Total RNA Fatty and Fibrous Tissue kit (Bio-Rad) as described 
in the instruction manual. Subsequently, a minus RT-PCR was performed with actin, beta 
(ACTB) primers on 1 μl RNA to confirm the absence of any DNA contamination (Additional 
file 3.9) as previously described (Lampo et al., 2007). If DNA was still present in the sample, 
an additional DNase treatment with RQ1 RNase-free DNase (Promega) and a spin column 
purification with Microcon YM-100 (Millipore) were carried out. 
The RNA concentration and purity of the samples were measured with the Nanodrop ND-
1000 Spectrophotometer (Isogen) and the RNA quality was determined by evaluation of the 
28S and 18S ribosomal bands on a 0.8% agarose gel. 
Then, 0.2-1 μg RNA was converted into cDNA with iScript cDNA synthesis kit (Bio-Rad) 
using random and oligo dT primers. A confirmation PCR on 10× diluted cDNA with ACTB 
primers (giving a different amplicon length on gDNA and cDNA) was performed. 
Specific primers, based on the aligned sequences of the different RPSA family members 
(Additional file 3.3) were designed for 8 members of the RPSA family and specificity was 
proven (see above). 
Due to the high level of nucleotide sequence identity among RPSA, RPSAP1, RPSAP7 and 
RPSAP9, it was not possible to develop specific primers for these, but we were able to 
develop several primer pairs which amplified different combinations of 2 to 6 RPSA family 
members. One primer for instance amplifies RPSA, RPSAP1, RPSAP7 and RPSAP11; 
another RPSA and RPSAP7 and a third one RPSA, RPSAP1, RPSAP5 RPSAP7 and 
RPSAP11. The obtained amplicons were sequenced to determine/confirm which 
(pseudo)gene was transcribed.  
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3.1.6 Additional files 
Primer name Sequence  Location Tm 
(°C) 
Amplicon length 
non processed 
(processed) (bp) 
OariRPSA 1F GGAGCCCTTGATGTCCTG exon 2 58 975 (156) 
OariRPSA 1R GGTCCTCTTCAGGTTTATGATGT exon 3 
  
OariRPSA 2F CCGGGAACCTTCACTAACCA exon 4 61 948 (224) 
OariRPSA 2R GCGAGCATCCACCACATC exon 5 
  
OariRPSA 3F GAGGAGTTTCAGGGCGAATG exon 6 61 301 (150) 
OariRPSA 3R TTCAGTGGAAGGCTGAGCAC exon 7 
  
OariRPSA 4F CCCTTGATGTCCTGCAAA exon 2 58 3179 (331) 
OariRPSA 4R GCCTGGATCTGGTTAGTGAAG exon 4 
  
OariRPSA 5F CGTCAGTGTCATCTCCTCCA exon 3 60 10118 (429) 
OariRPSA 5R GCCTGCTCTTCCTTTTCAATC exon 6 
  
OariRPSA 6F CACCAACCTTGACTTCCAAA exon 2 58 11590 (732) 
OariRPSA 6R GGCTGAGCACTCCAGTCTT exon 7 
  
OariRPSA 7F CCTTCCGTGCCCATTCA exon 6 61 340 (130) 
OariRPSA 7R CAACTCGCTGGTGGTTCCT exon 7 
  
OariRPSA 8F CGAGCTGTGCTGAAGTTTGC exon 4 61 338 (N/A) 
OariRPSA 8R GGCCTCAACTCCAAGCTCTA intron 4 
  
Additional file 3.1: Primers used for screening of the INRA BAC library. Characteristics of 
primers used for screening of the INRA BAC library: sequence, location, melting temperature 
and amplicon length. 
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Primername Sequence forward primer (5'-3')  
Sequence reverse primer (5'-3') 
Annealing 
temperature (°C) 
Amplicon length (bp) 
OariBAC15H1F GCCAGGGTAGATTTAGATGTGTT 61 
  GGGGCAAGAAGAGAGAGTAGTG 260 
OariBAC15H1R CCGCAAGCTGTTTCAAGT 61 
 GGGCCATGACAGTATTTATCTT 293 
OariBAC74D12F AGGGAACAGTGCGTCTACAAA 64 
 TGTCTGAATCTGGTTAGTGAAGGT 214 
OariBAC79C3F TCCCTCTTTACAACTTCCCATC 61 
 TGAACACAGAACACAGCCAAA 127 
OariBAC79C3R CGTCCTACCTCTGGAGACGA 64 
 CCGGCTAATCTGGATCTGTG 184 
OariBAC177E6F GGAGCACTGGCAAACAAA 60 
 TGAACCCACTTCCACTTACC 336 
OariBAC177E6R CAATGTTCGGGATGGTAAG 62 
 TTCTTGGTGTCAGGAGTGG 439 
OariBAC187G9F  GGGAAGCAGTCAGGAGGTT 60 
 TCCCTCAGATATTACCCTGGA 203 
OariBAC187G9R TAGTCATTCCCATCTTTCCA 62 
 TTTTGTAGACGCACTGTTCC 196 
OariBAC201D10F TCTTCTCACCCCACTCAC 60 
 GATGTTTACTCCTCATAGCAAC 234 
OariBAC203A8F GGGCTTCATCCTTACATTCAC 60 
 CTTCCCACAACCCAACTATG 107 
OariBAC203A8R AGGGAGGGAGAGACTGATT 62 
 GAAAGTGAAACCAACAGTAAGG 111 
OariBAC206C7F TGCTTGCGAGACAGAACACTGA 60 
  GTCGCCTGTTGCCCACTTCT 250 
OariBAC206C7R CATACGCAAGGGATGCAGTAA 62 
 GCTTAAATGGTCGGTGCAGT 174 
OariBAC239A10F CCTACGGCTGATTCCTGTTG 63 
  CTTCTCCCTGCATCCCATCT 183 
OariBAC239A10R CAGTTAGTACAGGGAAGTTTTGTTC 63 
 GATTTGGGTATATGCTCTAGGTTC 201 
OariBAC325C3F  CATGTGCGGCTTGCATCTGT 63 
 CGGCAACCAAACTTACGGTGAT 169 
OariBAC325C3R CTTCTTCAGTTATCGGTCTTTCC 64 
 ACCAGGATTGGAGGATTCAG 167 
OariBAC340G12F CCATATCAATAAGCACTCCA 64 
 GACAAATGAGCTTTTCCAC 156 
OariBAC340G12R CCTTACTGTTGGTTTCACTTTC 62 
 GCCCATTGCTAGTTTATCTG 257 
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Primername Sequence forward primer (5'-3')  
Sequence reverse primer (5'-3') 
Annealing 
temperature (°C) 
Amplicon length (bp) 
OariBAC343G5F TTGTGACTACTGAGATACATCAAGG 60 
 CATTCACCTCAGCTTGTTTCTT 109 
OariBAC343G5R TTCCAGGTATTAAGCAACAGTGTGTGA 62 
 TCTTCCCAGTCTCCTGTGTGAGG 104 
OariBAC357D10R GAACTGACCTTACGTGGTTGG 62 
 GAGTTTGGGGTTTGTGTTAGTG 190 
OariBAC398A10F CCTGGAGCAATGAACAACAA 60 
 AAAACCAAGCAGCAGAAACC 180 
OariBAC398A10R CTACTGGGGCGTGAGCTTGT 64 
 TGTTTGATTGGGTCTGCCTCT 159 
OariBAC418E6F GCTTCTAGGCAACATCCCTAC 62 
 TGCAACCTCTAACTCTGCATT 671 
OariBAC418E6R GTAAGATTTGGGGTGCTGTG 62 
 CTGGTCACTTTTCTGCTTCCT 296 
OariBAC419E10R CCTTTCATACAACCCATCC 62 
 GAGAGTTCATCCACATCCAC 219 
OariBAC426B6F TTTTGGGAGGGGAGGTATG 62 
 AGGAACGGATTTTGGTGTTC 184 
OariBAC426B6R AAACAAGGATAAACCCAGGAGAAG 62 
 CGTGTGGTAGAGGCAGTGGT 234 
OariBAC439D12F TTCTACCTTCTGTCCCTTATCTTC 62 
 TTTTACCGCCCTGTGACT 330 
OariBAC439D12R CAGGGAACAGAGGAACAGCA 64 
 CTTGGAAACTGAAAACACCTACAGA 220 
OariBAC457G3F GGTGAACTAGCCTGTGAAGAGGAG 62 
 CCCTGATTGGTTAATTGGTAGATTG 101 
OariBAC457G3R AGGGAAGTGGGAGGAGAGAA 62 
 GCACCAGCACAAGTAAGACAAG 243 
OariBAC487G6F CTGATGCTCCTGCAAAATAGG 63 
 GGGTTCAAAGCTACTGGTATTCA 189 
OariBAC487G6R AGACTGCTAACGCCACATAAC 63 
 CCAAGAAACTAGGCTGAGAGA 128 
OariBAC494A7F CTGAGGAATATGTGGCATTACG 62 
 TTCACCCTCCTTGATGAATTG 101 
OariBAC494A7R GACAAGGGAAATCAGGATAGAC 62 
 CACCTGTGACTTTATCGTTTCT 186 
OariBAC523F6F CCCTGTTTCATTTTGTGCTTGTG 63 
 TCCCTACCCTTGCCCTCTTG 159 
OariBAC523F6R GGATAGGGGAGAACAAGACA 63 
 TGGAACTCACAACCACCA 243 
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Additional file 3.2: STS primers BES. Characteristics of primers used for STS content 
mapping: sequence, annealing temperature and amplicon length. 
 
Primername Sequence forward primer (5'-3')  
Sequence reverse primer (5'-3') 
Annealing 
temperature (°C) 
Amplicon length (bp) 
OariBAC538A12F GCTTTCCAGTGATAGGAGCAA 63 
 AGCCCCACATACAACCAGA 220 
OariBAC538A12R TTGTTTCGCTCCCTTTGCT 62 
 CCAAGTCATCCCTCCTCCTT 250 
OariBAC569F2F CTCACATAATTTCATCCTCTCC 63 
 CCAAATGGATTCTTTCACAC 168 
OariBAC569F2R GAGGCTCGCCATGTCTACTT 63 
 CGTGGAAAACCGATAAAACTTC 152 
OariBAC583D12F TTCCATCTGTTTTCCTTCAC 62 
 GTGAGAGTTTTCAGACAATGG 111 
OariBAC802A10F GAGGTTCTCATTTGGTTGCTCATT 63 
 CAGGCAGGAAGGCACAGTAGA 555 
OariBAC802A10R ATGCTCCAGTTTTCTCCATCTAC 62 
 GCTCCTCACCTGCCTTCTT 237 
OariBAC850F2F AAGGGTAGGACTTGTAGGTGT 62 
 CCATTCAGCATCATCTCTC 349 
OariBAC852H10F ATCTTTTGGCAGGGGAGT 62 
 AACTTGGACTTGAGGGACAT 338 
OariBAC852H10R TCACCGCTTTCGCTCCTTAC 66 
 ACCATCTGTCTTTGATTGAGTGGA 162 
OariBAC890H12R TGTCTTAGGCTTGTCATGTT 64 
 CTGACCCAACTGCTCTTT 332 
OariBAC891D11R GACAGCACAGGATGACAAAA 63 
 CCACCAGAGAAGTCCCAGT 138 
OariBAC912D11F AACTGGTAGGTTATGTGTCGTG 62 
 AAGGCACTCTGGGAGATAAA 299 
OariBAC912D11R TCCGCTTTTCTTTTCCATCT 62 
 ATAACTGAACCCCTTTGCTCTAC 142 
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Additional file 3.3: Alignment of the mRNA of the ovine RPSA gene with 11 RPSA 
pseudogenes. The startcodon, stopcodon, poly-adenylation signal exon-exon junctions and 
interspersed repeats are highlighted in yellow. The primers used to screen the INRA BAC 
library are highlighted in green. 
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Pseudogene Promoter Sequence Score Promoter Transcription 
start site 
RPSAP1 AATCTACTCTATAACTAAGACGGCCC
AGCAGGATGCTTGTGTTTTTCTAC 
0.93  -155 
RPSAP2 AAAGTTTACTTTTATACACTGCCCAGA
GAAAGATCCATACAGCAATGTTC 
0.81  24 
RPSAP4 AAGGGAACAGTGCGTCTACAAAAGGG
AGCATGGTGGCATCTCCATCATGA 
0.99 TATA 
box 
207 
RPSAP8 TCTGAGATCCTAAAAAGGGCGTGCAC
CCAGCGGGTCTGACGTGGTGGATG 
1.00  294 
RPSAP9 ACGCTTCTCTTTAAAAATTCCCCAGCT
ACAGAGGACCTCCATAGACATTT 
1.00 TATA 
box 
166 
RPSAP10 TGTATTTCTTTAAAAATATCTCACGCA
GTTTTTCCTAAAGATAAATAAAT 
0.83  -192 
Additional file 3.4: In silico promoter prediction. The in silico predicted promoter sequence 
is shown with the transcription start site highlighted in bold and italic. Furthermore, the 
score of the prediction, identification of the promoter and location of the transcription start 
site in the sequence is shown. 
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15H1F 798 Cow: NC_007301 DAP3 89 53 364-634: L1MC4a 
(LINE /L1); 715-797: 
MER20 (DNA/hAT-
Charlie) 
15H1R 811 Cow: NC_007324   94 96 262-348: L1MA8 
(LINE/L1); 357-811: 
L1M2 (LINE/L1) 
74D12F 800 Sheep: EF649775 LOC789684 76 49 1-295: L1M3 (LINE/L1)  
74D12R 650 Cow: NC_007320  LOC789684 93 100 118-650: BovB 
(LINE/RTE-BovB) 
79C3F 565 Cow: NC_007305  94 100 No repeats 
79C3R 768 Cow: XM_583591 PCDHGA4 96 61 No repeats 
155C9F 716 Cow: NC_007301 ASH1L 93 97 72-395: MER2B 
(DNA/TcMar-Tigger); 
397-712: L1MB8 
(LINE/L1) 
155C9R 484 Cow: NC_007301 GON4L 92 100 1-150: L1M5 
(LINE/L1); 151-276: 
SINE2-2_BT 
(SINE/tRNA-Glu); 277-
325: L1M5 (LINE/L1); 
354-466: CHR2C_Ttr 
(SINE/tRNA-Glu) 
177E6F 620 Cow: NC_007320  84 99 500-620: L1-2_Ttr 
(LINE/L1) 
177E6R 648 Cow: NC_007320 RPSA 91 98 215 -413: MLT1J 
(LTR/ERVL-MaLR) 
187G9F 630 Cow: NC_007320   94 100 No repeats 
187G9R 576 Sheep: EF649775 LOC789684 84 33 11-250: L1M3 
(LINE/L1) 
201D10F 1047 Cow: NC_007320  93 92 No repeats 
201D10R 1049 Sheep: EF394773 RPSA 99 87 167 -351: Bov-tA3 
(SINE/BovA) 
203A8F 580 Cow: XM_001254336 PCDHGA7 95 41 No repeats 
203A8R 442 Cow: NC_007305  94 99 148-270: L1_Art 
(LINE/L1) 
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206C7F 830 Cow: NC_007324 LOC538046 88 93 No repeats 
206C7R 1002 Cow: NM_001034551  91 78 No repeats 
228H5F 297 Cow: NC_007320  LOC789684 94 97 16-271: L1MCa 
(LINE/L1) 
228H5R 223 N/A  N/A N/A 1-223: ART2A 
(SINE/RTE-BovB) 
239A10F 600 Cow: NC_007305  95 100 No repeats 
239A10R 645 Cow: NC_007305 PCDHGB3 94 100 149-172: (TTTC)n 
(Simple_repeat) 
325C3F 359 Cow: NC_007308  92 81 No repeats 
325C3R 750 Cow: NC_007308  90 99 82-394: L1MEc 
(LINE/L1) 
340G12F 566 Cow: NC_007305 PCDHGB3 94 97 458-481: (TTTC)n 
(Simple_repeat) 
340G12R 387 Cow: NC_007305  94 100 150-272: L1_Art 
(LINE/L1) 
343G5F 503 Cow: NC_007299  EPHA6 94 100 173-317: L2a (LINE/L2) 
343G5R 266 Cow: NC_007299  EPHA6 92 100 No repeats 
357D10F 121 Cow: NC_007305  93 100 4-131: MER4B-int 
(LTR/ERV1); 132-152: 
MER21-int 
(LTR/ERVL)  
357D10R 494 Human: BC152415 PCDHGB4 
PCDHGA8 
69 97 133-201: (TA)n 
(Simple_repeat) 
398A10F 480 Cow: NC_007325  94 88 No repeats 
398A10R 890 Cow: NC_007325  90 100 32-235: Bov-tA1 
(SINE/BovA); 641-781: 
MIR (SINE/MIR) 
418E6F 767 Cow: NC_007301  91 97 44-117: SINE2-1_BT 
(SINE/tRNA-Glu); 247-
361: MIR (SINE/MIR); 
424-566: CHRL1_BT 
(SINE/tRNA-Glu) 
418E6R 711 Human: BX647589 LOC100141009 70 33 111-296: Bov-tA2 
(SINE/BovA) 
419E10F 500 Cow: NC_007320  100 99 4-71: L1M2 (LINE/L1); 
244-497: MLT1J1 
(LTR/ERVL-MaLR) 
419E10R 776 Cow: NC_007320  91 100 91-222: L2b (LINE/L2) 
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426B6F 871 Cow: NC_007324  LOC401242 94 99 550-686: BOV-A2 
(SINE/BovA); 768-851: 
SINE2-1_BT 
(SINE/tRNA-Glu) 
426B6R 763 Human: AL671879 LOC538046 72 77 229-351: SINE2-1_BT 
(SINE/tRNA-Glu) 
439D12F 445 Cow: NC_007322  90 97 415-441: (TG)n 
(Simple_repeat) 
439D12R 784 Cow: NC_007322  91 100 6-238: L1MC5 
(LINE/L1); 610-782: 
MER5B (DNA/hAT-
Charlie) 
457G3F 699 Human: AY882013 GPX5 73 100 288-316: AT_rich 
(Low_complexity); 318-
699: L1MB2 (LINE/L1) 
457G3R 670 Human: 
NC_000006.11  
 67 81 No repeats 
466E9F 746 Cow: NC_007315  91 92 62-598: ART2A 
(SINE/RTE-BovB); 599-
746: BovB (LINE/RTE) 
466E9R 632 Cow: NC_007315  91 88 1-197: BovB 
(LINE/RTE-BovB); 199-
632: ART2A 
(SINE/RTE-BovB) 
487G6F 730 Cow: NC_007299 EPHA6 94 80 311-334: (CTG)n 
(Simple_repeat); 337-
594: BOV-A2 
(SINE/BovA) 
487G6R 643 N/A  N/A N/A 5-151: ERV2-1B-
LTR_BT (LTR/ERVK); 
148-489: ERV2-1C-
LTR_BT (LTR/ERVK); 
538-643: BTLTR1B1 
(LTR/ERVK) 
494A7F 419 Cow: NC_007299  EPHA6 95 83 No repeats 
494A7R 438 Cow: NC_007299 EPHA6 92 100 123-229: MamRep38 
(DNA/hAT); 245-437: 
L1-2_BT (LINE/L1) 
523F6F 712 Cow: NC_007301 DAP3 91 100 No repeats 
523F6R 757 Human: AL139410.20 ASH1L 69 57 No repeats 
538A12F 729 Cow: NC_007325   95 100 No repeats 
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538A12R 675 Cow: NC_007325   91 100 458-657: Bov-tA2 
(SINE/BovA) 
569F2F 756 Cow: NC_007320 LOC789684 91 100 385-627: BovB 
(LINE/RTE-BovB); 619-
756: BovB (LINE/RTE-
BovB) 
569F2R 890 N/A  N/A N/A 1-886: ERV2-1B-
LTR_BT (LTR/ERVK) 
583D12F 819 Cow: NC_007299 EPHA6 95 85 238-473: Bov-tA2 
(SINE/BovA) 
583D12R 829 Cow: NC_007299 EPHA6 93 80 50-190: BOV-A2 
(SINE/BovA); 228-336: 
AT_rich 
(Low_complexity); 469-
724: L1-2_Ttr 
(LINE/L1); 739-829: 
Bov-tA2 (SINE/BovA) 
802A10F 740 Cow: XM 001787161 LOC100138404 91 100 No repeats 
802A10R 742 Cow: NC_007320  88 100 168-209: GC_rich 
(Low_complexity) 
850F2F 667 Cow: NC_007320  LOC789684 92 100 No repeats 
850F2R 700 N/A  N/A N/A 1-700: L1-1_Ttr 
(LINE/L1) 
852H10F 464 Cow: NC_007315 MSI1 89 100 No repeats 
852H10R 543 Rhesus monkey: 
XM_001085795  
PXN 68 55 No repeats 
890H12F 666 N/A  N/A N/A 1-666: L1_BT 
(LINE/L1) 
890H12R 510 Cow: NC_007320  LOC789684 93 100 No repeats 
891D11F 358 Cow: NC_007301  86 100 1-308: Tigger1 
(DNA/MER2_type); 
310-358: CHR-2A 
(SINE/tRNA-Glu) 
891D11R 338 Cow: NC_007301 ASH1L 92 100 No repeats 
912D11F 462 Sheep: EF394773 RPSA 99 100 147-331: Bov-tA3 
(SINE/BovA) 
912D11R 678 Cow: NC_007322  91 99 524 -612: L1-2_BT 
(LINE/L1) 
Additional file 3.5: Characteristics of the 68 BES: BES length, orthologous sequences and 
genes, and repeats present in the BES. 
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Genes present in the mini-contigs 
    
ASH1L F CCGATTGAGTGGTTT
CTTTT 
61 Cow: XM_612098 97 79 
ASH1L R GTAGTGTCTTTGCTTC
TGTCTCTC 
220       
DAP3 F ATGCTCATCTTTGGGT
GAA 
61 Cow: XM_001787833 97 100 
DAP3 R AACGCTCATTTGCAG
TTTG 
121    
GON4L F TTTACAGACCAGCTC
CTTGATG 
63 Cow: XM_604484 96 63 
GON4L R AGGGGTTCGACAGTT
CCAG 
250       
LOC100138404 F GAGAGACAACAGAA
AAGGCAATCCA 
61 Cow: XM_001787161 92 97 
LOC100138404 R CCCTTACCTCCCCAA
GCACA 
161    
LOC100140389 F GCTTCCCTTATTTCTC
TTCTCC 
55 Cow: NC_007325  95 97 
LOC100140389 R GGACTCATAGGCATT
CACTTTC 
136       
LOC515736 F ACATTGGATGTTGCC
TTGTT 
65 Sheep: AY942616 99 100 
LOC515736 R CGGTTTCTCTTGAAGT
GCTG 
140    
LOC767868 F CTAGTGCCCCATTTTC
TG 
61 Cow: XR_042749 90 88 
LOC767868 R ACCTCTACAGTTTAT
GGATGG 
146       
LOC784055 F CACCCAGTGACCAAT
ACAACA 
63 Cow: XR_027816 87 99 
LOC784055 R TGCTTTGTCCCCTCTA
CCTC 
245    
MOBP F CGTTCACCTTCCTCAA
CTCC 
65 Cow: NM_001077879 98 100 
MOBP R CAGCAGATCCAGTCC
TCCTC 
103       
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MSTO1 F GGTAGGACTCCAAAA
CCA 
55 Cow: NM_001046408 98 48 
MSTO1 R CATCATGGTTGTACTT
GTGA 
118    
PCDHB13 F GGGAAATGGCTCTGA
AAGTTGG 
63 Cow: XM_596806 96 94 
PCDHB13 R TTCTCGGTGCTGGTGT
TCGT 
230       
PCDHB14 F CGGAGTCTGTGCCCT
ATTCT 
62 Cow: XM_865017.2 97 100 
PCDHB14 R TATCAGCAAATCCCC
AGTCA 
176    
PCDHB16 F GTGAGTGTGAAACCT
CTCTAAAAC 
52 Cow: XM_864193 96 100 
PCDHB16 R TAGCCATCTCTGCCA
ACC 
296       
PCDHGA1 F GGGGTGCTGTTTTAC
TTGG 
62 Cow: XM_001254475.2 93 76 
PCDHGA1 R ACCACTTTCTGTCCCA
TCTTT 
494    
PCDHGA2 F TGTCTCCACAGTTTAC
CATACC 
52 Cow: NM_001099368.1 94 100 
PCDHGA2 R AACCAGATACCCCAG
TTCC 
370       
PCDHGA3 F AAAGCTCACCCCGTC
AGTC 
62 Cow: XM_844235.1 82 81 
PCDHGA3 R CCAGTCCTCCGCACT
TTCT 
180    
PCDHGA5 F AGCCCAACTACGCAG
ACAC 
62 Cow: XM_588576.1 100 75 
PCDHGA5 R AACTTCTAGCTCTCTT
TCCTTTGC 
104       
PCDHGB1 F TCTTCCTGCTGTCATT
GTTGCTC 
60 Cow: XM_001254434.1  96 100 
PCDHGB1 R TCCCCATTCTCTGCTC
TCACAC 
190    
PCDHGB2 F TCTCAATATCACCCC
AGAAGTGGTT 
62 Cow: XM_870861.2 88 100 
PCDHGB2 R ATCCGAGGCAAATGG
GACAC 
109       
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PCDHGB3 F CGGCTCTGTATTTGG
AGCTGATT 
62 Cow: XM_588575.3 98 100 
PCDHGB3 R GCCGCAGAAAACCTG
AAAGTG 
158    
PLA2G1B F GCCATCTGCTTCTCA
AAGGT 
65 Cow: NM_174646 91 98 
PLA2G1B R TCAATGGGTGCTTTA
TTGGA 
154       
RBBP8 F TGGGCTAACCAAAGA
CTCC 
62 Cow: NM_001101966 97 100 
RBBP8 R GTGGACGAAGAGGG
ATTTTA 
137    
SIRT4 F CATCCCGGCTTCCTCT
ATC 
63 Sheep: FJ236701 100 98 
SIRT4 R TTTCCTGGGCTGTTTC
TTCT 
226       
SLC25A38 F TATGGGCTGCGTGGC
TTCTT 
69 Sheep: NM_001127275 98 58 
SLC25A38 R GATGTGTCTGCCAGG
CTCTCCT 
240    
TAF7 F ACAGCACCAAGAAAA
CGA 
61 Cow: NM_001046028.1 97 97 
TAF7 R TTCAGTTCATCCAGC
ACA 
180       
TRIM27 F ACTTTGTGGAGCCCA
TGATGC 
65 Cow: NM_001075799 98 99 
TRIM27 R TCTGGTCCTCCTCGCA
GTACA 
270    
ZNF24 F TGGATGTGTTGAGTG
TGG 
63 Cow: XM_001788500 97 99 
ZNF24 R TGTGTCTTCGCTGATG
TCT 
235       
ZNF397OS F CAATACCTCCAAGAC
GACTCC 
63 Cow: XM_584961 92 95 
ZNF397OS R TCGGGCTGAGACTTC
CTATACT 
228    
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Genes not present in the mini-contigs    
 
ARL6 F GGCCAGATTAGCATA
CCTGAA 
62 Cow: NM_001075782 92 100 
ARL6 R CCAGGCTGTGAAGAC
ATGAA 
203       
CABLES1 F CGAGATGGGCAGTGA
GTGGA 
67 Cow: XM_001787300 89 93 
CABLES1 R TCTGGGTGTGGCTGT
GAGGA 
128    
COX6A1 F GTAACCATACCCTAT
TCCATAACC 
63 Cow: NM_001077831 96 96 
COX6A1 R TAAGCCATCTCCTCCT
GCT 
250       
GNPNAT1 F CCCTGGAATGTCTAC
CACAAA 
56 Cow: NM_001075559 91 100 
GNPNAT1 R CCCACCAGCCCAAAG
TATC 
250    
INO80C F GAAAGCCACAAGCAT
CGTTC 
64 Cow: NM_001105404 94 96 
INO80C R TTGACAGCAGAAGTT
GTTTCCA 
117       
IQCA1 F GAGCCTTGGCATTAA
CAGGA 
59 Cow: XM_001790491 91 42 
IQCA1 R GAAGACCTGAGTGGG
AGCAA 
214    
LOC100138837 F TGAGGAAGGTGGTGA
AGGAG 
62 Cow: NM_001103305 81 83 
LOC100138837 R GGTTACAGCCCCACA
AGAAA 
243       
LOC100139972 F CTGGAACTTGGAATG
TGGAG 
63 Cox: XM_001788918 92 99 
LOC100139972 R CTGGTGCTCAGTAAG
GATGG 
239    
LOC507236 F CACTGCCTTACCATC
CATCAAAGA 
62 Cow: XR_042813 93 99 
LOC507236 R TGAACTCGCTTGTGT
CCAATCA 
281       
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LOC783956 F AAATCGAAATGTCTT
GCCCCTATACC 
61 Cow: XM_001252403 95 99 
LOC783956 R TCGCAGAACTGAGCA
CACAGAA 
249    
MDK F AGCCGACTGCAAGTA
CAAGTTTGAG 
61 Rabbit: NM_001082167 89 77 
MDK R CCTTCCCTTTCTTGGC
TTTGG 
179       
MYRIP F CCTCTCCAAGCACCA
GAAGT 
59 Cow: XM_600387 96 87 
MYRIP R TGAACTTACAGTCCC
CACAGC 
104    
PCDHB5 F AGGTATTCCATGCCA
GAAGAAACA 
65 Cow: XM_001253364 99 99 
PCDHB5 R AGAAGCAAATTCCCG
GTCGT 
164       
RPLP0 F GCTGATTAAGACCGG
AGACAAG 
62 Cow: BC102074.1 97 98 
RPLP0 R GCACTTCGGGGTTGT
AGATG 
134    
SERINC5 F CTGAGCAATCTCCTT
GGTTCT 
62 Cow: XM_580814 97 100 
SERINC5 R ATTCTTTAGGGGCAA
ACTGG 
214       
TUBA3D F TTCAGGGCTTCTTGGT
TTTC 
62 Cow: XM_001251618 96 97 
TUBA3D R GGTGGTGAGGATGGA
GTTGT 
179    
ZCWPW2 F TCTCCTTATCCCCTGA
AATCTT 
62,5 Cow: XM_001256329 93 97 
ZCWPW2 R CCACTTTGATGAAGC
TGAGAC 
333       
ZNF397 F TAGAGTGGCAGCAAG
GGAGT 
65 Cow: NM_001075262 95 100 
ZNF397 R TCTGGTGTTGTGTTAG
AGAAGAATG 
249    
Additional file 3.6: Primers used to annotate the mini-contigs. Characteristics of primers 
used to annotate the mini-contig: sequence, annealing temperature, amplicon size and 
annotation information. 
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Additional file 3.7: FISH experiments. Pictures of FISH experiments of the 11 RPSA 
pseudogenes. An arrow points towards the chromosomal location of the pseudogene. 
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5 NC_007303 .3 60831606-60832076 92% 478  
3 NC_007301.3 60353603 -60353976 86% 374  
3 NC_007301.3 94439030-94438772 85% 259  
29 NC_007330.3 23995266-23995495 84% 266  
4 NC_007302.3 19400828-19401199 83% 254  
4 NC_007302.3 19806678-19806275 83% 409  
7 NC_007305.3 51802201-51801057 81% 1144 Ortholog 
ovine 
RPSAP3 
17 NC_007315.3 65883767-65884909 81% 1142 Ortholog 
ovine 
RPSAP6 
28 NC_007329.3 LOC100139311 81% 867  
X NC_007331.3 55244047-55243185 79% 924  
9 NC_007307.3 24593279-24594167 78% 921  
22 NC_007320.3 2925139-2925856 78% 717 Ortholog 
ovine 
RPSAP4 
23 NC_007324.3 40274136-40274422 78% 282  
28 NC_007329.3 LOC789763 78% 893  
2 NC_007300.3 9848946-9849352 77% 430  
3 NC_007301.3 88329154-88328272 77% 918  
4 NC_007302.3 RPSAP1 77% 1156  
24 NC_007325.3 LOC100138378 77% 1131 Ortholog 
ovine 
RPSAP11 
3 NC_007301.3 16411109-16410143 75% 966 Ortholog 
ovine 
RPSAP2 
3 NC_007301.3 30172521-30171698 75% 879  
X NC_007331.3 LOC782805 75% 895  
X NC_007331.3 59384437-59383512 75% 952  
unknown  LOC789047 75% 762  
1 NC_007299.3 21108684-21108094 74% 637  
3 NC_007301.3 90483516-90484432 74% 938  
10 NC_007308.3 65161474-65161271 74% 218  
22 NC_007320.3 LOC100139861 74% 1048  
25 NC_007326.3 LOC783961 74% 828  
26 NC_007327.3 LOC786170 74% 817  
X NC_007331.3 LOC786360 74% 819  
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unknown  LOC100138910 = LOC100140401 74% 622  
3 NC_007301.3 LOC784429 73% 878  
5 NC_007303 .3 24927297-24927923 73% 670  
24 NC_007325.3 LOC786678 73% 1202  
28 NC_007329.3 LOC783589 73% 656  
28 NC_007329.3 LOC784951 73% 816  
29 NW_001494550.1 LOC789646 73% 1194  
1 NC_007299.3 108047741-108046865 72% 900  
4 NC_007302.3 LOC786771 72% 929  
12 NC_007310.3 7488001-7487317 72% 694  
19 NC_007317.3 LOC781120 72% 929  
unknown  LOC788586 72% 927  
unknown  LOC782843 72% 928  
unknown  LOC788398 72% 929  
3 NC_007301.3 LOC100141114 71% 928  
4 NC_007302.3 124304154-124305007 71% 927  
6 NC_007304 .3 12277767 -12278622 71% 887  
16 NC_007314.3 15414760-15415750 71% 975  
28 NC_007329.3 LOC786412 71% 941  
unknown  LOC788968 71% 928  
1 NC_007299.3 109323009-109323702 70% 716  
4 NC_007302.3 LOC786585 70% 907  
5 NC_007303 .3 20881822-20882659 70% 921  
12 NC_007310.3 25444804-25443920 70% 930  
16 NC_007314.3 16375770-16376261 70% 499  
2 NC_007300.3 14483627-14483026 69% 666  
7 NC_007305.3 26643396-26644254 69% 922  
7 NC_007305.3 46544047-46544722 69% 759  
29 NC_007330.3 20840439-20841275 66% 929  
6 NC_007304 .3 8795342-8795930 64% 602  
Additional file 3.8: Bovine RPSA pseudogenes. Characteristics of bovine RPSA pseudogenes 
predicted in silico by BLAST analysis of the bovine genome (reference assembly, based on 
Btau_4.0). In yellow are the pseudogenes that are annotated as ‘similar to Ribosomal protein 
SA pseudogene’. The bovine pseudogene RPSAP1 is highlighted in blue and the pseudogenes 
that aren’t annotated yet in white. 
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Additional file 3.9: minus-RT PCR control on RNA isolated from blood: RT-PCR with ACTB 
primers. Marker (M) is the Hyperladder V (Bioline). Samples are RNA isolated from blood, 
genomic DNA and water (-). 
 
Additional file 3.10: Specificity of the expression primer for RPSAP6. PCR with expression 
primer for RPSAP6. Marker (M) is the Hyperladder IV (Bioline). Samples are the respective 
unique BAC clones of all RPSA family members, genomic DNA and water (-).
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3.2.1 Abstract 
The ribosomal protein SA (RPSA), also known as 37-kDa laminin receptor precursor/67-kDa 
laminin receptor (LRP/LR), has been identified as a multifunctional protein, playing an 
important role in multiple pathologies like cancer and prion diseases. Since RPSA is involved 
in the binding and internalization of the prion protein, mutations in the ovine RPSA gene, 
influencing the RPSA-PrP
C
/PrP
Sc
 binding, can potentially play a part in the resistance to prion 
diseases. Our goal was to further characterize the complex RPSA gene family and to detect 
structural mutations which can play a role in this disease. In a prior study, 11 ovine 
pseudogenes were detected experimentally. As the whole genome shotgun (WGS) ovine 
genome became accessible, an in silico genome-wide screening was performed and 37 new 
pseudogenes (36 processed and one semi-processed pseudogene) were detected, bringing the 
total to 48 ovine RPSA pseudogenes. Additionally, the complete bovine genome was screened 
in silico and 56 pseudogenes were identified. Once these sequences were known, it was 
possible to analyze the presence of mutations in the coding sequence and exon-flanking 
regions of the ovine functional full-length RPSA gene without the interference of pseudogenic 
sequences. Nineteen mutations were found: one in the 5’ untranslated region (UTR), a silent 
one in the coding region, and seventeen in the exon-flanking regions, including an interesting 
mutation in the SNORA62 gene, localized in intron 4 of RPSA, leading to potential ribosomal 
defects. Structural mutations of the RPSA gene can be ruled out to play a role in transmissible 
spongiform encephalopathies but regulatory mutations still can have an effect on these 
diseases. 
3.2.2 Introduction 
The ribosomal protein SA (RPSA), also designated as the 37-kDa laminin receptor precursor 
(LRP)/67- kDa laminin receptor (LR), is a protein that is involved in a broad range of 
functions. It is located on the cell surface as well as in the cytoplasm, the perinuclear 
compartment, and the nucleus (Nelson et al., 2008). In the cytoplasm, the protein is involved 
in the maturation of the 40S ribosomal subunit, and in the nucleus it is associated with 
histones (Ardini et al., 1998; Kinoshita et al., 1998). The function in the perinuclear 
compartment has yet to be elucidated but Sato and colleagues (1996) postulate that RPSA is a 
ligand protein between the nuclear envelope and chromatin DNA. As cell surface receptor it 
binds with high affinity to laminin, an extracellular matrix protein, hence playing an important 
role in tumor invasion and metastasis. Furthermore, it binds to other extracellular matrix 
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molecules like elastin and carbohydrates. Besides cellular ligand, it acts as a receptor for 
different pathogens, e.g. viruses and respiratory tract pathogens (Nelson et al., 2008; Orihuela 
et al., 2009). RPSA also plays an important role in transmissible spongiform encephalopathies 
(TSEs). It not only acts as a receptor for cellular prion proteins (PrP
C
) and infectious prions 
(PrP
Sc
), but it is also involved in the propagation of prion diseases as well (Gauczynski et al., 
2001; Leucht et al., 2003; Gauczynski et al., 2006).  
The RPSA-PrP
C
/PrP
Sc
 interaction was proven by using the yeast two-hybrid technology and 
by in vivo experiments using various cell lines or tissue lysates (Gauczynski et al., 2001; 
Gauczynski et al., 2006). Additionally, the interacting binding domains of RPSA and PrP
C
 
were determined. On RPSA there are two binding domains, a direct binding domain located 
between aa 161 and 179 (encoded by the last part of exon 4 and the first part of exon 5) and 
an indirect heparan sulfate proteoglycan (HSPG)-dependent binding domain that is presumed 
to be located between aa 180 and 285 (encoded by the last part of exon 5, exon 6, and the first 
part of exon 7) (Hundt et al., 2001). On PrP
C
, the domain between aa 144 and 179 was 
identified as the direct binding domain to RPSA and the domain between aa 53 and 93 as the 
indirect HSPG-dependent binding domain to RPSA (Hundt et al., 2001).  
Differences in the amino acids involved in the RPSA-PrP
C
/PrP
Sc
 interaction could lead to 
variability in scrapie susceptibility. It is well established that the susceptibility to scrapie is 
influenced by polymorphisms of the PRNP gene encoding the PrP protein. In classical scrapie, 
codons 136 (A or V), 154 (R or H), and 171 (R, Q or H) are the major polymorphisms 
associated with variability in scrapie susceptibility. In atypical scrapie on the other hand, it is 
codon 154 (R or H), besides codon 141 (L or H), that has the greatest influence (Moum et al., 
2005; Hunter, 2007).  
It was already established that there is a high degree of sequence conservation between 
mammalian RPSA proteins, all of which are almost identical. The human RPSA protein has 
an amino acid identity of 98.99% with its porcine and murine ortholog and 98.3% with its 
bovine ortholog, as demonstrated by Knorr and colleagues (2007). RPSA exhibits multiple 
functions that are important for the cell viability, if not essential, and this is often reflected in 
extreme sequence conservation. RPSA proteins in vertebrates are sharing the ribosomal 
functions with their homologs in invertebrates and consequently have the lowest divergence 
in the first two-thirds of the protein where that function is localized. Later on in evolution, 
they acquired a laminin binding potential that is situated at the C-terminal of the protein and 
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that is also essential for cell viability, as has recently been demonstrated by Scheiman and 
colleagues (2010). This explains why also the last part of the sequence is highly conserved in 
mammals.  
On the other hand, it is possible that there are polymorphisms that do not affect the laminin 
binding capacity or ribosomal functions but have an effect on the RPSA-PrP
C
/PrP
Sc 
interaction. They could partially explain the species barrier which makes it more difficult to 
transmit a certain prion strain from one species to another which leads to longer incubation 
times. Furthermore, some species like rabbits, pigs, and dogs seem to be completely resistant 
to natural infection of prion diseases and this resistance is probably a consequence of the 
conformation of the prion protein of the host species and therefore the amino acid sequence of 
PrP (Lysek et al., 2005). Nevertheless, as the RPSA protein is necessary for prion propagation, 
differences in both the RPSA conformation and the PrP conformation can affect the binding 
between both proteins and have a putative role in the strength of the species barrier (Marcos-
Carcavilla et al., 2008).  
Mutation detection of the RPSA gene, however, has been hampered by the presence of 
multiple pseudogenes, with sequences highly similar to the functional full-length gene. 
Previously, we identified 11 ovine RPSA pseudogenes experimentally and named them 
RPSAP1 to RPSAP11 (Van den Broeke et al., 2010). Now that the sheep genome became 
accessible, we wanted to identify in silico as many additional ovine pseudogenes as possible 
with a sequence similarity with the functional full-length gene of at least 60% and study the 
conservation with their bovine orthologs. Once these sequences were known, it was possible 
to analyze the presence of mutations in the coding sequence and exon flanking regions of the 
functional full-length ovine RPSA gene without the interference of pseudogenic sequences. 
3.2.3 Results and Discussion 
3.2.3.1 In silico identification of ovine and bovine RPSA pseudogenes 
The availability of the Ovis aries 1.0 genome assembly (Archibald et al., 2010) enabled us to 
identify in silico 37 RPSA pseudogenes additional to the ones that were already discovered 
experimentally (Van den Broeke et al., 2010). This brings the total to 48 ovine RPSA 
pseudogenes (Table 3.6, Figure 3.6), a number that is in the same range of number of 
pseudogenes discovered by Balasubramanian and colleagues (2009) in their in silico genome-
wide screening study in fully sequenced genomes, namely 63 processed RPSA pseudogenes 
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in humans, 45 in mice, 52 in chimpanzee, and 45 in rat. Not all the experimentally discovered 
pseudogenes of our previous study were found in the whole genome shotgun sheep genome 
(Van den Broeke et al., 2010). The recent species specific ovine pseudogenes RPSAP1, 2, 5, 
7-10 were not present in the WGS sheep genome build. Because the International Sheep 
Genomics Consortium (ISGC) aligned ovine sequences to the bovine genome to create the 
whole genome shotgun sheep genome, we suppose that the pseudogenic sequences, which did 
not show any similarity with the bovine genome, could not be aligned to the bovine genome 
and thus were not included in the WGS build (Archibald et al., 2010). The ovine pseudogenes 
share between less than 60% and 98% nucleic acid sequence identity with the ovine 
functional full-length RPSA gene. The pseudogenes with a lower similarity were not detected 
due to our study design. 
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Figure 3.6: Schematic overview of ovine (ov) and bovine (bov) pseudogenes. Exons present in 
both ovine and bovine pseudogenes are drawn in dark blue while exons only found in one of 
the orthologs are drawn in light blue. Regions where the sequences are missing from the 
NCBI database are presented as green bars. Repeat sequences that are inserted in the 
pseudogenes are represented in red and the SNORA62 gene is represented in yellow. 
 
One newly found pseudogene (RPSAP19) is a rare “semi-processed” pseudogene still 
possessing a remnant intron 4 bearing the SNORA62 gene. The term “semi-processed 
pseudogene” was first proposed by Zhang and colleagues (2008) and is used for pseudogenes 
generated by retrotransposition of partially spliced premature mRNA. The other two “semi-
processed” pseudogenes of the ovine RPSA gene family, RPSAP8 and RPSAP9 (GenBank: 
GQ202537 and GQ202538), also bear intron 4 including the sequence of the SNORA62 gene. 
snoRNAs are often localized within introns of non-protein-coding genes (Dieci et al., 2009). 
They mostly do not have an independent promoter but are synthesized cotranscriptionally 
with their host genes. They are processed from pre-mRNA by exonucleolytic digestion of the 
debranched lariat (Kiss et al., 2004). “Semi-processed” pseudogenes are generated 
presumably from partially spliced premature mRNA. Normally, the spliceosome removes all 
the intronic fragments from the primary RNA transcripts. When an intron is still present in the 
pre-mRNA and it is reversely transcribed in cDNA, semi-processed pseudogenes arise. It is 
remarkable that all “semi-processed” pseudogenes of the RPSA gene family carry a snoRNA 
gene. Probably, the splicing of the introns with snoRNA gene is hampered in one way or 
another.  
All the other pseudogenes are processed and are exhibiting one or more typical features of 
processed pseudogenes. Some pseudogenes are disrupted by inserted sequences, mostly SINE 
(e.g. RPSAP38 and RPSAP43), while other pseudogenes have large sequence deletions (e.g. 
RPSAP4 and RPSAP35) (Figure 3.6). Most pseudogenes carry frameshift mutations or have 
premature stop codons in their sequences. The ORF of RPSAP7 (295 amino acids with 99% 
sequence identity to the functional RPSA protein), discovered in our previous study, was the 
longest ORF of all 48 pseudogenes.  
A BLAST analysis of the updated bovine genome (reference assembly, based on Btau_4.6.1) 
identified 56 potential bovine RPSA family members. In our previous study 60 bovine RPSA 
family members were identified in silico (reference assembly, based on Btau_4.0) but some of 
them were withdrawn from the current reference assembly. For instance, some unplaced 
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genomic scaffold turned out to be part of already annotated regions and therefore some 
pseudogenes with two LOC names were actually the same pseudogene (e.g. LOC789047 
withdrawn from current assembly is the same pseudogene as LOC783961). Some parts of 
certain bovine pseudogenes are designated in GenBank as “ribosomal protein SA-like” by an 
automated computational analysis tool (Table 3.6). However, the annotation is often not 
complete or incorrect. For instance, 3000 bp of the flanking intergenic region of the 
pseudogene RPSAP47 are annotated as a component of the pseudogene in LOC786360. 
LOC100297616 (RPSAP51) is annotated as “ribosomal protein S24-like” but is actually a 
pseudogene of RPSA. In LOC781120 (RPSAP55), some parts of the sequence are labeled as 
exons and other parts as introns but this is a processed pseudogene. In this study, the position 
of the pseudogenes and their features (the present exons, insertions, and deletions) are 
determined through careful sequence analysis and differ largely from the automatically 
generated data.  
The bovine pseudogenes are displaying 64–92% sequence identity with the bovine RPSA 
gene. Thirty-three bovine pseudogenes can be catalogued as “processed pseudogenes” and 17 
as “pseudogenic fragments” as they have lengths less than 70% of the parent protein (Zhang 
et al., 2004). The ovine pseudogenes cannot be catalogued because their sequence is often 
incomplete due to the absence of a complete version of the sheep genome (Figure 3.6, gaps in 
the sequence in green).  
Most processed pseudogenes described in literature are more truncated at the 5' site than at the 
3' site. Processed pseudogenes arise by incorporation of transcribed cDNA. As the reverse 
transcription process starts at the poly-A tail (3' site), the 5' site will be incomplete when there 
is premature termination of the process (Zhang et al., 2002). However, in our group of 
processed pseudogenes, the truncation is the highest at the 3' site and more experimental data 
is needed to clarify this inconsistency.  
Forty-two ovine pseudogenes have a bovine ortholog. The ovine and bovine orthologs share 
88–97% nucleic acid identity with each other. Six of the experimentally discovered ovine 
pseudogenes (RPSAP1, RPSAP5, RPSAP7, RPSAP8, RPSAP9, and RPSAP10) do not have a 
bovine ortholog. The surrounding sequences were found without the interruption of a bovine 
pseudogene. For fourteen bovine pseudogenes, no ovine ortholog could be found. As the 
current sheep genome sequence is a pool of short ovine sequences with a lot of gaps, this is 
not evidence that the ovine ortholog does not exist. As the whole sheep genome becomes 
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accessible, ovine orthologs of those bovine pseudogenes can be excluded completely. No 
conclusions on chromosomal rearrangements between the ovine and bovine genome can be 
made because the location on the ovine chromosomes is not experimentally verified. 
 
 
  
 
Table 3.6: Characteristics of the ovine and bovine RPSA pseudogenes.  
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RPSAP2 ACIV010279956/57 74% 91% NC_007301.5 16174977-5951 BTA3 75% in DAP3   
RPSAP3 ACIV010712079/80 80% 95% NC_007305.5 51656775-7870 BTA7 81%  intergenic  
RPSAP4 ACIV011799502/03 83% 91% NC_007320.5 2904735-5521 BTA22 78%  intergenic  LOC100336434 
RPSAP6 ACIV011534191/92 80% 92% NC_007315.5 65680450-1539 BTA17 81%  intergenic   
RPSAP11 ACIV011903422 76% 91% NC_007325.5 22503990-5049 BTA24 77% intergenic  
RPSAP12 ACIV010009098 71% 93% NC_007299.5 107388186-9062 BTA1 72% intergenic   
RPSAP13 ACIV010059570/71 75% 94% NC_007299.5 21075516-6747 BTA1 74% intergenic LOC781313: RPSA-like 
RPSAP14 ACIV010071859 81% 94% NC_007299.5 35555129-6675 BTA1 76% intergenic   
RPSAP15 ACIV010172107 67% 91% NC_007300.5 14516593-7247 BTA2 69% intergenic   
RPSAP16 ACIV010240662 87% 97% NC_007300.5 9868953-9366 BTA2 77% intergenic   
RPSAP17 ACIV010343175/76/77 85% 95% NC_007301.5 87426328-7261 BTA3 77% intergenic   
RPSAP18 ACIV010344762/63 77% 95% NC_007301.5 89553151-4114 BTA3 74% intergenic   
RPSAP19 ACIV010319172 79% 92% NC_007301.5 60009518-937 BTA3 86% intergenic LOC100295707 
RPSAP20 ACIV010349106 74% 88% NC_007301.5 93522075-339 BTA3 85% intergenic LOC100295233 
RPSAP21 ACIV010291498/99 70% 94% NC_007301.5 29984816-5704 BTA3 75% intergenic   
RPSAP22 ACIV010384986 82% 95% NC_007302.5 19529087-496 BTA4 83% intergenic LOC100336308: RPSA-like 
RPSAP23 ACIV010435878/79/80 74% 95% NC_007302.5 74842869-3978  BTA4 77% in 
ZNF804B 
RPSAP1 
RPSAP24 ACIV010491485 70% 92% NC_007303.5 20906129-7028 BTA5 70% intergenic   
RPSAP25 ACIV010527707 90% 90% NC_007303.5 60546599-7030 BTA5 92% intergenic   
RPSAP26 ACIV010495714 73% 96% NC_007303.5 24897357-908 BTA5 73% intergenic   
RPSAP27 ACIV010583245/46/47 72% 91% NC_007304.5 12231035-946 BTA6 71% intergenic   
RPSAP28 ACIV010645497 < 60% 94% NC_007304.5 8752937-349 BTA6 64% intergenic   
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RPSAP29 ACIV010706330/31/32 70% 94% NC_007305.5 46521540-2253 BTA7 69% intergenic   
RPSAP30 ACIV010688073/74 75% 97% NC_007305.5 26665996-6856 BTA7 69% intergenic   
RPSAP31 ACIV010870568/69 80% 92% NC_007307.5 25005295-6244 BTA9 78% intergenic LOC100139221: RPSA-like 
RPSAP32 ACIV010965166/67 75% 95% NC_007308.5 31709930-10694 BTA10 74% intergenic   
RPSAP33 ACIV011173083 73% 93% NC_007310.5 59551557-2032  BTA12 71% intergenic   
RPSAP34 ACIV011182489/855/856 73% 92% NC_007310.5 7464603-5384 BTA12 72% intergenic   
RPSAP35 ACIV011141860/61 73% 93% NC_007310.5 25331128-989 BTA12 70% intergenic   
RPSAP36 ACIV011267035 74% 92% NC_007311.5  76527703-8027 BTA13 70% in EYA2   
RPSAP37 ACIV011422416/17 75% 94% NC_007314.5 15416879-7876 BTA16 71% intergenic   
RPSAP38 ACIV011480743 79% 95% NC_007314.5 8270309-823 BTA16 82% intergenic   
RPSAP39 ACIV011465309 73% 90% NC_007314.5 6475545-850 BTA16 73% intergenic   
RPSAP40 ACIV011803302/03 70% 93% NC_007320.5 25190706-754 BTA22 73% intergenic   
RPSAP41 ACIV011873056 73% 93% NC_007324.5 39260430-710 BTA23 78% intergenic   
RPSAP42 ACIV0120867/68/69 82% 92% NC_007329.5 23314339-3486 BTA28 81% intergenic LOC100139311: RPSA-like 
RPSAP43 ACIV012088199/200 72% 94% NC_007329.5 25035168-6187 BTA28 73% intergenic   
RPSAP44 ACIV012097249/50/51 80% 95% NC_007329.5 33593767-2851 BTA28 71% intergenic LOC786412: RPSA-like 
RPSAP45 ACIV012126348 72% 93% NC_007330.5 23521114-2634 BTA29 72% intergenic   
RPSAP46 ACIV012192492 75% 92% NC_007331.4 59466130-5191 BTAX 75% intergenic LOC782805: RPSA-like 
RPSAP47 ACIV012199192 75% 95% NC_007331.4 67228718-9530 BTAX 74% intergenic LOC786360: RPSA-like 
RPSAP48 ACIV012190019/20/21 82% 94% NC_007331.4 55328763-9702 BTAX 79% in CCDC22  
RPSAP49     NC_007299.5 108688755-9571 BTA1 70% intergenic   
RPSAP50     NC_007301.5 125970082-69189 BTA3 71% intergenic LOC100141114: RPSA-like 
RPSAP51     NC_007302.5 19122655-781 BTA4 83% intergenic LOC100297616: RPS24-like 
RPSAP52     NC_007302.5 123658944-9840 BTA4 71% intergenic LOC100296290: RPSA-like 
RPSAP53     NC_007308.5 64883466-670 BTA10 74% intergenic   
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RPSAP54     NC_007314.5 16378105-596 BTA16 70% intergenic   
RPSAP55     NC_007317.5 64776546-7462 BTA19 72% intergenic LOC781120: RPSA-like 
RPSAP56     NC_007325.5 62698525-9833 BTA24 73% intergenic LOC786678 
RPSAP57     NC_007326.5 44073985-4896 BTA25 74% intergenic LOC783961: RPSA-like 
RPSAP58     NC_007327.5 5989909-197 BTA26 74% intergenic LOC786170: RPSA-like 
RPSAP59     NC_007329.5 378146-9070 BTA28 78% intergenic LOC789763: RPSA-like 
RPSAP60     NC_007329.5 45961803-2621 BTA28 73% intergenic LOC784951: RPSA-like 
RPSAP61     NC_007330.5 23846784-6989 BTA29 84% intergenic   
RPSAP62     NC_007330.5 20780510-1413 BTA29 66% intergenic   
*SI: sequence identity 
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3.2.3.2 Mutation detection of the RPSA gene in sheep 
In the present work, a mutation analysis was conducted to detect structural mutations of the 
ovine RPSA gene. When carrying out a mutation study of genes from gene families, one has 
to pay attention that only the desired gene is amplified and none of the related (pseudo)genes. 
In this mutation study, the strategy was to use exon-spanning primers situated in the introns as 
all of the discovered ovine pseudogenes were processed or semi-processed pseudogenes 
bearing a single intron. Because the genome of the sheep has not been fully sequenced yet, 
there is a chance that some ovine pseudogenes have not yet been discovered. However, we 
screened the fully sequenced bovine genome and discovered only processed or semi-
processed pseudogenes bearing a single intron (all ± 90% sequence identity with their ovine 
ortholog) and therefore we can assume that it is very likely that the ovine RPSA gene family 
also consists of those types of pseudogenes. This strategy was successful as none of the 
obtained data gave any evidence of co-amplifying pseudogenes. The mutation analysis of the 
whole coding and the exon-flanking region of RPSA was carried out on 33 unrelated sheep 
covering 7 different breeds, varying in PRNP genotype at codons 136, 154, and 171. Nineteen 
mutations were found: one in the 5' UTR, seventeen in different introns, and one in the coding 
region (Table 3.7). In four out of the nineteen mutations (10, 12, 15, and 19), a high 
percentage of the individuals (> 84.8%) were homozygous for one genotype and no 
homozygotes of the other genotype were detected. This could imply that one homozygous 
genotype is lethal but this conclusion can only be made if more animals are tested. Mutation 1 
is situated in the first exon that is a part of the 5' UTR. Transcription factor elements, 
including a TATA box, were detected using online prediction programs but mutation 1 was 
not situated in any of the detected transcription factor elements. The mutations 2–17 and 19 
are mutations in introns. None of the mutations are disrupting a splice site. On the other hand, 
the SNP 10 and the indel 15 are part of the small nucleolar RNAs SNORA6 and SNORA62 
respectively. These small nucleolar RNAs, located in introns 2 and 4 of RPSA, are H/ACA 
box snoRNAs that guide the isomerization of uridine into pseudouridine. They are 
characterized by two imperfect hairpins that contain two short antisense sequences that can 
base pair upstream and downstream of the targeted, unpaired uridine (Ganot et al., 1997). 
SNORA62 forms a base pair with the uridine at position 3830 and 3832 of 28S rRNA. The 
indel 15 affects the binding site of SNORA62 with the uridine at position 3830. Ni and 
colleagues (1997) demonstrated that a weakened binding site blocked the pseudouridylation 
of the uridine in question (Ni et al., 1997). Therefore, we can presume that the mutation 
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causes a loss of pseudouridine in the 28S rRNA and this could result in misfolding of the 
rRNA with a reduced rate of processing and potential defects in the assembly of the ribosome 
as a consequence.  
 
Table 3.7: Overview of the mutations detected in the ovine RPSA gene. 
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1 5’ UTR Exon 1 position 16 A→G 39.4 36.4 24.2 
2
* 
Intron Intron 1 position 138 A→G 39.4 36.4 24.2 
3 Intron Intron 1 position 264 A→G 51.5 33.3 15.2 
4
* 
Intron Intron 1 position 1372  A→G 87.9 9.1 3.0 
5
* 
Intron Intron 1 position 1426 A→G 87.9 9.1 3.0 
6
* 
Intron Intron 1 position 1463  G→A 75.8 9.1 15.1 
7 Intron Intron 2 position 12 C→A 75.8 9.1 15.1 
8 Intron Intron 2 position 19  G→A 39.4 36.4 24.2 
9 Intron Intron 2 position 38 C→T 75.8 18.2 6.0 
10 SNORA6 Intron 2 position 857  C→A 84.8 15.2 0 
11 Intron Intron 3 position 107  C→T 54.5 30.3 15.2 
12 Intron Intron 3 position 161  T→G 90.9 9.1 0 
13 Intron Intron 3 position 8807  G→A 54.5 39.4 6.1 
14
* 
Intron Intron 4 position 27  C→T 39.4 36.4 24.2 
15 SNORA62 Intron 4 position 75 Indel A 93.9 6.1 0 
16 Intron Intron 4 position 709  T→C 90.9 6.1 3.0 
17
* 
Intron Intron 5 position 10  G→A 90.9 6.1 3.0 
18
* 
CDS Exon 6 position 69  T→C 39.4 36.4 24.2 
19
* 
Intron Intron 6 position 9  C→G 84.8 15.2 0 
*
: mutations also present in Spanish breeds (Marcos-Carcavilla et al., 2008) 
As there were no homozygous animals detected carrying two indels, it is possible that the 
effect of the indel is lethal. SNP 10 on the other hand does not alter the H- or ACA-box or the 
28S rRNA U3616 PU guide of SNORA6. The folding of the RNA stays unchanged, too. 
Mutation 18, a T → C substitution at position 69 of exon 6 and a part of the indirect PrP-
binding domain, is a silent mutation T232T. It is known for a while that synonymous 
mutations can affect protein expression levels (Sharp et al., 1986). Additionally, the protein 
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folding can be influenced by a silent SNP, possibly changing the function of the protein 
(Kimchi-Sarfaty et al., 2007; Komar, 2007). It has yet to be examined if mutation 18 causes 
any of these events.  
None of the mutations were part of a possible target of microRNA. Most of the mutations are 
equally represented in different breeds.  
Mutation analyses of the RPSA gene were only carried out in Spanish and Chinese sheep 
breeds and recently one human study was published. Eight of our 19 mutations were also 
present in the Spanish breeds examined by Marcos-Carcavilla and colleagues (2008). They 
neither found polymorphisms that cause an amino acid change. The amino acid sequence of a 
local Chinese breed deposited by Qiao and colleagues (2009) however differs in four amino 
acids with the sequences mentioned above. These possible polymorphic amino acids cannot 
be confirmed by any EST of the NCBI databank. In the human mutation study 4 SNPs were 
observed, including a synonymous one in the coding region (exon 5) (Yun et al., 2011). An 
association study with sporadic Creutzfeldt-Jakob disease found no significant associations.  
We can conclude that the CDS of the RPSA gene is extremely well conserved in sheep, even 
between sheep of very different breeds. We could not find polymorphisms in the coding 
region of the RPSA gene that can play a direct role in the RPSA-PrP
C
/PrP
Sc
 interaction. 
Because the variability in scrapie susceptibility cannot be subscribed to structural mutations in 
the RPSA gene, other strategies have to be examined for the treatment of scrapie. For example, 
several research groups are investigating the downregulation of RPSA in different species like 
humans and mice (Leucht et al., 2003; Leucht et al., 2004). Complete knock-out of RPSA is 
not possible because it results in apoptosis due to the multiple essential functions of the 
protein (Ardini et al., 1998; Scheiman et al., 2010).  
The RPSA gene is very conserved not only in the ovine species, but also between different 
species. The three main ruminants, namely sheep, goat, and cattle, share 100% identity in 
their amino acid sequence (GenBank: ADE09296 (sheep), ADI56590 (goat), and DAA17125 
(cattle)). Because the RPSA protein is 100% identical in the three species, the observed 
species barrier for transmission of certain prion strains cannot be ascribed to polymorphisms 
in the RPSA protein.  
One can wonder if the two features of the RPSA gene observed in this study, namely a 
substantial amount of processed pseudogenes and extreme conservation, are linked to each 
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other. Processed pseudogenes arise by retrotransposition of the mRNA of the ancestral gene 
into the genome. Because the fixation in the genome requires gene expression in the germ line, 
it is evident that the majority of gene families with several processed pseudogenes are often 
housekeeping genes which are highly expressed in the germ line (Zhang et al., 2004). 
Secondly, housekeeping genes are under stronger selective constraints than tissue-specific 
genes and, therefore, evolve more slowly, hence are more conserved (Zhang and Li, 2004). 
Moreover, housekeeping genes are significantly more likely to have orthologs in other species 
relative to other genes (She et al., 2009). It is therefore not surprising that characteristics like 
high conservation and multiple pseudogenes are associated with each other. Consequently, 
when performing molecular analysis of a conserved gene, one has to keep in mind that those 
genes are often housekeeping genes and that there is a high possibility that pseudogenes can 
interfere with for example sequencing, mapping, polymorphism detection, genotyping, 
association analysis, and mRNA expression studies.  
3.2.4 Conclusions 
Until now 48 ovine RPSA pseudogenes have been discovered. All of them are processed 
except for 3 semi-processed ovine pseudogenes bearing a snoRNA in their remnant intron 4. 
Fifty-six bovine RPSA pseudogenes were detected (55 processed and 1 semi-processed) out 
of which 42 are orthologs of ovine pseudogenes. In a mutation analysis of the whole coding 
and exon-flanking non-coding region of the functional full-length ovine RPSA gene, 19 
mutations were discovered of out which 1 is positioned in the 5’ UTR, 17 in the different 
introns, and 1 silent mutation in the coding region. An interesting mutation was revealed in 
the SNORA62 gene, leading to potential ribosomal defects. No structural mutations that can 
play a direct role in the RPSA-PrP
C
/PrP
Sc
 interaction were found but regulatory mutations in 
the ovine RPSA gene still can have an effect on prion diseases. Furthermore, it was 
established that sheep, goat, and cattle have 100% identical RPSA proteins. Consequently, 
differences in the RPSA proteins are not responsible for the observed species barrier in prion 
diseases. 
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3.2.5 Materials and Methods  
3.2.5.1 In silico identification of ovine and bovine RPSA pseudogenes 
The whole genome shotgun (WGS) assembly Ovis_aries_1.0 (GenBank: ACIV010000000) is 
the current draft assembly of the sheep genome, composed of short ovine sequences (± 100–
1000 bp long), aligned using the bovine genome (reference assembly, based on Btau_4.0) as 
the initial guide, but still containing a lot of gaps (Archibald et al., 2010). This database was 
screened via BLAST (Altschul et al., 1990) with the ovine RPSA mRNA sequence (GenBank: 
EF649775), the ovine RPSA genomic sequence (GenBank: GQ202529), and the ovine and 
bovine RPSA pseudogene sequences previously described by Van den Broeke and colleagues 
(2010). 
The bovine genome on the other hand is completely sequenced (Elsik et al., 2009). This 
genome (reference assembly, based on Btau_4.6.1) was screened via BLAST (Altschul et al., 
1990) with the bovine RPSA mRNA sequence (GenBank: NM_174379), the bovine RPSA 
genomic sequence (GenBank: NC_007320.5), and the bovine and ovine RPSA pseudogene 
sequences described by Van den Broeke and colleagues (2010). 
Potential ovine and bovine pseudogenic matches were classified as pseudogenes if they had a 
homology of at least 60% with their RPSA gene. In one case (RPSAP28), the homology 
between the ovine pseudogene and RPSA was less than 60% but the pseudogenic sequence 
was classified as pseudogene since the homology of its bovine ortholog with bovine RPSA 
was 64%. A second requirement was a minimum length of 100 bp and a homology with at 
least 2 exons of the functional full-length RPSA gene.  
Open reading frames were detected with the online program NCBI Open Reading Frame 
Finder (NCBI ORF Finder Webserver) and sequences repeated with the RepeatMasker 
program (RepeatMasker Webserver).  
It was not possible to identify an ortholog of a particular ovine or bovine pseudogene by 
performing a screening via BLAST (Altschul et al., 1990) on the bovine or ovine genome 
respectively, using the sequence of that pseudogene because this resulted in multiple 
pseudogenes with sometimes higher sequence similarity with each other than with their 
putative ortholog. As orthologs of genes are located in syntenic regions, the flanking 
sequences of the pseudogenes were used to identify the corresponding orthologs. Pseudogenes 
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were classified as orthologs if their sequence and 200 bp upstream and downstream of their 
sequence shared a homology of at least 85%. 
3.2.5.2 Mutation detection of the RPSA gene in sheep 
Genomic DNA was isolated from 100 μl blood, via a proteinase K lysis as described in Van 
Poucke and colleagues (2005), of 33 unrelated Belgian sheep covering 7 breeds (5 Ardense 
Voskop, 4 Bleu du Maine, 5 Hampshire Down, 5 Rouge de l’Ouest, 4 Suffolk, 5 Texel, and 5 
Vlaams Kuddeschaap), 9 PRNP genotypes (based on codon 136, 154, and 171), and both 
sexes (Table 3.8). Five primer pairs, amplifying the whole coding and the exon-flanking 
region of RPSA, were developed with the software Primer3 (Rozen and Skaletsky, 2000) 
taking into account potential secondary structures of the amplicon by analysis with Mfold 
(Zuker, 2003). All primer pairs were designed to amplify the RPSA gene and none of the 
RPSA pseudogenes (for amplicon characteristics see Table 3.9).  
PCR was performed with 0.5 U FastStart Taq DNA Polymerase (Roche Diagnostics Belgium, 
Vilvoorde, Belgium), 2.0mM MgCl2, 200μM (each) dNTPs (Bioline Reagents Ltd., London, 
UK), 500nM of each primer, and 200 ng DNA. PCR conditions were 5 min at 95°C, 40 cycles 
of 30 s at 95°C, 30 s at the annealing temperature, 1 min at 72°C, and a final 10 min 
elongation at 72°C. All amplicons were sequenced as previously described in Van den Broeke 
and colleagues (2010). Sequencing data were analyzed with the Clustal W program (Larkin et 
al., 2007).  
Promoter elements and putative transcription factor binding sites were identified with 
programs as neural network promoter prediction (Reese, 2001), Cister (Frith et al., 2001), 
Signal scan (Prestridge, 1991), and TFSEARCH (Heinemeyer et al., 1998). miRBase was 
used to find possible targets of microRNAs in the RPSA gene (Kozomara and Griffiths-Jones, 
2011).  
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Table 3.8: Characteristics of the samples used in the mutation analysis. 
Sample Breed Sex Genotype PRNP NSP class* 
Sample 1 Ardense Voskop M ARQ / ARQ NSP1 
Sample 2 Ardense Voskop F ARQ / AHQ NSP1 
Sample 3 Ardense Voskop F ARR / ARR NSP1 
Sample 4 Ardense Voskop M ARR / ARQ NSP1 
Sample 5 Ardense Voskop F ARR / AHQ NSP1 
Sample 6 Bleu du Maine F ARQ / ARQ NSP1 
Sample 7 Bleu du Maine F VRQ / ARR NSP1 
Sample 8 Bleu du Maine F ARR / ARR NSP2 
Sample 9 Bleu du Maine M VRQ / ARQ NSP2 
Sample 10 Hampshire Down M ARQ / ARQ NSP2 
Sample 11 Hampshire Down F ARQ / ARQ NSP2 
Sample 12 Hampshire Down F ARR / ARR NSP2 
Sample 13 Hampshire Down F ARR / ARQ NSP2 
Sample 14 Hampshire Down F ARR / ARQ NSP2 
Sample 15 Rouge de l'Ouest M ARR / ARR NSP2 
Sample 16 Rouge de l'Ouest M ARR / ARR NSP2 
Sample 17 Rouge de l'Ouest F ARR / ARQ NSP2 
Sample 18 Rouge de l'Ouest F ARR / ARQ NSP2 
Sample 19 Rouge de l'Ouest M VRQ / ARR NSP3 
Sample 20 Suffolk F ARR / ARQ NSP3 
Sample 21 Suffolk M ARR / ARQ NSP3 
Sample 22 Suffolk M ARR / ARR NSP3 
Sample 23 Suffolk F ARQ / ARQ NSP3 
Sample 24 Texel F ARR / ARQ NSP3 
Sample 25 Texel F ARQ / ARQ NSP3 
Sample 26 Texel M ARR / ARH NSP3 
Sample 27 Texel F ARQ / ARH NSP3 
Sample 28 Texel M VRQ / ARR NSP3 
Sample 29 Vlaams Kuddeschaap M ARQ / ARQ NSP4 
Sample 30 Vlaams Kuddeschaap F ARR / AHQ NSP4 
Sample 31 Vlaams Kuddeschaap M VRQ / ARR NSP4 
Sample 32 Vlaams Kuddeschaap M ARR / ARR NSP4 
Sample 33 Vlaams Kuddeschaap F ARQ / ARQ NSP5 
*NSP classification system used in the United Kingdom for genetic resistance to scrapie with NSP1 
class, the genetically most resistant class, and NSP5, the genetically most susceptible class. F=female, 
M=male  
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Table 3.9: Characteristics of the primerpairs used in the mutation analysis. 
Primer Primer sequence Annealing 
temperature 
Amplicon 
length 
Location 
Amplicon 1 F CAGAGGTTTGTTCAGTGCTTTCC 60°C 804 bp 5'UTR 
Amplicon 1 R AAATGGGGTGTGCGTGTGT   intron 1 
Amplicon 2 F TTAGAAGGAATGCTGAAGG 58°C 817 bp intron 1 
Amplicon 2 R ACGACACATAACCTACCAGTT   intron 2 
Amplicon 3 F GAGATAGAAGCACGGAAGGATT 62°C 712 bp intron 2 
Amplicon 3 R GCGGCTCAAGAAAATACACA   intron 3 
Amplicon 4 F GCTTGCTTGGTGACATTGC 62°C 748 bp intron 3 
Amplicon 4 R AACCTCTGCCCCGTTCTTAT   intron 4 
Amplicon 5 F ACCAAGGGACCTAGACGATGA 64°C 867 bp intron 4 
Amplicon 5 R CCCATAGACGGAAATAAATGAACAC   3' UTR 
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4.1 Introduction 
TSEs such as CJD in humans, BSE in cattle and scrapie in sheep are caused by the conversion 
of cellular PrP
C
 to the disease associated form PrP
Sc 
(Dalsgaard, 2002). As this conversion 
appears to be the critical step in the pathogenesis and transmission of the diseases, it is 
important to understand what factors control this conversion. In transmissible prion diseases, 
the PrP
C
 misfolding is PrP
Sc
 induced. This means that PrP
C
 and PrP
Sc
 have to come in close 
contact with each other to start the conversion (Rigter et al., 2011). The Ribosomal Protein 
SA receptor (RPSA) binds to both the normal prion protein and the abnormal form and it is 
hypothesized that it plays a major role in the conversion of PrP
C
 to PrP
Sc
. RPSA is localized 
on the membrane and can internalize an exogenous PrP
Sc
 protein, thereby infecting new cells 
(Vana et al., 2009). 
Susceptibility to one type of prion disease differs greatly between species and incubation time 
can vary a lot when infectious prion strains are transmitted between species. This effect is 
referred to as the species or transmission barrier. The basis of the species barrier is probably 
the subtle difference between the tertiary structures of PrP of the different species. The 
folding of PrP is highly conserved among species, but small differences in the amino acid 
sequence give rise to structural variability, as well as between species as within a species (e.g. 
sheep) (Béringue et al., 2008). 
We wanted to examine if there is an additional factor that plays a role in the existence of the 
species barrier and the association between ovine PRNP polymorphisms and ovine TSE 
susceptibility. The structural variability of PrP and RPSA could also affect their binding 
affinity to each other. Since we demonstrated that the ovine RPSA protein is highly conserved 
and no structural variability exists (Chapter 3.2), we wanted to investigate if structural 
variability of PrP could also affect this binding. A lower binding ability between those two 
proteins, can potentially affect the internalization of the prion protein, the conversion to its 
malignant form and the propagation of the prion disease. Therefore, differences in 
susceptibility between species and within species may be partially explained by differences in 
binding ability between PrP to RPSA.  
To assess binding differences between RPSA and PrP molecules of different species and in 
the case of sheep, different genotypes, recombinant proteins of humans, cattle and sheep are 
required. The cloning and production of these recombinant proteins in Escherichia coli are 
discussed in this chapter. 
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4.2 Results and Discussion 
4.2.1 RPSA proteins  
cDNA clones of full-length ovine and human RPSA protein (295 amino acids long) were 
cloned into the pET15b vector (Novagen) to generate recombinant proteins carrying an N-
terminal His-tag (Table 4.1). This tag is composed of 6 histidine residues, making the 
purification of the recombinant protein easier as His-tags are known for their nickel affinity. 
The bovine RPSA protein is 100% identical to the ovine RPSA protein and therefore, just one 
construct was made for both species (Van den Broeke et al., 2013). The expected molecular 
weight of the recombinant proteins is around 35 kDa.  
 
Table 4.1: Overview of the names and amino acids present in the recombinant proteins of 
RPSA of the different species. 
Species Name Amino acids 
Expected 
molecular weight 
Sheep and Cattle FLSRPSA 1-295 35 kDa 
Human FLSRPSA 1-295 35 kDa 
kDA=kilodalton 
 
4.2.2 Prion proteins 
Mammalian prion proteins have an N-terminal signal sequence of 22 amino acids long and a 
C-terminal signal sequence of 23 amino acids encoding the attachment of the 
glycosylphosphatidylinositol (GPI) anchor. We produced ovine, bovine and human 
recombinant proteins without those signal peptides. Furthermore, we produced fragments of 
these proteins, namely a fragment corresponding to the protease resistant PrP 27-30 form and 
a fragment corresponding to the direct binding domain between PrP and RPSA. Ovine 
recombinant proteins were designed in three genotypes, an ARR, ARQ and a VRQ form. 
Clones could be generated from genomic DNA as the coding sequence of the PRNP gene 
resides in only one exon. All constructs were cloned into the pET15b vector (Novagen) to 
generate recombinant proteins carrying an N terminal His-tag. Table 4.2 gives an overview of 
the amino acids of the full length prion protein and those present in the recombinant proteins 
of the different species. 
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Table 4.2: Overview of the names and amino acids present in the recombinant proteins of 
PrP of the different species. 
 
 Full length without 
signal peptides 
(name) 
Protease resistant 
PrP 27-30 form 
Direct binding 
domain 
Expected 
molecular 
weight 
 25 kDa 17 kDa 6 kDa 
Species 
Geno-
type
1
 
Name 
Amino 
acids 
Name 
Amino 
acids 
Name 
Amino 
acids 
Sheep 
[GenBank: 
U67922] 
ARR FLSARR  25-233 PRSARR 96-233 DBSRR 144-182 
ARQ FLSARQ 25-233 PRSARQ 96-233 DBSRQ 144-182 
VRQ FLSVRQ 25-233 PRSVRQ 96-233 DBSRQ 144-182 
Cattle 
[GenBank: 
AB001468.1] 
 FLCPRP 25-241 PRCPRP 95-241 DBCPRP 144-179 
Human 
[GenBank: 
HM459606.1] 
 FLHPRP 23-230 PRHPRP 96-230 DBHPRP 144-179 
1
Genotypes refers to the amino acid at codon 136, 154 and 171 of the gene encoding for the prion 
protein. A=alanine, R=arginine, Q=glutamine, V=valine.  
kDA=kilodalton 
 
4.2.3 Expression 
All recombinant molecules were hyperexpressed in the total cell protein fraction. Sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) showed that the proteins had 
the expected molecular weight. Anti-His antibody detected the recombinant proteins on a 
western blot on the expected molecular height. The soluble fraction of the numerous cultures 
did not show any hyperexpressed recombinant protein (Figure 4.1, lane 1, 3 and 5) but the 
insoluble fraction did (Figure 4.1, lane 2, 4 and 6). 
As the proteins are not present in the soluble fraction following sonication and centrifugation, 
the purification of the insoluble proteins (typically in the form of inclusion bodies) will be 
more complicated. Recombinant proteins have to be solubilized by denaturation, purified and 
refolded again.  
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Figure 4.1: Production of human rPrP and rRPSA. Precision Plus Protein™ All Blue 
Standard marker (M). Soluble (lane 1, 3 and 5) and insoluble (lane 2, 4 and 6) fractions of 
PRHPRP (lane 1 and 2), FLHPRP (lane 3 and 4) and FLHRPSA (lane 5 and 6) were 
separated on an SDS-PAGE gel and colored with coomassie staining.  
 
4.2.4 Purification 
Various methods exist for the purification and refolding of recombinant proteins from 
inclusion bodies. We purified the FLHRPSA and FLHPRP protein to find an optimal protocol 
to purify the other recombinant proteins. Solubilizing of the proteins, aggregated in inclusion 
bodies, was performed by denaturing them with the strong denaturing agent guanidine 
hydrochloride. The recombinant proteins, all carrying a His-tag, were then bound to a nickel 
stacked column and renatured by washing the bound proteins with buffer lacking the 
denaturing agent. The recombinant proteins could be eluted by the addition of imidazole to 
the column buffer. Typical yields of soluble recombinant FLHRPSA were 500 µg per liter of 
culture and 1 mg per liter of culture of soluble recombinant FLHPRP (Figure 4.2).  
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Figure 4.2: Purification of recombinant FLHPRP. Precision Plus Protein™ All Blue 
Standard marker (M), E. coli BL21 (DE3) cells without insert (lane 1), insoluble fraction 
(lane 2), total cell protein fraction (lane 3), multiple elution fractions (lane 4, 5 and 6).  
4.3 Conclusions 
We showed that recombinant proteins of PrP and RPSA could be cloned and purified. The 
recombinant proteins, if refolded correctly, can be used in binding assays like surface plasmon 
resonance studies. Those quantitative binding studies can reveal if there are differences in 
binding affinity between RPSA and PrP molecules of different species like humans, cattle and 
sheep and in the case of sheep, between RPSA and PrP molecules of different genotypes. 
 
4.4 Materials and Methods 
4.4.1 RNA extraction, cDNA synthesis and DNA extraction 
Total RNA was isolated from fresh blood samples of humans, sheep and cattle using TRIR 
(ABgene) according to the manufacturer's instructions. Subsequently, a DNase treatment with 
RQ1 RNase-free DNase (Promega) and a spin column purification with Microcon YM-100 
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(Millipore) were carried out to remove genomic DNA. A minus RT-PCR was performed with 
actin beta (ACTB) primers on 20 ng RNA to confirm the absence of any DNA contamination 
as previously described (Lampo et al., 2007). 
The RNA concentration and purity of the samples were measured with the Nanodrop ND-
1000 Spectrophotometer (Isogen) and the RNA quality was determined by evaluation of the 
28S and 18S ribosomal bands on a 0.8% agarose gel. Then, 0.2–1 μg RNA was converted into 
cDNA with iScript cDNA synthesis kit (Bio-Rad) using random hexamers and oligo dT 
primers. A confirmation PCR on 10x diluted cDNA with ACTB primers (giving a different 
amplicon length on gDNA and cDNA) was performed. 
Genomic DNA was isolated from 100 µl blood of humans, sheep and cattle, via a proteinase 
K lysis as described in Van Poucke and colleagues (2005). 
4.4.2 Cloning of RPSA and PRNP into an expression vector 
A schematic overview of the cloning strategy to produce an expressing vector is given in 
Figure 4.3. 
Amplicons of cDNA (RPSA) and gDNA (PRNP) were produced by PCR using pairs of 
primers (listed in Table 4.3) containing restriction recognition sites for NdeI and BamHI at the 
ends of the amplicons. The PCR products were purified by gel electrophoresis and subsequent 
elution with the Geneclean II kit (Q Biogene). Finally, 900 ng of insert was ligated into the 
pCR2.1 vector (Invitrogen) with 8 U T4 ligase and 10x ligase buffer, and 5 µl of this mix was 
transformed into 50 µl DH5α competent cells (Invitrogen). Plasmid DNA was isolated using 
the Birnboim method (Birnboim and Doly, 1979). Isolated plasmid was digested with 10 U 
each of the restrictases NdeI and BamHI (New England Biolabs) and the resulting fragments 
were separated by gel electrophoresis on a 0.8% agarose gel. The separated fragments were 
then eluted with the Geneclean II kit (Q Biogene). Also 2 µg of the pET15b vector (Novagen) 
was digested with 10 U each of the restrictases NdeI and BamHI, and separated and eluted as 
described above. Finally, 900 ng of insert was ligated in 300 ng of the pET15b vector with 8 
U T4 ligase and 10x ligase buffer, and 5 µl of this mix was used for transformation in Nova 
Blue competent cells (Novagen). DNA was isolated with the Plasmid Midi kit (Qiagen) and 
the sequence of the insert in the vector was verified by sequencing with Promotor primer 
(TAATACGACTCACTATAGGG) and T7 Terminator primer 
(GCTAGTTATTGCTCAGCGG) using the BigDye Terminator v3.1 Cycle sequencing Kit 
(Applied Biosystems) on an Applied Biosystems 3730x1 DNA Analyzer. 
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Figure 4.3: Schematic representation of the cloning strategy to produce an expressing vector 
containing the CDS of human RPSA. 
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Table 4.3: Amplicon characteristics of the used primers. 
Primer name Sequence  
Tm 
Amplicon 
length 
OariRPSAbind 1F GAGAATTCCATATGTCCGGAGCCCTTGAT 64°C  
OariRPSAbind 1R GAGAATTCGGATCCTTACGACCACTCGGT 913 bp 
HsapRPSAbind 1F GAGAATTCCATATGTCCGGAGCCCTTGAT 64°C 
HsapRPSAbind 1R GAGAATTCGGATCCTTAAGACCAGTCAGTGGTT 913 bp 
OariPRNPbind 1F GAGAATTCCATATGAAGAAGCGACCAAAACCT  64°C 
OariPRNPbind 1R GAGAATTCGGATCCTATGCCCCCCT 657 bp 
OariPRNPbind 2F GAGAATTCCATATGGGTGGTAGCCACAGT 62°C 
OariPRNPbind 2R GAGAATTCGGATCCTATGCCCCCCT 444 bp 
OariPRNPbind 3F GAGAATTCCATATGTTTGGCAATGACTATGAGGAC 64°C 
OariPRNPbind 3R GAGAATTCGGATCCTAACAGTCATGCACAAAGTT  147 bp 
BtauPRNPbind 1F GAGAATTCCATATGAAGAAGCGACCAAAACCT  64°C 
BtauPRNPbind 1R GAGAATTCGGATCCTATGCCCCTCGT  681 bp 
BtauPRNPbind 2F GAGAATTCCATATGCCACATGGTGGTGGAG 64°C 
BtauPRNPbind 2R GAGAATTCGGATCCTATGCCCCTCGT  471 bp 
BtauPRNPbind 3F GAGAATTCCATATGTTTGGCAGTGACTATGAGGAC 64°C 
BtauPRNPbind 3R GAGAATTCGGATCCTAACAGTCATGCACAAAGTT 147 bp 
HsapPRNPbind 1F GAGAATTCCATATGAAGAAGCGCCCGAAGC  64°C 
HsapPRNPbind 1R GAGAATTCGGATCCTATCTCTGGTAATAGGCCT  648 bp 
HsapPRNPbind 2F GAGAATTCCATATGCACAGTCAGTGGAACAAGC  64°C 
HsapPRNPbind 2R GAGAATTCGGATCCTATCTCTGGTAATAGGCCT  429 bp 
HsapPRNPbind 3F GAGAATTCCATATGGACTATGAGGACCGTTACTATCGT 64°C 
HsapPRNPbind 3R GAGAATTCGGATCCTAGCAGTCGTGCACAAA  138 bp 
Restriction sites of NdeI (CATATG) and BamHI (GGATCC) are marked in italic script. 
 
 
Chapter 4: Recombinant proteins 
125 
 
4.4.3  Protein synthesis 
DNA of the pET15b plasmid containing the correct insert, was transformed into BL-21(DE3) 
E. coli cells. A single colony from a freshly streaked plate was inoculated in 5 ml Luria-Broth 
medium plus ampicillin (100 µg/ml) and grown overnight. This inoculum was transferred to 
100 ml Luria-Broth medium plus ampicillin (100 µg/ml) and the cells were grown at 37°C 
and active stirring until reaching an absorbance (at 590 nm) of 0,5 - 1 optical density (OD) 
using a Nanodrop spectrophotometer (Isogen). Protein expression was induced with the 
addition of isopropyl-β-D-thiogalactopyranoside at a final concentration of 1 mM. The culture 
was harvested 3 h after induction. 
To check if the expected recombinant proteins were expressed and in which fraction they 
were present, total cell protein, soluble and insoluble fractions were examined by SDS-PAGE 
and western blot. 
4.4.3.1 Total cell protein fraction 
A sample of 500 µl was centrifuged at 10,000x g at 4°C, and resuspended in 100 µl 1x PBS to 
produce the total cell protein fraction. The suspension was lysed with 100 µl of 4x SDS 
sample buffer and heated for 3 minutes at 85°C.  
4.4.3.2 Soluble fraction 
Forty ml of culture was centrifuged at 10.000x g at 4°C, and resuspended in 4 ml cold 20 mM 
Tris-HCl pH 7.5. The suspension was then sonicated on ice and the lysate was centrifuged at 
14.000x g for 5 minutes. Hundred µl of the supernatans was then added to 100 µl of 4x SDS 
sample buffer and heated for 3 minutes at 85°C. 
4.4.3.3 Insoluble fraction 
The insoluble pellet, obtained in the previous step, was washed and resuspended in 750 µl 20 
mM Tris-HCl pH 7.5. After centrifugation at 10.000x g for 5 minutes, the pellet was 
resuspended in 1.5 ml 1% SDS by heating and vigorous stirring. 100 µl of the sample was 
then added to 100 µl of 4 x SDS sample buffer and heated for 3 minutes at 85°C. 
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4.4.4 SDS-PAGE and western blot 
The lysate was loaded on a 10% Any kD Mini-PROTEAN
®
 TGX™ SDS_poly_acrylamide 
Precast Gel (Bio-Rad) and proteins were separated by gel electrophoresis using a Mini-
PROTEAN
®
 Tetra Cell (Bio-Rad). The gels were run with running buffer (2.5 mM Tris, 19.2 
mM glycine, 0.01% SDS, pH 8.3) at 220 V. After separation, the proteins were transferred to 
nitrocellulose membranes with blotting buffer (48 mM Tris pH 9.2, 39 mM glycine, 20% 
MeOH and 0.01% SDS) using a Mini-PROTEAN
®
 Tetra Cell system (Bio-Rad) and stained 
with Ponceau S (Sigma).  
4.4.5 ECL detection  
After Ponceau S staining (Sigma), the membrane was washed with 5% low fat milk in Tris 
buffered saline/Tween 20 (TBS/T). Subsequently, the membrane was washed in TBS/T and 
was then incubated in 1/1000 mice anti-His antibody in TBS/T during 1 hour. After washing, 
a second incubation with the anti-mice antibody conjugated with horseradish peroxidase was 
performed and finally the membrane was washed again with TBS/T. The signal was 
visualized with the enhanced chemiluminescence (ECL) visualization kit (Pierce). 
4.4.6 Protein purification 
Protein synthesis was conducted in the same manner as described before, only 1 liter of Luria-
Broth medium was inoculated instead of 100 ml. The cells were harvested by centrifugation at 
4,200 x g and resuspended in cell resuspension buffer (Table 4.4). The suspension was 
sonicated (3 times 30 second pulses at 100 W with 30–60 second gaps between pulses for 
cooling) and cell debris was then removed by centrifugation (4,000 x g for 15 minutes at 4°C).  
The supernatant was immediately applied to a nickel–sepharose column (HisPrep; GE 
Healthcare Life Science), connected to an ÄKTApurifier system (GE Healthcare Life 
Science), which had been previously equilibrated in buffer A and stacked with nickel sulphate. 
After the supernatans was pumped through the column, it was washed with buffer A, followed 
by buffer B. Elution was achieved by application of buffer C. Separated fractions were 
collected and each fraction was analyzed by SDS-PAGE to identify protein containing 
fractions. Protein containing fractions were then desalted on a HiPrep 26/10 Desalting column 
(GE Healthcare Life Science) in 50 mM Hepes buffer pH 7.5. 
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The concentration of soluble purified protein in the buffer was measured by a 
spectrophotometer using the Bradford protein assay (Bio-Rad). 
Table 4.4: Buffers used for protein purification. 
Buffer name Composition 
Cell resuspension buffer 6 M guanidine hydrochloride, 50 mM Hepes-OH, pH 7.5, 150 
mM sodium chloride and 10% (v/v) glycerol  
Buffer A 6 M guanidine hydrochloride, 50 mM Hepes-OH, pH 7.5, 500 
mM sodium chloride and 10% (v/v) glycerol 
Buffer B 50 mM Hepes-OH, pH 7.5, 500 mM sodium chloride and 10% 
(v/v) glycerol 
Buffer C 250 mM imidazole, 50 mM Hepes-OH, pH 7.5, 500 mM 
sodium chloride and 10% (v/v) glycerol  
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5.1 Discussion 
Transmissible spongiform encephalopathies (TSE) or prion diseases are a group of lethal 
neurodegenerative diseases affecting humans and a wide range of animal species (Imran and 
Mahmood, 2011). They manifest as sporadic, transmissible, iatrogenic or genetic diseases. 
The key mechanism in the pathogenesis of prion diseases is the conversion of PrP
C
 to PrP
Sc
. 
Because the dissemination of PrP
Sc
 aggregates in the body of TSE infected sheep is far more 
extensive compared to cattle, sheep are posing a major threat for public health if they could 
get infected with BSE, a zoonotic TSE causing vCJD in humans. A second reason which 
makes sheep an important species in prion disease research is the well-known variability of 
the PRNP gene. The genotype of the ovine PrP
C 
protein is highly associated with the 
susceptibility and clinical course of TSE in sheep. After a decade of selective breeding 
however, it is clear that this association is not 100%. Therefore, it is essential to evaluate other 
genes that are candidates in playing an additional role in TSE susceptibility of sheep. Basic 
research on their exact mechanism in the TSE pathway can help us to understand the 
pathogenesis of TSE diseases and this can possibly lead to the development of new treatments 
for prion diseases in men. 
The conversion from the normal prion protein to the abnormal form in vivo has to start by the 
internalization of an abnormal prion protein. Subsequently, the normal prion protein has to 
come in close contact with the abnormal form. In both processes, the Ribosomal Protein SA 
receptor (RPSA) plays an important role. It is a receptor that binds to both the normal prion 
protein and the abnormal form and is responsible for the active internalization of the prion 
protein (Gauczynski et al., 2001; Gauczynski et al., 2006). Moreover, the receptor is 
important in the propagation of the disease (Leucht et al., 2003).  
Genetic diversity of the RPSA protein can also play a role in the susceptibility to TSE 
diseases. If structural mutations of the RPSA gene are affecting the tertiary structure of the 
receptor and are creating an altered binding affinity of the receptor to the prion protein, the 
internalization of PrP
Sc
 and the propagation of the disease can be hampered.  
Moreover, studying this receptor in sheep can act as a model for prion therapy in humans as it 
plays an important role in the propagation of prion diseases. Multiple therapeutic pathways 
based on RPSA are currently investigated in human medicine (Zuber et al., 2007a; Zuber et 
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al., 2007b; Zuber et al., 2008a; Zuber et al., 2008c; Pflanz et al., 2009a; Pflanz et al., 2009b; 
Vana et al., 2009).  
However, little is known about the genetic background of RPSA. Before studying the 
structural variability of a protein and the consequences of this variability on a disease, the 
gene family of this protein has to be characterized. It is expected that the genetic background 
of RPSA in sheep is complex because previous studies in other species have shown that 
RPSA is a member of a multicopy gene family, containing large numbers of pseudogenes 
(Zhang et al., 2002). Pseudogenes with high similarity to their functional paralog can interfere 
with gene identification and annotation studies such as sequencing or mapping of a gene 
because primers used to amplify a certain part of a gene from genomic DNA, can also amplify 
the pseudogene, causing errors in the sequence. Therefore, one has to be absolutely sure that 
primers used in a sequencing study, are specific enough to only amplify the desired gene.  
In several studies in other species, mostly processed pseudogenes were discovered. In pig for 
example, 2 processed pseudogenes with a high nucleotide similarity to the porcine RPSA 
cDNA were discovered while isolating the functional gene (Knorr et al., 2007). The authors 
state that they encountered severe problems during isolation of the functional gene due to 
these pseudogenes and that a profound characterization of the porcine RPSA gene family was 
necessary. The human genome possesses 26 RPSA gene family members, of which at least 19 
are processed pseudogenes (Jackers et al., 1996). In mice, three members of the RPSA gene 
family, probably one functional copy and two pseudogenes, were detected during a cDNA 
study (Fernandez et al., 1991). At last, one processed pseudogene, displaying a high sequence 
identity with the functional RPSA gene, was completely characterized in cattle (Germerodt et 
al., 2004). 
Most but not all of these pseudogenes are nonfunctional. In mice, a processed pseudogene of 
the RPSA protein is transcribed in heart, liver and skeletal muscle. The protein encoded by the 
pseudogene bears no premature stop codon and is sharing 96 % amino acid identity with the 
RPSA protein. It causes degradation of the myocardium by binding to one of the 
heterochromatin complex proteins, leading to right ventricular dysplasia (Asano et al., 2004).  
Recent studies also showed that not only the translated protein but also the transcribed mRNA 
of some pseudogenes can have a function. They can regulate the effect of microRNA on the 
ancestor gene by competing for microRNA binding (Swami, 2010). Until now, no such 
function has been found for RPSA pseudogenes. 
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At the start of this PhD study, an mRNA sequence of the ovine RPSA gene became available 
in the NCBI databank GenBank but the genomic structure or the existence of pseudogenes 
was unknown (Qiao et al., 2009).  
Therefore, it was our first goal to identify and sequence all the RPSA gene family members 
with a high nucleotide similarity to the functional gene in sheep and the genomic region 
surrounding them (Chapter 3). We used three strategies to identify RPSA gene family 
members, each with their own advantages and disadvantages. The first strategy was to use an 
experimental approach (Chapter 3.1). 
In order to detect as many pseudogenes as possible, the known mRNA sequence was aligned 
to every ovine RPSA EST in the GenBank database showing similarity to the RPSA mRNA 
sequence and a conserved sequence was created. Primer pairs were designed in conserved 
regions and were always intron spanning, representing every exon at least once so that 
pseudogenes consisting of just two exons would get detected as well. Moreover, a low 
binding temperature was used in the PCRs, making the binding less specific so that family 
members carrying one or two mutations at the primer binding sites would still bind to the 
primer and get amplified. In a preliminary experiment, the primers were tested on ovine 
genomic DNA and each primer amplified several bands. The bands were cloned and several 
bands consisted of different subclones, making it obvious that it was not possible to 
characterize the gene family on genomic DNA but that screening a BAC library was 
compulsory. A BAC library is an organized collection of BAC clones. We screened the ovine 
INRA BAC library (Vaiman et al., 1999), each carrying an insert of approximately 123 kb 
and covering the genome 3.4 times. This means that the RPSA gene is normally 3.4 times 
present in the library. If by coincidence, the genetic code is cut at the location of a family 
member and therefore, the sequence of the family member is located in two different BAC 
clones, other BAC clones should be present in the library that possess the uninterrupted 
sequence. Furthermore, as each part of the ovine genome is represented 3.4 times in the 
library, mini-contigs of overlapping BAC clones can be constructed and large genomic 
regions surrounding the family members can be studied. As the full length active RPSA gene 
is approximately 13 kb and other family members are supposed to be smaller or have 
approximately the same length, the genomic region surrounding the family members is at 
least 10 times larger than the family member itself, making it probable that the surrounding 
regions bear other genes that can be identified.  
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We isolated 34 BAC clones with which we could construct 12 mini-contigs, all possessing a 
unique member of the ovine RPSA gene family. Each member was sequenced by direct 
sequencing. We isolated the functional full length RPSA gene and eleven pseudogenes. The 
sequencing of the family members was possible because a BAC clone carries only one 
fragment of the genome, and therefore no other family members were co-amplified unlike 
amplification in a genomic environment.  
The advantages of screening a BAC library to identify members of an extensive gene family 
are multiple. The sequences are determined experimentally by the researcher himself and 
should therefore be complete and correct. Secondly, the sequencing is less hampered by co-
amplifying family members unlike amplification in a genomic environment. Only family 
members that are located very close to another family member, mostly duplicated non-
processed pseudogenes, can be present in the same BAC of 123 kb and cause co-amplification 
problems but this was never the case in our experiment. Thirdly, the genomic region around 
the family member can be analyzed too. Disadvantages of this strategy are labor intensity and 
the fact that only family members which share a high level of sequence identity with their 
ancestor gene can be identified. We countered this problem as much as possible by using 
primer pairs that were designed in conserved regions and using multiple primer pairs. 
Moreover, a low binding temperature was used to allow aspecific binding. We proved that 
this experimental design was valid, as analysis of the primer binding sites in the isolated 
pseudogenes showed that our screening primers could anneal to targets down to 83% 
sequence identity. 
Despite these measures, family members with a very low level of sequence identity with the 
functional full length gene could not be isolated. This is not a problem in studies to identify 
family members interfering with molecular studies on the functional full length gene as only 
the ones sharing a high level of sequence identity will interfere. It is neither a problem when 
the goal is to identify family members that could be transcribed and could have a function as 
these family members are showing generally a high sequence identity with the functional full 
length gene. In conclusion, the strategy to screen a BAC library was sufficient to fulfill our 
first objective. On the other hand, when conducting a general gene family study, other 
strategies are more eligible. 
Another strategy to characterize a gene of a multicopy gene family is to do a genome-wide in 
silico study of the gene family in a fully sequenced species. At the time of the study, there 
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was no ovine reference genomic sequence available in the NCBI database, only the ovine 
mitochondrial DNA was sequenced so this was not an option at that point. In June 2014 
however, the fully annotated sequence of the sheep genome became available (Jiang et al., 
2014). From now on, it is therefore possible to perform an in silico study but one has to be 
careful for errors in the database (see below).  
A third strategy is to conduct a genome-wide in silico study in a fully characterized species 
that is closely related to the goal species, identify all pseudogenes in that species and then 
experimentally validate the existence of the orthologs in the goal species with family member 
specific primer pairs. In 2009, we did an in silico genome-wide study of the cattle genome, a 
species that is closely related to sheep (Chapter 3.2). Of the eleven ovine pseudogenes 
discovered in the BAC library screening, only 5 had a bovine ortholog. Moreover, all the 
ovine pseudogenes with a high nucleotide similarity to the functional gene and therefore the 
most interesting as they would have the greatest interference in molecular studies, did not 
have a bovine ortholog. This result can be explained by the fact that pseudogenes accumulate 
mutations in their sequences during evolution (Zhang et al., 2002). Lineage specific 
pseudogenes are arisen after the divergence between cattle and sheep, and are consequently 
younger than pseudogenes arisen before that divergence. As a consequence, the chance that 
pseudogenes are highly identical to their “ancestor gene” is greater for lineage specific than 
lineage aspecific pseudogenes. Therefore, the strategy to conduct a genome-wide in silico 
study in a closely related species appeared to be not helpful in order to detect interfering or 
functional pseudogenes (in other words, pseudogenes with high sequence identity with the 
functional full length gene) but the comparison between orthologous gene families stays very 
interesting to study evolutionary dynamics. 
In 2010, a draft assembly of the sheep genome, namely the whole genome shotgun (WGS) 
assembly Ovis_aries_1.0, became available. It is composed of short ovine sequences (± 
between 100 and 1000 bp long), aligned using the bovine genome as the initial guide 
(Archibald et al., 2010). Therefore, it was possible to do an in silico study of the ovine 
genome but this cannot be described as genome-wide as the draft sequence still contains a lot 
of gaps (Chapter 3.2). Moreover, the gaps are mostly situated in regions between genes and 
in introns, the regions where most pseudogenes are situated.  
Advantages of in silico studies are the lack of labor intensity and the fact that family members 
with a low level of sequence identity with their ancestor gene can be detected. A major 
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disadvantage is the presence of large mistakes in the databases whereby careful sequence 
analysis and experimental validation of the results are required.  
We identified 37 RPSA pseudogenes additional to the ones that we already discovered 
experimentally, bringing the total to 48 ovine RPSA pseudogenes. Not all of the experimental 
discovered pseudogenes of our previous study were found in this draft assembly of the sheep 
genome, supposedly due to the many gaps in the assembly. Probably, other pseudogenes than 
the experimentally found ones are also situated in gaps of this assembly. In June 2014, the 
fully annotated sequence of the sheep genome became available (Jiang et al., 2014), making it 
possible to discover more ovine RPSA pseudogenes. However, one should be cautious with 
the automatically generated information in the database. We showed that two sequences 
designated in GenBank as two different bovine pseudogenes were actually copies of the same 
pseudogene. In addition, the annotation was often incorrect. Some parts of processed 
pseudogenes were labeled as introns, some flanking intergenic regions were labeled as 
pseudogene and some RPSA pseudogenes were named after another member of the ribosomal 
protein family, namely RPS24.  
In conclusion, the first strategy (BAC library screening) proved to be the best strategy to 
detect family members that can be functional or can interfere with further molecular studies, 
in other words family members with a high sequence identity to the ancestor gene, but yielded 
only 11 family members. The in silico study proved to be the best strategy to detect a large 
number of family members (37 new pseudogenes) but this study failed to detect family 
members with high sequence identity with their ancestor gene. None of the family members 
with a sequence identity above 85% namely RPSAP1 (93%), RPSAP5 (90%), RPSAP7 (99%), 
RPSAP8 (86%), RPSAP9 (98%) and RPSAP10 (94%), isolated in the BAC library study, 
were discovered in the in silico study. However, in the in silico study, 2 of the 37 new 
pseudogenes shared a sequence identity with their ancestor gene above 85% and were not 
isolated in the BAC library screening study. This is probably due to their short length. 
RPSAP16 (87% sequence identity) is composed of only one exon and could not be isolated in 
the BAC library study due to our study design that used intron spanning primers. RPSAP25 
(90% sequence identity) is composed of only three exons. Moreover, it could be that those 
short family members were not present in the BAC library since the library has a genome 
equivalent of only 3.4. 
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Furthermore, a mini-contig around the full length active RPSA gene was constructed and the 
gene was sequenced as well. At that time, Marcos-Carcavilla and colleagues (2008) published 
the partial genomic sequence of the ovine functional RPSA gene. We could confirm their 
results and complete it with the 8846 bp long sequence of intron 3 that was missing in their 
published sequence. Annotation of the mini-contig constructed around the ovine RPSA gene 
showed that the three genes identified in the ovine BAC mini-contig were present in the 
corresponding bovine region. Moreover, the orientation and order of the genes was identical, 
supporting the conserved linkage between these two species.  
Our second objective was to identify all RPSA gene family members that could have an effect 
on the RPSA-PrP binding and assess their functionality (Chapter 3.1). 
A first step to achieve this goal was to perform an expression profile of the active full length 
RPSA gene and the other RPSA family members. We aligned all identified family members 
from the BAC library study with each other and constructed primers that were specific for one 
or more family members. Specific primers, based on the aligned sequences of the different 
RPSA family members were designed for 8 members of the RPSA family. Due to the high 
level of nucleotide sequence identity between RPSA and three pseudogenes, another strategy 
had to be developed to evaluate transcription of those (pseudo)genes. Primer pairs that 
amplified different combinations of 2 to 6 RPSA family members were developed and the 
obtained amplicons were sequenced to determine/confirm which (pseudo)gene was 
transcribed. All generated amplicons were sequenced to verify that the detected transcription 
profile belonged to a certain family member. RPSA was expressed in all tissues included in 
this study, namely blood, cerebrum, cerebellum, muscle, spleen, lymph node and duodenum. 
This is in agreement with the results of Marcos-Carcavilla and colleagues (2008) and Qiao 
and colleagues (2009). However, both studies did not use family member specific primerpairs 
to evaluate expression. Analysis of their data shows that the authors used primers that could 
also amplify RPSAP1 or RPSAP1 and RPSAP7. Observed bands in their RT studies could 
therefore be a mix of expression of the full length gene and expression of one or more 
pseudogenes. Because we proved that RPSAP1 and RPSAP7 are not expressed in any tissue 
(see below), we can conclude that the expression profile published in both studies, is indeed 
the expression profile of the full length RPSA gene and not of another family member.  
Besides the active full length RPSA gene, we proved that several other family members are 
also transcribed. We showed that the expression pattern differed largely between the different 
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pseudogenes. Some pseudogenes are expressed in all tissues except blood but other 
pseudogenes are only transcribed in one or more brain regions. Some pseudogenes are not 
expressed in any of the tested tissues, including RPSAP7 which has the same ORF as RPSA 
(295 amino acids) and differs only in one amino acid compared to the functional protein. This 
is in accordance with the recent findings of Tonner and colleagues (2012) who found that 17 
pseudogenes of ribosomal proteins are transcribed in various tissues unlike their ancestor 
ribosomal protein genes that are constitutively expressed in almost all tissues. 
We did not find a relationship between the transcription profile of the various pseudogenes 
and the in silico prediction of possible promoters. For some pseudogenes, an upstream 
promoter sequence was predicted but no transcription was observed in any tested tissue, and 
for other pseudogenes, transcription was found in certain tissues although we could not 
predict any promoter. As we tested the transcription of the pseudogenes in the tissues of one 
animal, it could be possible that some pseudogenes are not expressed in our animal but that 
they are in another animal and vice versa. To assess this differential gene expression, a large 
study containing a higher amount of animals is necessary but this was outside the scope of 
this study. However, it would be interesting to do a quantitative gene expression study of both 
the functional RPSA gene as well as the pseudogenes in multiple animals of different PRNP 
genotype in the near future.  
A second step in assessing a possible function of the pseudogenes was to check their 
sequences for open reading frames. RPSAP2 and RPSAP11, transcribed in all tested tissues 
except blood, have ORFs of 70 and 107 amino acids respectively but those ORFs only show 
56 and 46% sequence identity respectively with the ORF of the full length active RPSA gene. 
The ORFs of RPSAP3 and RPSAP5, transcribed in one or more brain regions, are situated in 
the intracellular region of the receptor. The ORF of RPSAP4, transcribed in multiple brain 
regions and the spleen, is also only located in the intracellular region. At last, RPSAP8, has an 
ORF that contains the binding domains of PrP and is expressed in multiple brain regions but 
has a sequence identity with the full length gene that is too low (80% sequence identity) to act 
as an alternative binding partner for PrP. 
Three of the six transcribed pseudogenes (RPSAP2, RPSAP4 and RPSAP5) are located in 
intronic regions of another gene. We hypothesize that the observed transcription of those 
pseudogenes is only a consequence of transcription of the other gene. The three other 
transcribed pseudogenes are situated in intergenic regions. Only for RPSAP8, we found a 
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promotor sequence by in silico promotor prediction. The mechanism of the transcription of 
RPSAP3 and RPSAP11 remains unclear. 
At least one processed RPSA pseudogene is known to be expressed and exhibits a function, 
namely the previously mentioned processed RPSA pseudogene that causes right ventricular 
dysplasia in a certain line of mice (Asano et al., 2004). To the best of our knowledge, this is 
the only published RPSA pseudogene with a proved functionality. 
Furthermore, only two additional family members (RPSAP16 and RPSAP25) which were 
identified in the in silico study shared a sequence identity with their ancestor gene that was 
high enough to, when expressed, have a function that could affect the binding between RPSA 
and PrP, namely 87% and 90% sequence identity respectively. RPSAP16 contains just exon 2 
and would, when expressed, consist of only the intracellular domain of the receptor and 
therefore have no influence on the binding with PrP. 
RPSAP25, on the other hand, does contain the binding region and can potentially exhibit a 
role in the RPSA-PrP binding if expressed. Analysis of the data of the expression study of the 
family members identified in the BAC library screening, revealed that the specific primer, 
designed to test the expression of RPSAP8, can theoretically also amplify RPSAP25. 
However, all amplicons, generated in the expression study of RPSAP8 were sequenced and all 
of them turned out to be RPSAP8. No evidence of transcription of RPSAP25 was found.  
In conclusion, no other ovine RPSA gene family member, besides the active full length RPSA 
gene, is a candidate to have an effect on the binding between RPSA and PrP, either due to no 
expression, to low sequence identity with RPSA or the absence of the binding domains with 
PrP in their transcribed polypeptide. 
The third objective was to perform a mutation detection of transcribed RPSA gene family 
members in the Flemish sheep population (Chapter 3.2). The PrP binding affinity of RPSA 
could be influenced by amino acid polymorphisms in their binding region. As no other ovine 
RPSA gene family members were a possible candidate to influence the binding between 
RPSA and PrP, only mutation detection of the full length active RPSA gene was carried out. 
We only included the CDS in this mutation detection to reveal structural mutations and did 
not look at mutations located in regulatory regions, like the promoter region, that could cause 
variation in expression level. Besides the function as receptor for multiple proteins and 
viruses, RPSA plays an important role as housekeeping gene and is essential for the survival 
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of the cell. Mutations in regulatory regions that cause variation in expression level would 
compromise the essential function as ribosomal protein and are therefore not expected to be 
fixed in the genome. Structural mutations that are located in the binding region with PrP and 
could have an effect on TSE susceptibility however, would not hamper the essential 
ribosomal protein function as this function is located in the first two-thirds of the protein 
(Ardini et al., 1998) and the binding domains with PrP are located in the last third.  
Structural mutation detection could only be conducted once the ovine RPSA gene family was 
fully characterized. Otherwise, co-amplifying pseudogenes could hamper the sequencing of 
the RPSA gene. Exon-spanning primers situated in the introns were used as all previous 
discovered ovine pseudogenes (Chapter 3.1 and 3.2) were processed or semi-processed 
pseudogenes. This strategy turned out to be successful as none of the obtained data gave any 
evidence of co-amplifying pseudogenes. Nineteen mutations were detected but none of the 
discovered mutations caused an amino acid polymorphism and therefore could bear an effect 
on the binding of RPSA with PrP. A mutation study in humans showed that the RPSA gene is 
also highly conserved between different individuals. Yun and colleagues (2011) detected four 
SNPs including three SNPs located in the 5’- UTR region and introns of RPSA and one SNP 
in the coding region. This SNP, located in the direct PrP binding domain, is however a 
synonymous SNP which does not lead to the substitution of an amino acid. Structural 
mutations in the ovine RPSA gene or in other ovine RPSA gene family members can 
consequently not cause the variation in scrapie susceptibility in sheep. 
There is a great variance between the susceptibility of different species to one type of prion 
disease. Moreover, when two species are both susceptible for one prion strain, clinical signs 
and incubation time can vary a lot between these species. This effect is referred to as the 
species or transmission barrier. The basis of the species barrier is probably the subtle 
differences between the tertiary structures of PrP of the different species. The better the PrP 
structure of the abnormal prion protein resembles the structure of the cellular protein, the 
more efficient the conversion from normal prion protein to abnormal prion protein will be. 
Nevertheless, as the RPSA protein is necessary for the internalization and propagation of PrP, 
differences between species in RPSA conformation that are affecting the binding between 
RPSA and PrP, can also have a putative role in the strength of the species barrier (Marcos-
Carcavilla et al., 2008). We therefore assessed the conservation of the RPSA gene between 
the three main ruminants, namely sheep, goat and cattle (Chapter 3.2) and discovered that 
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they share 100% identity in their amino acid sequence. The observed species barrier for 
transmission of certain prion strains between the different ruminant species can therefore not 
be ascribed to structural differences in the RPSA protein of the three species.  
In conclusion, we hoped to detect structural mutations that could have an effect on the binding 
affinity between RPSA and PrP. However, we showed that the RPSA gene is highly 
conserved and therefore the variation in scrapie susceptibility between sheep and the species 
barrier between different ruminant species can not be explained by structural variance of the 
RPSA gene. 
Therefore, we could not fulfill our fourth objective, namely performing a binding affinity 
study between all transcribed RPSA gene family members that showed amino acid 
polymorphisms in the binding region and the PrP protein, as there were no candidate gene 
variants to test. 
A last, as structural variability of the RPSA receptor in sheep does not cause variation in TSE 
susceptibility, perhaps variability in the ovine PRNP gene could result in altered binding 
affinity with RPSA, and influence the variation in TSE susceptibility through that mechanism. 
Polymorphisms of the PRNP gene and their effect on TSE resistance are well studied in sheep. 
The best way to examine differences in binding affinity between two proteins in a quantitative 
manner is performing a surface plasmon resonance study in which the binding affinity 
between receptor and ligand are assessed. By conducting this study we can observe if there 
are different association/dissociation rates between RPSA and ARR, ARQ and VRQ prion 
proteins. Binding affinity assessments between RPSA and PrP proteins of different species 
can also be included in this study. Furthermore, as one of the two bindingsites between RPSA 
and PrP is dependent of HSPG and evidence is rising that Glypican-1, an HSPG, is an 
important co-factor in prion propagation, it would also be interesting to assess the effect of 
adding Glypican-1 to the binding affinity study. If we observe differences in binding affinity 
between two prion proteins, we can than differentiate between direct binding or HSPG 
dependent binding with RPSA. Recombinant human, bovine and ovine prion proteins of 
different genotypes (ARR, ARQ and VRQ) and recombinant human, bovine and ovine RPSA 
proteins (Chapter 4) that can be used in this research were produced.  
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5.2 General conclusions 
In this study, the hypothesis that genetic diversity of the ovine RPSA protein can play a role 
in the susceptibility to TSE diseases was closely examined. Structural mutations of the RPSA 
gene that affect the tertiary structure can create an altered prion protein binding affinity. The 
multicopy ovine RPSA gene family was characterized with multiple strategies and 49 RPSA 
gene family members were identified. The full length functional RPSA gene is expressed in 
all tested tissues namely blood, cerebrum, cerebellum, muscle, spleen, lymph node and 
duodenum. None of the other RPSA gene family members is a candidate to have an effect on 
the binding between RPSA and PrP, either due to no expression, to low sequence identity with 
RPSA or the absence of the binding domains with PrP in their transcribed polypeptide. A 
mutation detection of the CDS of the full length RPSA gene revealed no mutations that cause 
amino acid polymorphisms and subsequent effects on the structure of the protein. The 
observed variation in scrapie susceptibility in sheep can consequently not be explained by 
structural mutations in the ovine RPSA gene or in other ovine RPSA gene family members. 
Furthermore, we proved that the ovine, bovine and caprine RPSA proteins are 100% identical 
and that the observed species barrier for transmission of certain prion strains between those 
ruminant species can not be ascribed to structural differences in the RPSA protein. 
5.3 Perspectives 
In this study, structural variance in the ovine RPSA gene family was characterized but only a 
start was made to determine the functional implications of variation of the ovine PRNP gene 
on the binding affinity to RPSA. Therefore, it would be interesting to purify all the 
constructed clones of Chapter 4 and carry out binding affinity studies e.g. surface plasmon 
resonance studies between the ovine/bovine and human RPSA protein on the one hand and 
the ovine, bovine and human PrP proteins on the other hand. In sheep, it will be interesting to 
study if there are binding affinity differences between the ARR, ARQ and VRQ variants and 
the RPSA protein.  
Moreover, in this PhD study, we only assessed structural variance of the RPSA protein. 
Variation in expression levels, however, could also have an effect on TSE susceptibility in 
sheep. It would therefore be interesting to do a quantitative gene expression study of the 
functional RPSA gene in multiple animals of different breeds and different PRNP genotypes. 
If there is variation in the expression levels of RPSA, a mutation study of regulatory regions 
of RPSA could be a next step in this research followed by a functional analysis of the 
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regulatory mutation. Genetic association studies between those mutations and TSE 
susceptibility could be performed and if there would be an association present, selection 
towards this mutation would strengthen the selective breeding program towards less scrapie 
susceptible sheep. It has been shown that the selective breeding program in Belgium reaches 
its goal in changing the genotype frequency towards more ARR haplotypes and less VRQ 
haplotypes (Dobly et al., 2013). However, as atypical scrapie, of which the genetic resistance 
in sheep is different compared to classical scrapie, is also occurring in Belgium, there is still 
room to improve the selective breeding program. 
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Summary 
Transmissible spongiform encephalopathies or prion diseases are a group of lethal 
neurodegenerative diseases affecting humans and a wide range of animal species. The best 
known TSEs are vCJD in humans and BSE and scrapie in ruminants. TSEs are caused by 
infectious misfolded proteins called prions (PrP
Sc
). These prions are in fact conversions of the 
body-own cellular prion protein (PrP
C
), into the pathological misfolded form. When a human 
or animal gets infected by prions, a cascade of conversions of the body-own cellular prion 
protein into the misfolded protein will take place, leading towards neurodegenerative 
symptoms and ultimately death. 
The PrP protein is encoded by the PRNP gene. In sheep, a major association between 
polymorphisms in the PRNP gene and scrapie susceptibility was found. It is clear, however, 
that no PRNP genotype is associated with 100% TSE resistance. Therefore, it is essential to 
evaluate other candidate genes that can possibly play an additional role in scrapie 
susceptibility. Moreover, the study of other genes involved in the TSE pathway can lead to the 
development of new treatments for prion diseases in humans. 
The RPSA protein is responsible for the binding, internalization and propagation of PrP
Sc
 in 
the cell and is therefore a promising candidate gene. Structural mutations in this gene could 
lead to loss of binding affinity of RPSA to PrP and therefore have an effect on the 
pathogenesis and propagation of the disease. 
In Chapter 1, an introduction on TSEs is given, starting with an overview of the diseases 
occurring in humans and animals. Furthermore, the pathogenesis of prion diseases is 
described followed by a detailed discussion of TSE diseases in ruminants, revealing the 
importance of the species sheep in prion disease research. The influence of PRNP genotype 
on TSE susceptibility in humans, cattle, sheep and goat are further on discussed. Besides 
prions, other proteins and cofactors could be necessary for the propagation of TSEs. They are 
discussed at the end of the first part of Chapter 1.  
A potentially important protein involved in the propagation is RPSA, a ribosomal protein. In 
the second part of the first chapter, the involvement of this protein in prion diseases, its 
function and the genetic properties of the ribosomal proteins are elucidated. Ribosomal 
proteins are often part of a large gene family consisting of a single functional gene and 
multiple pseudogenes. The practical implications of the presence of pseudogenes in a genome, 
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such as the interference of the pseudogenes with molecular studies of the corresponding 
functional gene, are explained.  
At last, therapies for prion diseases that are currently under development or already developed 
are listed. Conventional and innovative therapies are discussed. Multiple therapies based on 
the RPSA protein are currently being explored. 
Chapter 2 lists the objectives of this PhD study. The general aim of this study was to identify 
and sequence all the members of the RPSA gene family in sheep, characterize them and 
assess their functionality. We wanted to assess if the binding regions with PrP of all 
functional RPSA gene family members showed structural variation that could have an 
influence on the binding affinity of the receptor, leading towards differences in susceptibility 
to TSEs. 
We characterized 12 ovine RPSA gene family members by screening a BAC library, 
constructing BAC mini-contigs and sequencing the family members in Chapter 3.1. The 
already described partial genomic sequence of the ovine functional RPSA gene was 
confirmed and completed with the missing sequence of intron 3. In addition to the ovine 
RPSA gene, we identified 11 new members of the ovine RPSA gene family. They were all 
processed pseudogenes and were named RPSAP1-RPSAP11. Two RPSA gene family 
members contain a remnant intron, which suggests that they were derived from semi-
processed RNA transcripts. They are called semi-processed pseudogenes and are reported 
very rarely. 
The construction and annotating of the BAC mini-contigs was described which revealed the 
presence of 40 genes in the flanking regions of the RPSA family members of which 37 genes 
had not been previously described in sheep. The flanking regions of the RPSA family 
members showed conserved synteny with the orthologous bovine counterparts and the 
locations were confirmed by FISH. Five pseudogenes have a bovine counterpart. In silico 
analysis predicted the presence of 55 more RPSA pseudogenes in the bovine genome. 
Compared to the functional RPSA transcript, the RPSA family members differ significantly 
both in structure and sequence identity, ranging from structurally identical pseudogenes 
sharing 99% sequence identity to pseudogenes lacking half of the gene or containing many 
deletions throughout the whole gene, sharing only 74% sequence identity. In addition, the 
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transcription profile of all RPSA family members was determined by RT-PCR in 7 tissues. A 
remarkable result is that at least 6 of the 11 pseudogenes are transcriptionally active. Some  
RPSA family members are transcribed in all tested tissues, except blood, others only in one or 
more brain regions.  
The characterization of the RPSA family members revealed that no other ovine RPSA gene 
family member, besides the active full length RPSA gene, is a candidate to have an effect on 
the binding between RPSA and PrP, either due to no expression, to low sequence identity with 
RPSA or the absence of the binding domains with PrP in their transcribed polypeptide. 
In Chapter 3.2, another approach to identify RPSA pseudogenes in sheep was explored. In 
addition to the 12 experimentally discovered RPSA family members, another 37 RPSA family 
members were identified in silico. This brings the total to 48 ovine RPSA pseudogenes. All of 
the newly discovered RPSA family members are processed except for 1 semi-processed ovine 
pseudogene. They all exhibit one or more typical features of processed pseudogenes like 
disruption by inserted sequences or deletion of large sequences. Most pseudogenes carry 
frameshift mutations or have premature stop codons in their sequences. 
A BLAST analysis of the updated bovine genome identified 56 potential bovine RPSA family 
members out of which 42 are orthologs of ovine pseudogenes. 
Once the sequences of the RPSA pseudogenes were known, it was possible to analyze the 
presence of structural mutations of the ovine functional full-length RPSA gene without the 
interference of pseudogenic sequences. A mutation analysis on 33 unrelated sheep covering 7 
different breeds, varying in PRNP genotype at codons 136, 154, and 171, was conducted. We 
used exon-spanning primers situated in the introns as strategy to avoid co-amplifying of other 
RPSA family members. Nineteen mutations were found: one in the 5' UTR, seventeen in 
different introns, and one silent mutation in the coding region An interesting mutation was 
revealed in a gene located in an intron of the RPSA gene: the SNORA62 gene. This mutation 
could possibly lead to the misfolding of rRNA due to loss of pseudouridine in the 28S rRNA. 
No structural mutations that could play a direct role in the RPSA-PrP
C
/PrP
Sc
 interaction were 
found. Furthermore, we proved that sheep, goat, and cattle have 100% identical RPSA 
proteins.  
Because no structural variability of the ovine RPSA protein was observed, we wanted to 
investigate if structural variability of PrP could affect the binding between RPSA and 
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PrP
C
/PrP
Sc
, leading to differences in susceptibility to prion diseases between species and 
within species. To assess binding differences between RPSA and PrP molecules of different 
species, recombinant proteins are required. In Chapter 4, the cloning, protein synthesis and 
purification of recombinant proteins of PrP and RPSA of humans, cattle and sheep in 
Escherichia coli are discussed. In the case of sheep, recombinant PrP proteins of different 
genotypes were constructed as well. 
The general discussion and conclusions are presented in Chapter 5: 
-The multicopy ovine RPSA gene family was characterized with multiple strategies and 49 
RPSA gene family members were identified.  
-The full length functional RPSA gene is expressed in all tested tissues namely blood, 
cerebrum, cerebellum, muscle, spleen, lymph node and duodenum. 
-None of the other RPSA gene family members is a candidate to have an effect on the binding 
between RPSA and PrP.  
- A mutation detection of the CDS of the full length RPSA gene revealed no mutations that 
cause amino acid polymorphisms and subsequent effects on the structure of the protein. The 
observed variation in scrapie susceptibility in sheep can consequently not be caused by 
structural mutations in the ovine RPSA gene or in other ovine RPSA gene family members.  
-The ovine, bovine and caprine RPSA proteins are 100% identical and therefore the observed 
species barrier for transmission of certain prion strains between those ruminant species can 
not be ascribed to structural differences in the RPSA protein. 
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Samenvatting 
Overdraagbare spongiforme encefalopathieën of prionziekten zijn een groep van dodelijke 
neurodegeneratieve ziektes die bij de mens en een breed scala van diersoorten voorkomen. De 
meest bekende TSE’s zijn vCJD bij de mens en BSE en scrapie bij de herkauwers. TSE's 
worden veroorzaakt door besmettelijke abnormaal gevouwen eiwitten die prionen (PrP
Sc
) 
worden genoemd. Deze prionen zijn in feite omzettingen van het lichaam-eigen cellulaire 
prion eiwit (PrP
C
) in de pathologische abnormaal gevouwen vorm. Wanneer een mens of dier 
wordt geïnfecteerd met prionen vindt een cascade van omzettingen plaats van het 
lichaamseigen cellulaire prioneiwit tot de abnormaal gevouwen vorm wat tot 
neurodegeneratieve symptomen en uiteindelijk de dood leidt. 
Het PrP proteïne wordt gecodeerd door het PRNP-gen. Bij schapen werd er een sterke 
associatie gevonden tussen polymorfismen in het PRNP-gen en resistentie tegen scrapie. Het 
is echter duidelijk dat er geen enkel PRNP-genotype geassocieerd is met 100% TSE 
resistentie. Daarom is het essentieel om andere kandidaatgenen te evalueren die eventueel ook 
een rol kunnen spelen in resistentie tegen scrapie. Bovendien kan de studie van genen die een 
rol spelen in de TSE pathway leiden tot de ontwikkeling van nieuwe therapieën die toegepast 
kunnen worden bij de mens. 
Het gen coderend voor het RPSA eiwit is een veelbelovend kandidaatgen aangezien het RPSA 
eiwit verantwoordelijk is voor de binding, internalisatie en vermeerdering van PrP
Sc
 in de cel. 
Structurele mutaties in dit gen kunnen leiden tot een vermindering van de bindingsaffiniteit 
tussen het RPSA eiwit en PrP en kunnen daarom gevolgen hebben voor de pathogenese en 
verspreiding van de ziekte.  
In hoofdstuk 1 wordt er een inleiding gegeven over TSE's, te beginnen met een overzicht van 
de ziektes die voorkomen bij mens en dier. Verder wordt de pathogenese van prionziekten 
beschreven, gevolgd door een gedetailleerde bespreking van TSE-ziektes bij herkauwers. Het 
belang van schapen in het priononderzoek wordt benadrukt. De invloed van het PRNP-
genotype op TSE gevoeligheid bij de mens, rundvee, schapen en geiten wordt verder 
besproken. Buiten prionen kunnen andere eiwitten en cofactoren nodig zijn voor de 
vermeerdering van TSE. Ze worden besproken aan het einde van het eerste deel van 
hoofdstuk 1. 
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Een veelbelovend eiwit dat mogelijks betrokken is bij de pathogenese en vermeerdering van 
prionziekten is RPSA, een ribosomaal eiwit. In het tweede deel van het eerste hoofdstuk 
wordt de betrokkenheid van RPSA in prionziekten, de functie en de genetische eigenschappen 
van ribosomale eiwitten besproken. Ribosomale eiwitten zijn vaak een onderdeel van een 
grote genfamilie, bestaande uit één functioneel gen en meerdere pseudogenen. De praktische 
implicaties van de aanwezigheid van pseudogenen in het genoom zoals het interfereren van de 
pseudogenen met moleculaire studies van het overeenkomstige functionele gen, worden 
uitgelegd.  
Als laatste worden de priontherapieën die momenteel in ontwikkeling zijn of reeds toegepast 
worden, vermeld. Zowel de conventionele als de innovatieve therapieën worden besproken. 
Er worden momenteel meerdere therapieën, gebaseerd op het RPSA eiwit, onderzocht op hun 
toepasbaarheid en doeltreffendheid. 
Hoofdstuk 2 bevat de doelstellingen van dit doctoraatsonderzoek. Het algemene doel van 
deze studie was om alle leden van de RPSA genfamilie bij schapen te identificeren en te 
sequeneren en vervolgens hen te karakteriseren en te beoordelen op hun functionaliteit. Van 
alle functionele RPSA gen familieleden wilden we nagaan of structurele variatie in hun 
bindingsregio met PrP invloed heeft op de bindingsaffiniteit van de receptor, die kan leiden 
tot verschillen in de resistentie voor TSE’s. 
We identificeerden 12 RPSA gen familieleden bij het schaap door het screenen van een BAC-
bibliotheek, de constructie van BAC mini-contigs en het sequeneren van de familieleden in 
hoofdstuk 3.1. De reeds beschreven gedeeltelijke genomische sequentie van het functionele 
RPSA gen bij schapen werd bevestigd en aangevuld met de ontbrekende sequentie van intron 
3. Naast het functionele RPSA gen, identificeerden we 11 nieuwe leden van de schapen RPSA 
genfamilie. Het waren allen processed pseudogenen en ze werden RPSAP1-RPSAP11 
genoemd. Twee RPSA gen familieleden bevatten nog een intron, wat suggereert dat ze 
ontstaan zijn uit semi-processed RNA-transcripten. Ze worden semi-processed pseudogenen 
genoemd en komen maar zelden voor. De constructie en annotatie van de BAC mini-contigs 
leidde tot de identificatie van 40 genen in de flankerende gebieden van de RPSA familieleden. 
Zevenendertig genen die nog niet eerder werden beschreven bij het schaap werden 
geïdentificeerd. De flankerende gebieden van de RPSA familieleden toonde geconserveerde 
synteny met de boviene orthologen en de genomische locaties werden bevestigd met FISH. 
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Vijf oviene pseudogenen hebben een boviene ortholoog. In silico analyse voorspelde de 
aanwezigheid van 55 RPSA pseudogenen in het runder genoom. 
De RPSA familieleden werden vergeleken met het functionele RPSA transcript en de leden 
verschillen significant van elkaar voor zowel structuur als sequentie identiteit, gaande van een 
structureel identiek pseudogen dat 99% sequentie-identiteit heeft met het functionele gen tot 
een pseudogen waarvan de helft ontbreekt door een groot aantal deleties en die slechts 74% 
sequentie overeenkomst heeft met het functionele RPSA transcript. Bovendien werd het 
transcriptie profiel van alle RPSA familieleden bepaald door RT-PCR in 7 weefsels. Een 
opmerkelijk resultaat is dat tenminste 6 van de 11 pseudogenen transcriptioneel actief zijn. 
Sommige RPSA familieleden komen tot transcriptie in alle geteste weefsels, behalve bloed, 
andere slechts in één of meer gebieden van de hersenen. De karakterisatie van de RPSA 
familieleden toonde aan dat geen enkel ander RPSA gen familielid, naast het actieve RPSA 
gen, kandidaat is om een effect te hebben op de binding tussen RPSA en PrP, hetzij als gevolg 
van de afwezigheid van expressie, lage sequentie identiteit met RPSA of de afwezigheid van 
bindingsdomeinen met PrP in het tot expressie komende polypeptide. 
In hoofdstuk 3.2 werden de RPSA pseudogenen bij het schaap geïdentificeerd door een in 
silico studie. Naast de 12 experimenteel gevonden RPSA familieleden werden nog eens 37 
RPSA familieleden geïdentificeerd in silico. Dit brengt het totaal op 48 oviene RPSA 
pseudogenen. Alle nieuw ontdekte RPSA familieleden zijn geprocessed, behalve 1 semi-
processed pseudogen. Ze vertonen allemaal één of meer typische kenmerken van geprocesste 
pseudogenen zoals disruptie door inserties of deleties van lange sequenties. De meeste 
pseudogenen vertonen frameshift mutaties of premature stopcodons in hun sequentie. Een 
BLAST analyse van het geactualiseerde runder genoom identificeerde 56 potentiële runder 
RPSA familieleden waarvan 42 orthologen van pseudogenen die voorkomen bij het schaap. 
Eens de sequenties van de RPSA pseudogenen bekend waren, was het mogelijk om het 
functionele RPSA gen te onderzoeken op de aanwezigheid van structurele mutaties zonder de 
interferentie van sequenties van pseudogenen. We voerden een mutatie analyse uit op 33 niet-
verwante schapen van 7 verschillende rassen, variërend in PRNP genotype op codons 136, 
154, en 171. We gebruikten exon overbruggende primers die gelegen zijn in de introns als 
strategie om co-amplificatie van andere RPSA familieleden te voorkomen. Negentien 
mutaties werden gevonden: één in het 5 'UTR, zeventien in de verschillende introns en één 
stille mutatie in de coderende regio. Er werd een interessante mutatie gevonden in een gen dat 
Chapter 6: Summary - Samenvatting 
154 
 
gelegen is in een intron van het RPSA gen: het SNORA62 gen. Deze mutatie kan mogelijks 
leiden tot de abnormale opvouwing van rRNA door een vermindering van pseudouridine in 
het 28S rRNA. Er werden geen structurele mutaties gevonden die een directe rol spelen in de 
RPSA-PrP
C
 / PrP
Sc
 interactie. Bovendien werd aangetoond dat het RPSA eiwit van schapen, 
geiten en runderen 100% identiek is. 
Omdat er geen structurele variabiliteit van het oviene RPSA eiwit werd gevonden, wilden we 
onderzoeken of structurele variabiliteit van het PrP eiwit invloed kan hebben op de binding 
tussen RPSA en PrP
C
/PrP
Sc
, die kan leiden tot verschillen in gevoeligheid voor prionziekten 
tussen soorten en binnen soorten. Om de bindingssterkte tussen RPSA en PrP moleculen van 
verschillende soorten te beoordelen, zijn recombinante eiwitten nodig. In hoofdstuk 4 wordt 
het klonen, de eiwit synthese in Escherichia coli en de zuivering van PrP en RPSA 
recombinante eiwitten van de mens, het rund en het schaap besproken. Bij schapen werden 
recombinant PrP eiwitten van verschillende genotypes geconstrueerd. 
De algemene discussie en conclusies worden gepresenteerd in hoofdstuk 5:  
- de complexe oviene RPSA gen familie werd gekarakteriseerd door gebruik te maken van 
verschillende strategieën en er werden zo 49 RPSA gen familieleden geïdentificeerd.  
- het functionele RPSA gen komt tot expressie in alle geteste weefsels namelijk in het bloed, 
de grote en kleine hersenen, de spieren, de milt, de lymfeklieren en de twaalfvingerige darm. 
- geen enkel ander RPSA gen familielid dan het functionele RPSA gen is een kandidaat om 
een effect te hebben op de binding tussen RPSA en PrP.  
- de mutatiedetectie van de coderende sequentie van het functionele RPSA gen toonde geen 
mutaties aan die een polymorfisme veroorzaken en derhalve een effect hebben op de structuur 
van het eiwit. Structurele mutaties in het RPSA gen of in andere RPSA gen familieleden 
kunnen dus niet leiden tot de geobserveerde variatie in gevoeligheid voor scrapie bij schapen. 
- het schapen, runder en geiten RPSA eiwit is 100% identiek en structurele verschillen in het 
RPSA eiwit kunnen daarom de geobserveerde speciesbarrière tussen herkauwers voor 
bepaalde prion stammen niet verklaren. 
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